Protocol Amendment 12, date December 4, 2014 1 
 
SCHEMA 
(STUDY SYNOPSIS) 
 
 
A Phase II Study of Gemcitabine and nab-Paclitaxel in Combination with 
Vismodegib (GDC-0449; Hedgehog Path way Inhibitor) in Patients with 
Previously Untreated Metastatic Adenocarcin oma of the Pancreas 
 
 
 
Johns Hopkins Protocol Number: J1013, NA_00036883 
 
 
IND Number: 108819 
 
 
Sponsor: Stand Up to Cancer (SU2C)  
 
 
 
 
 
  
 
Key Principal Investigator:  Daniel Laheru, M.D.  

Protocol Amendment 12, date December 4, 2014 2    (Johns Hopkins)                      The Sidney Kimmel Comprehe nsive Cancer Center  
                                                      at Johns  Hopkins  Bunting Blaustein Canc er Research Building 
 1650 Orleans Street, 4M09  Baltimore MD 21231-1000  (410) 955-8974  laherda@jhmi.edu   
 
Co-Principal Investigator:  Ana De Jesus-Acosta MD 
       (Johns Hopkins)                   The Sidney Kimmel Comprehensive Cancer Center  
                                                      at Johns  Hopkins  Bunting Blaustein Canc er Research Building 
 1650 Orleans Street, 4M08  Baltimore MD 21231-1000 
          adejesu1@jhmi.edu  
 
 Principal Investigators:         Ramesh K. Ramanathan, MD                                                  
                                                     Peter O’Dwyer MD                                                  Co-Investigators :                     Anirban Maitra, MD     
  (Johns Hopkins)                     Ross Donehower, MD 
                                                  Luis Diaz, MD                                                   Dung Thi Le, MD                                                   David Cosgrove, MBBCh                                                    Nilofer S Azad, MD 
                                                  Lei Zheng, MD PhD 
                                                  Marcia Irene Canto, MD                                                   Eun Shin, MD                                                   Zeshaan Rasheed, MD   
  Pamela Johnson, MD   Emily Petito, CRNP   Keith McIntyre, CRNP   Atif Zaheer, MD   Ilene Browner, MD 
                                                                                                Study Coordinating Center:  Sidney Kimmel Comprehensive Can cer Center at Johns Hopkins 
 
Study Center (s):      Translational Genomics Research Institute, Scottsdale AZ 
University of Pennsylvania, PA  
          
 
              
       
Protocol Amendment 12, date December 4, 2014 3Statistician:                            Study Coordinator:   
 Elizabeth Sugar Yvette Cetasaan, CCRP 
 615 North Wolfe St, W5010 550 North Broadway, Suite 415  Baltimore, MD 21205 Baltimore, MD 21205  410-502-3913 410-955-4035  Fax: 410-502-4621 Fax: 443-287-6566  esugar@ jhsph.edu freemyv@jhmi.edu  
Responsible Research Nurse: Responsible Data Manager: 
 Rosalind Walker Yvette Cetasaan, CCRP 
 550 North Broadway, Suite 415 550 North Broadway, Suite 415  Baltimore, MD 21205 Baltimore, MD 21205  410-955-9628 410-955-4035  Fax: 443-287-6566 Fax: 443-287-6566  Rwalker3@jhmi.edu freemyv@jhmi.edu    
Summary of the protocol versions:  
 
Protocol Version Date of Protocol IRB Approved Date 
Initial Protocol May 3, 2010 July 6, 2010 
Amendment 1 June 8, 2010 N/A 
Amendment 2 June 11, 2010 N/A 
Amendment 3 July 6, 2010 July 23, 2010 
Amendment 4 August 16, 2010 Oct 19, 2010 
Amendment 5 February 1, 2011  March 8, 2011 
Amendment 6 August 3, 2011 Aug 30, 2011 
Amendment 7 January 11, 2012 February 7, 2012 
Amendment 8 February 15, 2012 March 6, 2012 
Amendment 9 February 22, 2013 February 26, 2013 
Amendment 10 April 16, 2013 May 15, 2013 
Amendment 11 August 16, 2013 September 11, 2013 
 
            
Protocol Amendment 12, date December 4, 2014 4 
Study Phase:  Phase II                   
 
Patient Population :  Patients with untreated metast atic pancreatic adenocarcinoma  
                                               
Concept and Rationale 
 
Pancreatic cancer is one of the mo st dismal malignancies in the gastrointestinal tract and remains the 
fourth leading cause of cancer re lated mortality.   The majority of patients with pancreatic 
adenocarcinoma have evidence of metastatic disease at  presentation with a median survival of 6 months.  
New therapies are urgently needed. The Hedgehog (Hh) signaling pathway is persistent ly activated in severa l malignancies including 
pancreatic cancer leading to activ ation and nuclear localization of GL I1 transcription factors, with 
subsequent induction of Hh target genes, many of which are involved  in proliferation, survival and 
angiogenesis. The Hh signaling pathway also plays a role in maintaining subpopulations of cancer stem 
cells (CSC) in pancreatic cancer. Based on previous  preclinical studies, panc reatic CSC comprise 0.2-
0.8% of all pancreatic cancer cell s, are highly tumorigenic and posse ssed the ability of self-renew and 
produce a differentiated progeny. These CSC can elicit  tumor progression and me tastases and confer 
potential resistance to availabl e therapeutic approaches includ ing chemotherapy and radiation.  
 In preclinical studies pharmacol ogic blockade of the Hh signalin g pathway using Hh inhibitors 
decreased tumor proliferation, incr eased survival in animal models  and decreased CSC markers in 
primary and metastatic tumors. Inhibition of the Hh signaling pathway in pancreatic cancer may provide 
a therapeutic strategy by treating the primary tumor,  systemic metastases and targeting CSC by Hh 
pathway inhibition. Other postulated mechanisms for clin ical benefit using Hh inhibitors in pancreatic 
cancer include modulation of surrounding stroma and in creased drug delivery of cytotoxic agents into 
tumor tissue. 
 In a phase I study in patients with advance soli d tumors GDC-0449 was well tolerated with no dose 
limiting-toxicities. We hypothesize that the combin ation of GDC-0449 with chemotherapy (gemcitabine 
and nab-paclitaxel) will provide clinical benefit as measured by progression free survival in patients 
with metastatic previously untre ated pancreatic adenocarcinoma. 
  
Primary Objective (s) 
 To evaluate whether the addition of a vismode gib (GDC-0449; Hedgehog Pathway Inhibitor) to 
cytotoxic chemotherapy (Gemcitabine and nab- paclitaxel) in patients with metastatic 
adenocarcinoma of the pancreas increas es progression free survival (PFS).   
 
Secondary Objectives (s) 
 To evaluate overall survival 
 To evaluate for tumor response (complete res ponse, partial response), stable disease and 
progressive disease  
 To evaluate the safety of the combination gemcitabine + nab-paclitaxel with GDC-0449 in 
patients with metastatic ade nocarcinoma of the pancreas 
Protocol Amendment 12, date December 4, 2014 5 To evaluate the presence of pa ncreatic CSC in tissue and periphe ral blood and it s changes with 
therapy using above combination 
 To evaluate changes of Hh signaling pathway using GDC-0449 
 To evaluate if serum and/ or tumor biomar kers predict clinical benefit with GDC-0449 
 
Primary Endpoints(s)  
 PFS as defined by the time from first therapy received to the earlier documented disease 
progression or death from any cause. PFS will be de termined by the investigator. Imaging studies 
to assess response will be evaluated by expe rt radiologists using RECIST 1.1 criteria. 
 
Secondary Endpoint(s) 
 
Efficacy endpoints 
 Overall survival from the time of cycle 1, day 1 until death from any cause 
 Objective tumor response (partial  response, complete response) or stable disease based on CT 
scans (or MRI scans if patient is allergic to cont rast agent or has some other contraindication to a 
CT scan). These will be evaluate d according to RECIST 1.1 criteria. 
 
Safety endpoints 
 Number of grade 3 and 4 toxicities according to  National Cancer Ins titute Common Toxicity 
Criteria for Adverse Events (NCI CTCAE; Ve rsion 4.0) that occur after Cycle 1, day 1 
 Incidence, nature and severity  of all adverse events that occur on or after Cycle 1, Day 1 
 
Correlative studies endpoints 
 Quantitative pancreatic CSC identification using functional assays and phenotypic assays. 
Functional assays include immunohi stochemistry or RT-PCR for AL DH bright cells. Phenotypic 
assays include immunohistochemi stry, quantitative RT-PCR or fl ow cytometry for pancreatic 
cancer stem cell markers (CD24+/CD44+/ESA+ and CD133+) in tissue biopsy and peripheral 
blood.  
 Semi-quantitative measurement of Hh ligand expr essions in pre-post trea tment biopsies and Hh 
signaling pathway downregulation as  measured by Gli 1 and Patch 
 Biomarker changes as measured by serum CA19-9 and plasma and tumor SPARC  
 
 
  
Protocol Amendment 12, date December 4, 2014 6Study Design: 
 
This is an open-label, single arm, multi-cente r, Phase II trial to evaluate progression free  
survival in patients with metastatic adenocarcinoma  of the pancreas treated with a Hh inhibitor and 
chemotherapy. This trial will also  assess for objective tumor response and ev aluate changes in 
pancreatic CSC markers and Hh  signaling pathway inhibition us ing the Vismodegib (GDC-0449; 
hedgehog pathway inhibitor) in combination with chemotherapy (gemcitabine and nab-paclitaxel). 
Following the determination of eligibility pa tients will receive the following treatment:  
1.  One cycle of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 (28 
days cycle) then 
2.  Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days cycle 
in combination with oral GDC-0449 150 mg daily 
 Number of Patients:  72 patients 
 
 
Duration of Intervention and Evaluation 
 
Patients may continue on treatment regimen until th ey experience progressive disease or unacceptable 
toxicity, require palliative radiot herapy, withdraw consent or the physic ian feels it is no longer in their 
best interest to continue on treatment. If a patient is removed from treatment he/she will be followed to 
gather information of overall survival.  If an individual is lost to follow- up, then they will be censored at 
the time of the last contact.  
Statistical Methods  
 
The patient demographics will be described using su mmary statistics (mean, S. D., median, range, count, 
percentage).  Kaplan-Meier techniques will be us ed to summarize time to event outcomes (progression 
free survival and overall survival) graphically and to estimate th e median and one-year survival 
outcomes with 80% confidence intervals.   The pe rcent change from the pre to the post-treatment 
biopsies will be calculated for th e correlative outcomes.  The outco mes will be su mmarized using 
means, standard deviations, medians and ranges.    The study is power to determine whether the addi tion of GDC-0449 provides benefit over chemotherapy 
alone (gemcitabine and nab- paclitaxel).  The primary outcome is pr ogression free survival.  In previous 
trial using chemotherapy with gemcitabine and nab-pa clitaxel, the median progression free survival was 
5.5 months. We have powered our study with the assumption of 24 months accrual. Based upon these 
assumptions, a sample size of 72 patients will have an  80% power to detect an increase in the median 
progression free survival to 7.15 months from the null rate of 5.5 months using a one sided type 1 error 
of 0.10.  Up to an additional 10% wi ll be accrued in order to control for loss to follow-up.  The expected 
accrual rate is between 4-5 patients per month.  
  
Protocol Amendment 12, date December 4, 2014 7Funding, Regulatory, and Feasibility Issues:  Genentech will provide GDC-0449. Abraxis will provide 
nab-paclitaxel. Gemcitabine will be  obtained by commercial means.  
 Patient Acceptability/Ethics and Concepts Issues:  None 
   
Contents 	
SCHEMA ........................................................................................................................ ................ 1  
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS ................................................. 10  
1. OBJECTIVES .................................................................................................................... ... 12 
1.1. Primary Objectives ......................................................................................................... 12  
1.2. Secondary Objectives ..................................................................................................... 12  
2. BACKGROUND .................................................................................................................. 1 2 
2.1  Study Disease ................................................................................................................  12 
2.2    Rationale for this study ............................................................................................... ..... 15 
2.3    Correlative Studies .................................................................................................... ....... 16 
2.4  Study Drugs .................................................................................................................. . 16 
2.4.1 GDC-0449 ............................................................................................................... 16  
2.4.2 nab-paclitaxel .......................................................................................................... 20  
2.4.3 Gemcitabine: ............................................................................................................ .... 22 
3. PATIENT SELECTION ....................................................................................................... 23  
3.1  Eligibility Criteria .........................................................................................................  23 
3.2  Exclusion Criteria .......................................................................................................... 25 
3.3  Inclusion of Women and Minorities .............................................................................. 27  
4. REGISTRATION PROCEDURES .......................................................................................... 27  
4.1 General Guidelines ........................................................................................................ ...... 27 
4.2 Data Submission Procedures............................................................................................... 2 7 
5. TREATMENT PLAN ........................................................................................................... 29  
5.1 Time and Events Schedule ..................................................................................................  29 
5.1.1 Screening and Pre-study Assessments ......................................................................... 30  
5.1.2 Assessments during the study period ........................................................................... 31  
5.1.3 Beginning of each cycle ............................................................................................... 3 2 
Protocol Amendment 12, date December 4, 2014 85.1.4 Follow up assessments ................................................................................................. 3 3 
5.2  Agent Administration .................................................................................................... 36  
5.2.1 GDC-0449 ................................................................................................................ .... 36 
5.2.2 nab-paclitaxel .......................................................................................................... ..... 37 
5.2.3 Gemcitabine ............................................................................................................. .... 37 
5.2.4      Other Modality (ies) or Procedures ..................................................................... 38  
5.3 General Concomitant Medication a nd Supportive Care Guidelines ................................... 38  
5.3.1 GDC-0449 ................................................................................................................ .... 38 
5.3.2 Other Considerations ................................................................................................... 41 
5.4 Duration of Therapy ....................................................................................................... 42  
5.5 Duration of Follow Up ................................................................................................... 42  
5.6 Criteria for removal from Study ..................................................................................... 42  
6. DOSING DELAYS/DOSE MODIFICA TIONS/DOSE OMISSIONS ................................ 42  
6.1 GDC-0449 .................................................................................................................. ......... 43  
6.2 Gemcitabine and nab-Paclitaxel ......................................................................................... 43  
7. ADVERSE EVEN TS ............................................................................................................ 48  
7.1 Adverse Events (AE) definition .......................................................................................... 4 8 
7.2 Serious Adverse Events (SAE) Definition .......................................................................... 49  
7.3 Grading and Assessing Causality ........................................................................................ 50  
7.4 Potential Risks for Study Drugs .......................................................................................... 53 
7.5 Reporting Adverse Events ..................................................................................................  58 
7.6  Safety Reporting Require ments for IND Holders .............................................................. 62  
7.7 Data and Safety Monitoring Plan ........................................................................................ 63  
8. PHARMACEUTICAL INFORMATION ................................................................................. 64  
8.1 GDC-0449 ......................................................................................................................  65 
8.2 nab-Paclitaxel ................................................................................................................ . 66 
8.3  Gemcitabine ..................................................................................................................  69 
8.3  Study Medication Accountability and Destruction ....................................................... 71  
(GDC-0449 and nab-Paclitaxel) ............................................................................................... 7 1 
9. CORRELATIVE/SPECIAL STUDIES ................................................................................ 71  
10. STUDY CALENDAR ....................................................................................................... 78  
11. MEASUREMENT OF EFFECT........................................................................................ 79  
Protocol Amendment 12, date December 4, 2014 912. STATISTICAL CONSIDERATIONS............................................................................... 87  
REFERENCES .................................................................................................................... ......... 92  
APPENDICES .................................................................................................................... .......... 94  
APPENDIX A .................................................................................................................... ....... 94 
APPENDIX B .................................................................................................................... ....... 95 
APPENDIX C .................................................................................................................... ......... 1 
APPENDIX D .................................................................................................................... ......... 2 
APPENDIX E .................................................................................................................... ......... 3 
APPENDIX F..................................................................................................................... ......... 7 
APPENDIX G: PROTOCOL  SIGNATURE PAGE .................................................................. 8  
APPENDIX H: MEDICAL MONITOR SIGNATURE PAGE .................................................. 9  
APPENDIX I: AMENDMENTS SUMMARIES ..................................................................... 10  
       Amendment # 1, June 8, 2010 ............................................................................................ ... 10 
       Amendment 2, June 11, 2010 ............................................................................................. ... 10 
       Amendment 3, July 6, 2010 .............................................................................................. ..... 10 
       Amendment 4, August 16, 2010 ........................................................................................... . 11 
       Amendment 5, February 1, 2011 .......................................................................................... . 13 
       Amendment 6, August 3, 2011 ............................................................................................ .. 13 
       Amendment 7, January 11, 2012……………………………………………………………15 
       Amendment 8, February 7, 2012…………………………………………………………....15        Amendment 9, February 22, 2013…………………………………………………………..16        Amendment 10, April 16, 2013……………………………………………………………..16        Amendment 11, August 16, 2013…………………………………………………………...16        Amendment 12, December 4, 2014…………………………………………………………16  APPENDIX J: Genentech SAE Fax Cover Sheet…………………………………………..17&18 
       
APPENDIX K: TASTE AND SM ELL QUESTIONNAIRES…………...………………….19-26 
 
          
Protocol Amendment 12, date December 4, 2014 10 
 
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS 
 
Abbreviation Definition 
ADR   Adverse Drug Reaction 
AE          Adverse Event 
ALDH Aldehyde dehydrogenase 
ALT (SGPT)        Alanine Aminotransferase (SGPT) 
ANC   Absolute Neutrophil Count 
ASCO American Society of Clinical Oncology 
AST (SGOT)       Aspartate Aminotransferase (SGOT) 
β-hCG                 
                    Beta subunit of human chorionic gonadotropin 
(hCG) 
BSA Body Surface Area 
BUN      Blood Urea Nitrogen 
CA19-9               Carbohydrate Antigen 19-9 
CBC Complete Blood Count 
CI   Confidence Interval 
CrEL Cremophor-EL 
CRAB Cancer Research and Biostatistics 
CR     Complete Response 
CRO Clinical Research Organization 
CSC Cancer Stem Cells 
CT    Computed Tomography 
CTC Circulating Tumor Cells 
CTCAE                             Common Terminology Criteria for Adverse 
Events 
DLT Dose Limiting Toxicity 
ECG Electrocardiogram 
ECOG Eastern Cooperative Oncology Group 
eCRF Electronic Case Report Form 
EOS End of Study 
FDA   Food and Drug Administration 
G-CSF              Gr anulocyte Colony-Stimulating Factor 
Hh Hedgehog 
Hgb   Hemoglobin 
IB   Investigator Brochure 
ICF                   Informed Consent Form 
IHC Immunohistochemistry 
IND Investigational New Drug 
IRB Institutional Review Board 
IV Intravenous(ly) 
MRI                   Magnetic Resonance Imaging 
Protocol Amendment 12, date December 4, 2014 11MTD Maximum Tolerated Dose 
NCI National Cancer Institute 
NIH National Institutes of Health 
NCI CTCAE National Cancer Institute Common 
Terminology Criteria of Adverse Effects 
PD Progressive Disease 
PE   Paraffin Embedded 
PFS   Progression-free Survival 
PK     Pharmacokinetics 
PR Partial Response 
PT Prothrombin Time 
PTCH Patched 
PTT Partial Thromboplastin Time 
RECIST              Respons e Evaluation Criteria in Solid Tumors 
SAE   Serious Adverse Event 
SD     Stable Disease 
S.D.                  Standard Deviation 
SGOT   Serum Glutamic Oxaloacetic Transaminase 
SGPT Serum Glutamic Pyruvic Transaminase 
SKCCC Sidney Kimmel Compre hensive Cancer Center 
SMO Smoothened 
SPARC             
                 Secreted Protein Acidic a nd Rich in Cysteine (a 
glycoprotein) 
ULN Upper Limit of Normal 
US United States 
WBC White Blood Cell 
  
  
Protocol Amendment 12, date December 4, 2014 121. OBJECTIVES 
 
1.1. Primary Objectives 
 
 To evaluate whether the addition of a Vismodegib (GDC-0449; Hedgehog Pathway 
Inhibitor) to cytotoxic chemotherapy (Gemcitabine and nab-paclitaxel) in patients with  
metastatic adenocarcinoma of the pancreas in creases progression free survival (PFS).   
 
1.2. Secondary Objectives 
 
 To evaluate overall survival 
 To evaluate for tumor response (complete res ponse, partial response), stable disease and 
progressive disease  
 To evaluate the safety of the combination gemcitabine + nab-paclitaxel with GDC-0449 in 
patients with metastatic ade nocarcinoma of the pancreas 
 To evaluate the presence of pancreatic cancer stem cells in tissue a nd peripheral blood and its 
changes with therapy with above combination 
 To evaluate changes of hedgehog signali ng pathway with ther apy with GDC-0449 
 To evaluate if serum and/ or tumor biomar kers predict clinical benefit with GDC-0449 
 
 
2. BACKGROUND 
 
2.1  Study Disease 
 
Pancreatic cancer continues to be one of the most dismal malignancies in the gastrointestinal tract and remains the fourth leading cause of cancer rela ted mortality. In the United States an estimated 
total of 42,470 pancreatic cancers are expected  in the year 2009 with 35, 240 estimated deaths 
among these patients[1].  The majori ty of patients with pancreatic adenocarcinoma have evidence of 
metastatic disease at presentation with a median surv ival of 6 months [2].  More recent strategies 
have focused on improving the efficacy of Gemcitabi ne by either improving the method of delivery 
or by combining Gemcitabine with other non-cross re sistant agents. However, the clinical benefits, 
response rates, and the duration of  responses have been modest.  
 The most recent advance for the management of th is disease was achieved with the combination of 
gemcitabine and nab-paclitaxel. Th e phase I/ II study with this combination was presented at the 
American Society of Clinical Oncology (ASCO) 2009 annual meeting and demonstrated promising 
results with improvement of response rate and overa ll survival [3].  Given these findings a phase III 
trial with that particular combination is unde r way. Novel therapeutic approaches and a better 
understanding of disease’s biology for tumo r driven disease progression are needed. 
 
  
Protocol Amendment 12, date December 4, 2014 13Hedgehog Signaling pathway in pancreatic cancer  
 
The Hedgehog (Hh) signaling pathway regulates epit helial and mesenchymal interactions in a 
variety of tissues during mamma lian embryogenesis[4]. The Hh ligand in the extracellular space 
binds to Patched (PTCH), a 12 pass transmembrane receptor on the surface of cells. Hh binding 
relieves the inhibitory effect  of PTCH on Smoothened (SMO), a 7 pass transmembrane domain 
protein and a member of the G-protein coupled  receptor superfamily. Signal transduction by SMO 
then leads to the activation and nuc lear localization of GLI1 transc ription factors and induction of 
Hh target genes, many of which ar e involved in proliferation, surviv al and angiogenesi s in different 
malignancies.  Investigations suggest that the Hh  signaling pathway is persistently activated in several malignancies 
including pancreatic ade nocarcinoma [5], [6].  Berman and colleagues demonstrated that upper 
gastrointestinal malignancies derived from the esophagus, biliary tract, stomach, and pancreas 
display increased Hh pathway activity. Cell grow th was mediated by endoge nous expression of Hh 
ligands through demonstration of th e growth inhibitory activity of  Hh-neutralizing antibody and the 
growth stimulatory activity of exogenously added Hh ligand [6]. Hh pathway activation is mediated 
either through aberrant ligand overexpression by panc reatic cancer cells [5], aberrant activation of 
Hh signaling pathway in the surrounding stromal co mpartment through a paracrine model [7-9] or  
alternative proposed mechanism through sile ncing of the pathway inhibitor human Hh interacting 
protein by  promoter hypermethylation [10]. The Hh signaling promotes epithelial-mesenchymal 
transition and increases motility and invasiveness of pancreatic cancer cells. Several genes have been 
identified as potential hedgehog do wnstream targets in the setting of pancreatic cancer including 
BIRC3, TGM2, PLAU, and BMP2 and these ge nes have been previously found to be 
mechanistically involved in tumor cell proliferation, invasion/migrati on, and metastatic tumor spread 
[11].  
 
Relation with pancreatic cancer stem cells 
 
More recent interest has emerged w ith the identification of cancer st em cells (CSC) and it is believed 
that these cells can elicit tumor progression and meta stases. In pancreatic can cer two different subset 
of CSC have been identified. Fi rst Li et al identified CD24+/CD 44+/ESA+ cells [12]. These cells 
composed 0.2-0.8% of all pancreat ic cancer cells, were highly tumo rigenic and possessed the ability 
of self-renew and produce a differentiated progeny. More recently, Hermann and colleagues 
identified a subset of CD133+ cells and found that  this marker also discriminates for cells in 
pancreatic cancer and pancrea tic cell lines with enhanced proliferative capacity [13].  
 
The clinical significance of pancreatic CSC is related to resistance to available therapeutic 
approaches. In other malignancie s including chronic myeloid leuke mia, brain tumors, and colon 
cancer, stem cells have been found to be resistan t to conventional chemotherapy and radiation. In 
pancreatic cancer some evidence suggests resi stance of pancreatic CSC to chemotherapy and 
radiation in cell lines. Hermann and colleag ues found that CD133+ popul ations in the L3.6 
pancreatic cancer cell line were enriched after exposure to gemcitabine. Treatment with ionizing 
radiation and the chemotherapeutic agent ge mcitabine resulted in enrichment of the 
CD44+CD24+ESA+ population in human pancreatic ca ncer xenografts. These fi ndings indicate that 
novel therapies that target  CSC may be crucial for successful an ti-cancer therapy. One approach to 
Protocol Amendment 12, date December 4, 2014 14do so is by identifying signaling pathways that may sustain such stem cells and developing targeted 
therapies against it.  The hedgehog signaling pathway plays a role in ma intaining subpopulations of cancer cells with 
increased tumorogenic potential  [12, 14].  Several points s uggest an element of hedgehog 
dependence in a subset of pancreatic cancer cel ls with tumor-initiating properties. First Sonic 
Hedgehog ligand (SHH) might be specifica lly overexpressed in a subpopulation of 
CD24+/CD44+/ESA+ pancreatic cancer cells with increased tumorigenic potential and other stem 
cell-like properties [12]. Second, overexpression of Gli1, the major activating hedgehog transcription 
factor, is observed at the mRNA  level in a subset of SSC-low  /aldehyde dehydrogenase (ALDH)-
“bright” cells with increa sed clonogenic potential [12]. 
 
Pharmacologic blockade of Hh in pancreatic cancer 
 
Several small molecules with capacity of Hh pathway inhibition have  been studied in  
the preclinical setting.  
 
Studies with Cyclopamine: Cyclopamine is a steroidal alkaloid  that inhibits Hh signaling through 
direct interaction with SMOH. In vitro  Hh blockade with cyclopamine in  pancreatic cancer cell lines 
led to tumor growth inhibition [11]. In vivo,  cyclopamine retarded the growth of s.c. pancreatic 
cancer xenografts [5, 6], prolonge d the median survival of tran sgenic mouse models, [11], and 
prevented metastatic tumor spread using murine orthotopic xenograft models  of human pancreatic 
cancer [14].  Cyclopamine caused downregulation of the Hh targ et genes Gli1 and Ptch in 
genetically engineered mouse mode ls of pancreatic cancer [11]. 
 
Studies with IPI-269609: Feldman and colleagues te sted IPI-269609, another inhibitor of the Hh 
pathway, using in vitro  and in vivo  model systems. Single agent IPI inhibited systemic metastases in 
orthotopic xenografts established fr om human pancreatic cell lines. Hh blockade had minimal effect 
on primary tumor volume, but the phenotype observed  within the treated primary tumor showed a 
reduction in the population of aldehyde dehydrogenase -bright cells (which has been previously 
identified as clonogenic tumor-initiating populati on in pancreatic cance r). Selective ex-vivo 
depletion of aldehyde dehydrogenase-bright cell s with IPI-269609 was accompanied by significant 
reduction in tumor engraftment rates in athymic mice. Their data suggested that pharmacologic 
blockade of aberrant Hh signaling might be an effective strategy for inhibition of systemic 
metastases in pancreatic cancer by targeting subs ets of cancer cells with tumor-initiating, or CSC 
properties[15].   Studies with GDC-0449: GDC-0449 is a small-molecule antagonist of the Hh signaling pathway 
that binds to and inhibits SMO,  blocking Hh signal transduction. In vitro and in vivo  preclinical 
studies have demonstrated i nhibition of Hh signaling followi ng GDC-0449 administration.  GDC-
0449 has demonstrated anti-tumor activity against a variety of primary human tumor xenografts and 
tumor cell line xenograft models (Investigator Brochure) . These include CRC, in  which activity was 
seen both as a single agent and in combination with  cytotoxic agents, as we ll as in primary xenograft 
models of pancreatic carcinoma.  In murine models, the anti-tum or effect of GDC-0449 correlates 
with blockade of the Hh pathway measured  by reduction in the expression of stromal Gli1 mRNA, 
which is itself a transcriptional target of Hh  signaling. Specifically, sustained reduction of Gli1 
Protocol Amendment 12, date December 4, 2014 15expression is associated with inhibition of tumor growth. Nonclinical efficacy studies suggest that 
sustained inhibition of Hh signaling is necessary to achieve an anti-tumor effect. For this reason, regimens of continuous dosing over 28 days are be ing examined. In a phase I studies, in patients 
with advance solid tumors, GDC-0449 was well to lerated with no dose lim iting-toxicities.  The 
recommended Phase II dose is 150 mg by oral ad ministration on a continuous  daily schedule[16] 
[17]. Phase II studies using GDC -0449 150 mg orally once daily on  a continuous schedule are 
ongoing in first-line metastatic CRC, recu rrent ovarian cancer,  and advanced BCC. 
 
Pharmacologic blockade of Cancer Stem Cells: Jimeno et al used a direct pancreatic cancer 
xenograft model as a platform for CSC therapeu tic development. Tumors from a gemcitabine-
sensitive xenograft were treated with gemcitabine induction firs t, and randomized, after tumor 
regression to continuing treatment with gemcitabi ne, a Hh inhibitor alon e (cyclopamine) or in 
combination with gemcitabine. They tested marker s described in association with CSC such as 
CD24, CD44, ALDH, nestin and the hedgehog pathwa y. After induction with gemcitabine, treated 
tumor showed enrichment in CSC markers such as ALDH and CD24. Subsequently, combined treatment with gemcitabine and Hh inhibitor (c yclopamine) induced further tumor regression, 
decreased CSC markers and Hh signaling. Hh inhibito rs as part of a dual compartment therapeutic 
approach were able to further reduce tumor grow th and decreased both stat ic and dynamic markers 
of CSC[18]. 
 
Other proposed mechanisms for Hh inhibitors in pancreatic cancer 
 
In addition to the CSC theory, other mechanisms for potential clinical benefit using Hh inhibitors in 
the setting of pancreatic cancer have been described. The Hh si gnaling pathway is active in a 
paracrine model in which the tumor cells secret e Hh ligand to induce tumor-promoting Hh target 
genes in adjacent stroma [7-9]. Olive and collea gues found that IPI-926, a small molecule inhibitor 
of SMO, can be a strategy to enhance drug delivery and overcome the well-known chemoresistance 
of pancreatic cancer if combined with gemcitabine in genetically engineered  models of pancreatic 
cancer. IPI-926 targets the Hh path way in the stroma of malignant  tumors reducing the fibrotic 
reaction that occurs with  pancreatic cancer. IPI-926 was able to increase the intratumoral vascular 
density and increase intratumoral c oncentration of gemcitabine [19].  
 
2.2    Rationale for this study 
 
The emergence of new small molecules with capac ity of blocking the Hh signaling pathway provides 
a novel therapeutic approach in pancreatic ade nocarcinoma treating the primary tumor, stroma, 
systemic metastases and CSC by Hh pathway inhibi tion. These preclinical fi ndings and the lack of 
significant effective therapies in patients with metastat ic pancreatic cancer resulted in our interest to 
do this clinical trial.  We propose an open label pha se 2 clinical trial eval uating the progression free 
survival (PFS) in patients with previously untreated me tastatic pancreatic adenocarcinoma. Given 
the promising survival advantage on recent clinical  trial with the combinat ion of gemcitabine and 
nab-paclitaxel both agents will be included in th is study and will be c onsidered our historical 
control[20]. The combination of ge mcitabine with our without nab- Paclitaxel is currently been 
evaluated in a multi-institutional phase III clinical trial.   We hypothesize that the combination of cytotoxic ag ents (gemcitabine and na b-paclitaxel) with the 
Protocol Amendment 12, date December 4, 2014 16Hh inhibitor GDC-0449 may increase PFS in patie nts with previously untreated metastatic 
adenocarcinoma of the pancreas. We will include correlative stud ies to attempt to understand the 
stem cell biology and mechanism for any observed clin ical benefits with th e use of Hh inhibitor 
GDC-0449. We will evaluate the changes in Hh path way downregulation and changes in pancreatic 
CSC markers with pre and post treatment biopsies. Fi nally this study will also evaluate the incidence 
of detectable Hh expression in pancreatic adeno carcinoma to assess whether Hh expression might be 
used as a predictive factor for GDC-0449 clinical benefit, which may be n ecessary for appropriate 
patient selection in future trials. Given the lack of  prior experience with the combination of the three 
drugs, the he safety of GDC-0449 when combin ed with chemotherapy gemcitabine and nab-
paclitaxel will also be monitored continuously du ring the study by evaluating adverse event rate.  
  
2.3    Correlative Studies 
 
We will evaluate the changes in the pre- and po st-treatment Hh signaling pathway down regulation 
and the presence of pancreatic CSC. The biopsies will be obtained by core biopsy or fine needle aspiration (FNA) both pre and post treatment. The findi ngs will be correlated with clinical response 
to GDC-0449.  1. To identify presence of pancreatic cancer stem cells in biopsy samples 
 By functional assay with Aldehyde de hydrogenase (ALDH) bright cells  
by immunohistochemistry if core biopsy is obtained or RT-PCR for ALDH if fine needle 
aspiration is obtained. 
 By phenotypic assays CD24+/ CD44+/ESA+ and CD133+ by immunohistochemistry if core 
biopsy is obtained or by quantitativ e RT-PCR if FNA is obtained.     
 2. To evaluate for hedgehog signaling pathway downregulation 
 
 Evaluate for the Hh target genes Gli1 a nd Ptch at the mRNA level in primary tumor 
 
3. Circulating pancreatic can cer stem cells in periphera l blood by flow cytometry 
 
      
2.4  Study Drugs 
 
2.4.1 GDC-0449 
 
GDC-0449 is a small-molecule inhibitor of the Hh signal  pathway with a molecular 
weight of 421.30 g/mol. The International Un ion of Pure and Applied Chemistry name 
for GDC-0449 is 2-chloro- N-(4-chloro-3-pyridin-2-yl- phenyl)-4-methanesulfonyl-
benzamide. Its structure is shown in Figur e 1. GDC-0449 binds to and inhibits SMO that 
Protocol Amendment 12, date December 4, 2014 17results in blocking of the Hh signal. GDC-0449 has proven to be efficacious in 
nonclinical tumor models of both muta ted and ligand-overexpressing tumors. 
 Figure 1: Clinical Structure of GDC-0449 
 
 
GDC-0449 is a small-molecule antagonist of the Hh signal pathway. Specifically GDC-
0449 has demonstrated anti-tumor activity ag ainst a variety of primary human tumor 
xenografts and tumor cell line xenograft models (Investigat or Brochure). These include 
CRC, in which activity was seen both as a single agent and in  combination with cytotoxic 
agents, as well as in primary xenograft mode ls of pancreatic carcinoma (Investigator 
Brochure). In murine models, the anti-t umor effect of GDC-0449 correlates with 
blockade of the Hh pathway measured by reduction in the expression of stromal Gli1 
mRNA, which is itself a transcriptional targ et of Hh signaling. Specifically, sustained 
reduction of Gli1 expression is associated with  inhibition of tumor growth. 
  
Preclinical studies with GDC-0449:  A range of preclinical st udies in the appropriate 
species have been completed with GDC-0449 including single  and repeat-dose toxicity 
studies and toxicity studies.  A thorough discussion of these is included in the 
Investigator’s Brochure (IB). Preclini cal studies had combined GDC-0449 with 
gemcitabine in a pancreatic model without  any evidence of antagonism or unexpected 
toxicity. 
 
 
Clinical Experience 
 
GDC-0449 was studied in Phase I and is currently undergoing Phase II studies 
(Investigator Brochure, Edition 3).   
Phase 1 study with GDC-0449 

Protocol Amendment 12, date December 4, 2014 18 
In the Phase I study (SHH3925g), GDC-0449 wa s given orally on a continuous daily 
schedule to patients with advanced solid malig nancies that were refractory to standard 
therapy or for whom no standard therapy exis ts. Enrollment in this study occurred in two 
stages. Stage 1 was the dose-escalation porti on of the study, with a “3+3” design and 
modified dose-doubling. The objectiv es for Stage 1 were to asse ss safety, tole rability, and 
pharmacokinetics/pharmacodynamics of GDC-0449 and to determine the MTD. In Stage 
1, GDC-0449 is administered or ally as a single dose on Da y 1, followed by a 7-day PK 
observation period, and then continues on Day 8 as a once-daily regi men on a continuous 
28-day schedule (Cycle 1 = 35 days). Patients  who withdraw without  DLT in the first 
cycle are replaced. Stage 2 had th ree cohorts to collect additi onal safety data, preliminary 
efficacy in advanced BCC, and safety/PK data  with the new Phase II drug product (150 
mg). Patients treated in Stage 2 received GDC-0449 orally once daily on a continuous, 
uninterrupted 28-day schedule.   The phase 1 study SHH3925g enrolled a total of 68 patients by December 2008 and has been completed to date. The recomme nded Phase II dose is 150 mg GDC-0449 given 
orally on a continuous daily schedule. Dose-lim iting toxicities (DLTs) were not seen with 
GDC-0449; however, reversible Grade 3 fati gue and asymptomatic hyponatremia have 
been reported beyond the DLT window.  Study SHH4318g was conducted with a single re fractory medulloblastoma pediatric 
patient and has also been completed. Study SHH4433g was a healthy volunteer 
pharmacokinetic (PK) study to further charac terize and understand the unique plasma PK 
profile observed during the Phase I dose-esca lation trial, in which GDC-0449 displayed 
an unusual pharmacokinetic profile with  high sustained micromolar plasma 
concentrations and a long terminal half-life. 
 
Potential Risks 
 
GDC-0449 has been given to 68 patients in  the Phase I study SHH3925g. The following 
side effects were observed in a small numbe r of patients and may be related to GDC-
0449: changes in or lack of taste sensati on for food; loss of appetite; heartburn and 
stomach upset; nausea; vomiting; weight loss;  decrease in sodium and magnesium levels 
in the blood; severe fatigue; loss of hair on the scalp, body, eyelashes, and face; joint 
pain; acne-like skin rash; skin peeling; nu mbness; and muscle spasms (cramps). There 
may be risks that have not yet been identif ied and that were not predicted by nonclinical 
testing.   In this Phase I clinical study, Grade 3 adverse events attribut able to study drug have been 
reversible and minimal in number. No Grad e 4 or 5 events related to study drug have 
been reported. The safety profile of GDC-0449 supports single-agent studies of this drug 
in the Phase II setting.   Notable findings in the nonclini cal toxicity studies included tr emors, alopecia, follicular 
cysts and pilomatricoma, effects on male and female reproductive parameters, and 
Protocol Amendment 12, date December 4, 2014 19alterations of epiphyses and in cisors in rats, as well as d ecreased platelet count and red 
cell mass, increased serum cholesterol, alope cia, localized skin inflammation, and paw 
swelling in dogs. Because of the relatively slow clearance of GDC-0449 in humans, the 
exposures achieved at the highe st doses that were tolerated in the repeat- dose toxicity 
studies were comparable to those that are typically observed in patients. However, with the exception of pharmacologically mediated alopecia, the toxicities evident in the 
nonclinical studies were not cl early correlated with drug-related adverse events in the 
Phase I clinical trial.  In general, the results of  the nonclinical toxicity st udies conducted with GDC-0449 
demonstrate a favorable safety profile to s upport the proposed clinical  trials. The finding 
of pilomatricoma (a benign, cutaneous neoplasm that is readily excisable in humans) at a 
low incidence at the high dose level in the chronic rat toxic ity study is not considered to 
substantially impact the risk/benefit profile for cl inical trials in patients with late-stage or 
advanced cancers.  As of 14 July 2009, there has been one IND safe ty report from this study.  This Grade 3 
atrial fibrillation AE was assessed as serious, unexpect ed, and related to study drug. 
 As of January 2011 the following list of IN D safety reports have been submitted as 
related to GDC-0449: atrial fibrillation, c onvulsion, dyspnea, lung infiltration, pulmonary 
embolism, diarrhea, renal failure, dehydration, abdominal pain, parano ia, gastroenteritis, 
cholestasis, elevated hepatic  enzymes, pneumonia, cholesta sis, cardiac failure, syncope. 
One episode of sudden death assessed due to myocardial infart was reported as non-
related by investigator  and assessed as re lated by Genentech. 
 
The toxicities possibly related to GDC-0449 repor ted in previous phase 1 clinical trial 
included:  
 
• Constitutional:  Fatigue, weight loss 
 • Cardiovascular : atrial fibrillation 
 • Gastrointestinal:  anorexia, dyspepsia (heartburn or stomach upset), nausea, vomiting 
 
• Metabolic:  hyponatremia, hypomagnesemia 
 
• Neurologic:  hypoesthesia (sensory neuropathy), dysge usia (taste alteration), numbness 
 • Musculoskeletal:  arthralgia, muscle spasms 
 • Skin and subcutaneous tissue disorders: skin exfoliation, al opecia (scalp, body, 
eyelashes and face), dermatitis acneiform 
 
Reproductive and developmental Toxicity 
 
Protocol Amendment 12, date December 4, 2014 20Studies to assess the reproduc tive and developmental toxi city of GDC-0449 have not 
been conducted to date. However, based on the central role of the Hh signaling  pathway 
in embryogenesis and published studies w ith other small-molecule Hh pathway 
inhibitors, GDC-0449 is expected to be te ratogenic to humans, and pregnant women 
should avoid exposure to the compound. The teratogenic potential of Hh pathway 
inhibitors has been well established with observational and experimental studies in 
animals. A description of all these observati onal studies is included in the investigator 
brochure. 
 
Women who are pregnant, plan to  become pregnant, or are l actating (during the study or 
for up to 7 months after the last dose) are ex cluded from all clinical studies with GDC-
0449. Pregnancy prevention measures will be undertaken in this study.  Proposed dose for GDC-0449 
 Based on the PK parameters and the lack of  AEs observed, the proposed starting dose for 
oral administration of GDC-0449 to can cer patients is 150 mg/day (92.5 mg/m
2/day) 
 
Other ongoing phase II studies with GDC-0449 
 
Study SHH4429g is an ongoing randomized, pl acebo-controlled, double-blind Phase II 
trial of GDC-0449 added to biochemotherapy standard of care regimens (FOLFOX or 
FOLFIRI chemotherapy with bevacizumab) for first-line metastatic colorectal cancer 
(CRC). The primary goal of this study is  to determine if adding GDC-0449 to the 
standard of care therapy increases antitu mor efficacy as measured by PFS when 
compared with the standard of care therapy alone.  
 
2.4.2 nab-paclitaxel  
 
Nab- paclitaxel is a Cremophor EL-free, album in-bound paclitaxel particle with a mean 
size of approximately 130 nm.  Each 50 mL vial contains 100 mg of paclitaxel, and 
approximately 900 mg of human albumin, as a white to yellow sterile  lyophilized powder 
for reconstitution with 20 mL of 0.9% Sodium Chloride Injection.  
 
Nab- paclitaxel is a unique protein formula tion of a non-crystalline, amorphous form of 
paclitaxel in an insoluble particle state.  It has been developed to  reduce the toxicities 
associated with Taxol (paclitaxel) Injecti on (in which paclitaxel - from the native 
crystalline form - is in solution with Cr emophor EL/ethanol as the solvent) while 
maintaining or improving its chemotherapeutic e ffect.  Nab- paclitaxel has been approved 
in the US, Canada, India, the EU, Korea and China (and is under review in a number of 
other countries) for the treatment of women with metastatic breast  cancer (MBC).  Nab- 
paclitaxel alone and in combination is being evaluated in a number of cancers including: 
metastatic melanoma, pancreatic cancer, cervical cancer and other solid tumors. 
Conditions which are responsive to paclitax el such as non-hematological solid tumor 
malignancies are good clinical candidates fo r treatment with nab- paclitaxel.  
 
Protocol Amendment 12, date December 4, 2014 21Preclinical studies with nab- paclitaxel:  A range of preclinical studies in the 
appropriate species have been completed with nab- paclitaxel  including single and repeat-
dose toxicity studies, carcinoge nicity evaluations, reproductive toxicity assessments, and 
mutagenicity and toxicity st udies.  A thorough di scussion of these is included in the 
Investigator’s Brochure (IB).  
 Preclinical studies comparing nab-paclitaxel to  Taxol demonstrated lower toxicities, with 
a MTD approximately 50% higher for nab-paclit axel compared to Taxol. At equitotoxic 
doses of paclitaxel, nab-paclitaxel was found to  be markedly more efficacious in animal 
models than Taxol.  In an on-going study of nab- paclitaxel in combination with gemcitabine administered 
weekly (Abraxis Protocol CA040; updated results as of October 2008), a total of 41 
patients with advanced metastatic pancreatic cancer were treated with doses ranging from 
100 to 150 mg/m
2
. Though results are preliminary and follow-up is on-going, 27 patients 
(66%) experienced at least 1 treatment-related  AE and 11 (27%) patients experienced at 
least one treatment-emergent SAE.  With the exception of the “Gastrointestinal: 
Dehydration”, “not classified” and “pain: other” categorie s (2 (5%) events each), no 
treatment-emergent SAE categories had more than a single event. 
 Dose delays were mainly due to blood/ bone marrow treatment-related AEs (mostly 
neutrophils). There we re no nab- paclitaxel dose interru ptions due to treatment-related 
AEs, and 2 instances of dose interruptions for gemcitabine (dermatology/skin: injection 
site reaction).  Also, 2 patients had a to tal of 3 treatment-related AEs involving 
blood/bone marrow (neutrophils and platelet s) resulting in dos e reductions and 2 
treatment-related AE resulted in dose discontinuation (gastrointestinal: diarrhea and infection: systemic).  There were 3 treat ment-emergent AEs resulting in death (lung 
infection, systemic infection, and gastro intestinal obstruction), but only systemic 
infection was considered treatment-related.  Patients treated with nab- paclitaxel in combination with gemcitabine had levels of myelosuppression cons istent with those 
expected following treatment with taxanes.     
Potential Risks for nab- paclitaxel based on prev ious clinical studies 
 
Nab- paclitaxel is not formulated in Cremoph or and thus the risk of hypersensitivity 
reactions is much less than that of Taxol. Th e major risks of nab- paclitaxel have been 
assessed in clinical trials in patients with a variety of malignances and reflect the known 
toxicities of paclitaxel.  See the IB for a comp lete description of all toxicities reported in 
conjunction with nab- pacl itaxel administration. 
 
The most common toxicities reported in pr evious clinical trials included:  
 
•  Myelosuppression, predominantly neutropenia . Grade 4 neutropenia was reported 
and typically resolved in < 7 days and did not  require colony stimul ating factor support.  
 
•  Peripheral neuropathy, predominantly sensory . Grade 3 peripheral neuropathy 
Protocol Amendment 12, date December 4, 2014 22was reported and typically improved to Grade 1 or 2 within 21 days of interrupting the 
nab-paclitaxel dose. Following resolution of the peripheral neuropathy to acceptable 
levels, clinicians were able to restart na b-paclitaxel dosing at a lower dose levels.  
 
•  Nausea and vomiting . Nausea and vomiting were see n, typically at Grade 1 or 2 
levels. This AE responded well to standard anti-emetic regimens.  
 
•  Myalgias and arthralgias . Myalgias and arthralgias were reported and typically 
were Grade 1 or 2; these were responsiv e to standard acet aminophen-containing 
medication.  •  Mucositis . Mucositis was reported typically Gr ade 1 or 2. It was not dose limiting 
 •  Alopecia . Alopecia was reported by most patien ts and was similar to that seen 
with Taxol. 
 
2.4.3 Gemcitabine:  
 
Gemcitabine is approved for the treatment of  metastatic pancreatic cancer. For more 
information please refer to package insert . The most common toxicities reported with 
gemcitabine are: 
 
• Hematological - In studies in pancreatic can cer, myelosuppression is the dose-
limiting toxicity with Gemzar®, but <1% of  patients discontinued therapy for anemia, 
leukopenia, or thrombocytopenia. Red blood cell  transfusions were required by 19% of 
patients. The incidence of sepsis was le ss than 1%. Petechiae or mild blood loss 
(hemorrhage), from any cause, was reported in 16 % of patients; less than 1% of patients 
required platelet transfusions. Patients s hould be monitored for myelosuppression during 
Gemzar therapy and dosage modified or suspended according to the degree of 
hematologic toxicity.    
• Gastrointestinal  - Nausea and vomiting were co mmonly reported (69%) but were 
usually of mild to moderate severity. Se vere nausea and vomiti ng (WHO Grade 3/4) 
occurred in <15% of patients. Diarrhea was reported by 19% of pati ents, and stomatitis 
by 11% of patients.   
 
 • Hepatic - In clinical trials, Gemzar was associ ated with transient elevations of one 
or both serum transaminases in approximately 70% of patients, but there was no evidence 
of increasing hepatic toxicity with either longer duration of exposure to Gemzar or with 
greater total cumulative dose. Serious hepato toxicity, including liver failure and death, 
has been reported very rarely in  patients receiving Gemzar.   
• Renal  - In clinical trials, mild proteinuri a and hematuria were commonly reported. 
Hemolytic Uremic Syndrome (HUS) has been  reported rarely (0.25%) with the use of 
Gemzar. Renal failure may not be reversible even with discontinuation of therapy and 
dialysis may be required.   
Protocol Amendment 12, date December 4, 2014 23• Fever  - The overall incidence of fever wa s 41%. This is in contrast to the 
incidence of infection (16%) a nd indicates that Gemzar may cause fever in the absence of 
clinical infection. Fever was frequently asso ciated with other flu-like symptoms and was 
usually mild and clinically manageable.   
 
 • Rash  - Rash was reported in 30% of patients.  The rash was typically a macular or 
finely granular maculopapular pruritic eruption of mild to moderate severity involving 
the trunk and extremities. Pruritus was reported for 13% of patients.   
 
• Pulmonary - In clinical trials, dyspnea, unrelat ed to underlying di sease, has been 
reported in association with Gemzar therapy.  Dyspnea was occasion ally accompanied by 
bronchospasm. Pulmonary toxicity has been  reported with the use of Gemzar. The 
etiology of these effects is  unknown. If such effects develop, Gemzar should be 
discontinued. Early use of supportive care  measures may help ameliorate these 
conditions. 
 
• Edema : Edema (13%), peripheral edema (20%) %), and generalized edema (<1%) 
were reported. Less than 1% of pa tients discontinued due to edema. 
 
 • Neurotoxicity  - There was a 10% incidence of mild  paresthesias and a <1% rate of 
severe paresthesias  
• Flu-like Symptoms  - “Flu syndrome” was reported for 19% of patients. Individual 
symptoms of fever, asthenia, anorexia, headache, cough, chills, and myalgia were commonly 
reported. Fever and asthenia were also reported frequently as isolated symptoms. Insomnia, 
rhinitis, sweating, and malaise were reported infrequently. Less than 1% of patients discontinued due to flu-like symptoms.   
 
• Infection  - Infections were reported for 16% of patients. Sepsis was rarely reported.   
• Alopecia - Hair loss, usually minimal, was reported by 15% of patients 
 
 
Please see gemcitabine prescribing info rmation for more details on the known 
precautions, warnings, and adverse reactions of gemcitabine (current version of 
Prescribing Information is pr ovided in the Study Manual).  
  
3. PATIENT SELECTION 
 
3.1  Eligibility Criteria 
 
3.1.1 Patients must have histologically or  cytologically confirmed metastatic 
adenocarcinoma of the pancreas. Patients w ith islet cells tumors are excluded. Biopsy 
is required within 14 days before starting treatment. 
 
Protocol Amendment 12, date December 4, 2014 243.1.2 Patients must have measurable disease, de fined as at least one lesion that can be 
accurately measured in at least one dimens ion (longest diameter to be recorded) as 
>20 mm with conventional techniques or as >10 mm with spiral CT scan.  See 
Section 11 for the evaluation of measurable disease. 
 
3.1.3 Patient must have received no previous  radiotherapy, surgery or chemotherapy or 
investigational drug therapy for the treatment of metastatic disease. Radiotherapy, 
chemotherapy or investigational therapy in the adjuvant setting should be completed 
3 weeks prior to enrollment. Prior therapy w ith 5FU, gemcitabine or other agents in 
the adjuvant setting is allowed. If a patie nt received gemcitabine in the adjuvant 
setting, tumor recurrence must have occurred  at least six months  after completing the 
last dose of gemcitabine 
 
3.1.4 Age >18 years .  Because no dosing or adverse event data are currently available on 
the use of   GDC-0449 in combination with nab-paclitaxel and gemcitabine in 
patients <18 years of age, children are excluded from this study but will be eligible for future pediatric phase 2 combination trials. 
 
3.1.5 Life expectancy of greater than 1 month. 
 
3.1.6 ECOG performance status <1 (K arnofsky >70%; see Appendix A). 
 
3.1.7 Patients must have adequate organ and marrow function as defined below: 
 
- leukocytes      >3,000/mcL 
- absolute neutrophil count  >1,500/mcL 
- platelets      >100,000/mcL 
- total bilirubin     < 1.5 ULN - AST(SGOT)/ALT(SGPT) <2.5 X institu tional upper limit of normal, unless 
liver metastases are clearly present, then < 5X ULN is allowed 
- creatinine      within normal institutional limits 
OR 
- creatinine clearance   Crea tinine clearance >50 mL/min/1.73 m
2 for 
patients. Serum creatinine < 2 mg/mL 
 
3.1.8   Patients should be asymptomatic for jaundice and ascites prior to Day 1. Pain                     
           symptoms should be stable. 
 
 
3.1.9 The effects of GDC-0449 on the developi ng human fetus at the recommended 
therapeutic dose are unknown.  For this reason and because Hh signal pathway 
inhibitors are known to be teratogenic, women of child -bearing potential and men 
must use two forms of contraception (i.e., barrier contraception and one other method 
of contraception) at least 4 weeks prior to study entry,  for the duration of study 
participation, and for at least 7 months post-treatment. For appropriate methods of 
Protocol Amendment 12, date December 4, 2014 25contraception considered acceptable see Appendix B.  Should a woman become 
pregnant or suspect she is pregnant while  participating in th is study, she should 
inform her treating physician immediately. 
   
Pregnancy Testing.  Women of childbearing po tential are required to have a negative 
serum pregnancy test (with a sensitivity of at least 25 mIU/mL) within 10-14 days 
and within 24 hours prior to the first dos e of GDC-0449 (serum or urine).  A 
pregnancy test (serum or urin e) will be administered ever y 4 weeks if their menstrual 
cycles are regular or every 2 weeks if thei r cycles are irregular  while on study within 
the 24-hour period prio r to the administration of GDC -0449.  A positive urine test 
must be confirmed by a serum pregnancy test.  Prior to dispensing GDC-0449, the 
investigator must confirm and document the patient’s use of two contraceptive 
methods, dates of negative pregnancy test, and confirm the patient ’s understanding of 
the teratogenic potential of GDC-0449.  Women of childbearing potenti al are defined as follows: 
• Patients with regular menses • Patients with amenorrhea, irregular cycl es, or using a contraceptive method that 
precludes withdrawal bleeding • Women who have ha d a tubal ligation 
 Women are considered not to be of childbe aring potential for th e following reasons: 
• The patient has undergone hysterect omy and/or bilateral oophorectomy. 
• The patient is post-menopausal defined by amenorrhea for at least 1 year in a 
woman > 45 years old.  
3.1.10 For sexually active males, use of barrier form  of contraception, even  if they have had 
a vasectomy, during the study and for 2 m onths after stopping GDC-0449 is required. 
Males should not donate sperm during treatmen t or up to three months after last dose. 
 3.1.11 All patients should agree not to donate  blood products for 7 months after stopping 
GDC-0449 
 
3.1.12  Ability to understand and the willingness to sign a written informed consent 
document. 
 
3.2  Exclusion Criteria 
 
3.2.1 Patients who have had chemotherapy or  radiotherapy for metastatic disease 
 3.2.2 Patients may not be receiving a ny other investigational agents. 
 3.2.3   Patient has known brain metastases, unless prev iously treated and well              
           controlled for at least three months (defined as clinically stable, no edema, no                    
           steroids and stable  in 2 scans at le ast 4 weeks apart) 
 
Protocol Amendment 12, date December 4, 2014 263.2.4 History of allergic reactions attributed to  compounds of similar chemical or biologic 
composition to GDC-0449 or other agents used in the study. 
 3.2.5 Patients taking medications with narrow th erapeutic indices that are metabolized by 
cytochrome P450 (CYP450), including warfar in sodium (Coumadin®) are ineligible. 
 3.2.6 GDC-0449 inhibits CYP2C8, CYP2C9, and CYP2C19 drug metabolism enzymes in 
vitro  at concentrations that may be clinica lly relevant.  Therefore, caution should be 
exercised when dosing GDC-0449 concurrently with medications that are substrates 
of CYP2C8, CYP2C9, and CYP2C19 a nd have narrow therapeutic windows. 
 
In addition, GDC-0449 is a substr ate of CYP3A4; however, the in vitro metabolic 
conversion of GDC-0449 is low.  Effect s of CYP inducers (e.g., carbamezepine, 
phenobarbital, phenytoin, rifabutin, rifampi n, St. John’s wort, and troglitazone) on 
clinical concentrations of GDC-0449 are unknown.  Likewi se, the effects of strong 
inhibitors of CYP3A4 (e.g., clarith romycin, erythromycin, itroconazole, 
ketoconazole, nefazodone, and telithromyci n) on GDC-0449 clinical concentrations 
are unknown, and caution should be exercise d when dosing GDC-0449 concurrently 
with inhibitors of CYP3A4 (refer to Appendix C for a list of drugs that may 
potentially interact with CYP3A4).   
 3.2.7 Uncontrolled illness including, but not limited to, ongoing or active infection 
requiring IV antibiotics, symptomatic congest ive heart failure not controlled with 
medication, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social 
situations that would limit comp liance with study requirements. 
 
3.2.8 Pregnant and nursing women are exclude d from this study because GDC-0449 is  a 
Hh pathway inhibiting agent with the potential  for teratogenic or abortifacient effects. 
Women planning to become pregnant during treatment and for 7 months after last 
dose of treatment are excluded from this study. Because there is an unknown but potential risk for adverse events in nursi ng infants secondary to treatment of the 
mother with GDC-0449, breastf eeding should be discontinued if the mother is treated 
with GDC-0449.  These potential risks may also  apply to other agents used in this 
study.  
 
                  3.2.9   Patient has undergone a major surgery, other than diagnostic surgery (i.e.    
                             surgery done  to obtain a biopsy for diagnosis without removal of an organ) 
                             w ithin four weeks prior to Da y 1 of treatment on this study. 
                                      3.2.10 History of other di sease, metabolic dysfunction, physical examination finding,  
                            or clini cal laboratory finding giving reasonab le suspicion of a disease or 
                            condition that  contraindicates use of an inve stigational drug or that might 
                            affect interpre tation of the results of the study or render the patient at high risk 
                            from treatment complications  
Protocol Amendment 12, date December 4, 2014 273.3  Inclusion of Women and Minorities 
 
Both men and women and members of all races and ethnic groups ar e eligible for this trial.  
 
  
4. REGISTRATION PROCEDURES 
 
4.1 General Guidelines 
 
 All sites should call the Study Coordinator Yvette Cetasaan, CCRP at 410-955-4035 (or 
Rosalind Walker at 410-955-9628) to  verify agent availability.  A signed informed consent 
document must be obtained prior to entry onto the study.   This study uses a web based data 
entry system for data submission through Ca ncer Research and Biostatistics (CRAB).  
Patient enrollment materials may be acces sed online through the study website at:  
www.crab.org/SU2C .  
 
Eligibility criteria must be verified accordi ng to the eligibility checklist located in Appendix 
F and stored in the patient chart.  The Principa l investigator of each site is responsible to 
verify that all the eligibility criteria are met.  Following completion of the eligibility checklist, 
subjects must be registered on the CRAB st udy website to be considered on study.  Each 
patient will be automatically a ssigned a patient identification number following enrollment.   
 Signed and completed informed consent forms should be faxed to Yvette Cetasaan at 443-
287-6566.  
 
Following registration, patients shou ld begin protocol treatment within 14 days.  Issues that 
would cause treatment delays should be discussed with the Principal Inves tigator.  If a patient 
does not receive protocol ther apy following registration, the patient’s registration on the 
study may be canceled.  The Study Coordinator s hould be notified of can cellations as soon as 
possible.  Agents may be ordered by a partic ipating site only after the initial IRB approval for the site 
has been forwarded by the Coordinating Center. 
 
 
4.2 Data Submission Procedures 
 
Data will be completed and submitted electro nically using the study web based system 
provided by CRAB.  Electronic case report forms (eCRFs) can  be accessed on-line through 
the study website at:  www.crab.org/SU2C.  This website is used to register patients and 
submit data using eCRFs.  In addition, study resource information (SAE submission forms, protocol documents and other study gui delines) can be found on the website. 
 
 
Protocol Amendment 12, date December 4, 2014 28 
   
4.3 Coordinating Center Guidelines 
 
        Responsibili ty of the Protocol Chair  
        The Protocol Chair is responsible for th e coordination, development, submission, and 
approval of the protocol as we ll as its subsequent amendments .  The protocol must not be 
rewritten or modified by anyone  other than the Protocol Ch air.  There will be only one 
version of the protocol, and each participa ting institution will use that document.  The 
Protocol Chair is responsible for assuring that all participa ting institutions are using the 
correct version of the protocol. 
        The Protocol Chair is responsible for the ove rall conduct of the study at all participating 
institutions and for monitoring its progress.  All reporting requi rements are the responsibility 
of the Protocol Chair.  
        The Protocol Chair is responsible for the timel y review of Adverse Events (AE) to assure 
safety of the patients. 
        The Protocol Chair will be responsible for the review of and timely submission of data for 
study analysis. 
 
Responsibilities of the C oordinating Center (SKCCC)  
 
       The Coordinating Center will maintain docum entation of AE reports.  The Coordinating 
Center will submit AE reports to th e Protocol Chair for timely review. 
      The Coordinating Center is responsible for ov erseeing and approving the distribution of the 
investigational study medication, GDC -0449, to each participating site. 
Responsibilities of the CRO: Cancer Research And Biostatistics (CRAB): 
 Each participating institution will have an appropriate assurance on file with the Office for Human 
Research Protection (OHRP), NIH.  CRAB is responsible for assuring that each participating 
institution has an OHRP assurance and must ma intain copies of IRB approvals from each 
participating site. 
 CRAB is responsible for providing an electronic data capture (EDC) system and maintaining the 
study web based system that is used for registra tion and data submission.  CRAB is responsible for 
assuring IRB approval has been obtained at each particip ating site prior to the first patient registration 
from that site.  During the registration process, CR AB will collect the date each patient signs the 
informed consent form and HIPAA authorization form. 
 CRAB is responsible for the preparation of all s ubmitted data for review by the Protocol Chair. 
 CRAB is responsible for conducting on-site monitoring  as described in Section 7.7 – Data and Safety 
Monitoring Plan.  
 Due to budget constraints CRO QA will conduct on -site monitoring as described in Section 7.7 – 
Data and Safety Monitoring Plan however CRA B will continue to monitor the CRAB database.  
 
 
Protocol Amendment 12, date December 4, 2014 29 
    
5. TREATMENT PLAN 
 
Following the determination of eligibility pa tients will receive the following treatment:  
1.  One cycle of Gemcitabine 1000 mg/m
2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15  (28 
days cycle) then 
2.  Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days cycle 
in combination with oral GDC-0449 150 mg daily 
 
Table 1. Drug Schedule 
 
Week 1 2 3 4 5 6 7 8 
Gemcitabine + nab- paclitaxel Cycle 1 Cycle 2 onward 
 X X X  X X X  
GDC-0449     Daily Dose Administration 
  
5.1 Time and Events Schedule 
 
An overview of the schedule of study assessments is provided in the Study Calendar in section 10. 
 
Informed consent will be obtained prior to any study procedures being perf ormed. Each participant 
will be given a copy of the signed informed cons ent form (ICF). The ICF must be approved by an 
Institutional Review Board (IRB)/Ethics Committee (EC).  A complete medical history and physical examinati on will be conducted on each  patient for a review 
of systems and determination of any concurrent symptoms or condi tions prior to th e first dose of 
study drug. Routine study evaluations will be conducte d to monitor for existing adverse events and 
the development of new adverse events.   Patients are to be encouraged to call the site to report any unexp ected symptoms or problems they 
encounter between study visits. Medical symptoms  or conditions present at or before study drug 
administration that manifest with the same in tensity or frequency subsequent to study drug 
administration do not need to be recorded as adverse events in the CRF. However, any pre-existing 
condition that presents with increased intens ity or increased frequency following study drug 
administration, or any exacerbation of an event that is present at the time of study drug 
administration, should be considered an adverse ev ent. All adverse events occurring from initial 
dosing through study end, inclusive, should be followed as outlined in section 7.  All adverse events must be completely and promptly  recorded in the patient's sour ce document (e.g., patient hospital 
records, patient clinic charts, and laborator y reports) and on the CRF. Note that individual 
signs/symptoms should not be recorded in the CRF as adverse events. If a unifying diagnosis is 
Protocol Amendment 12, date December 4, 2014 30known, it is the diagnosis th at should be recorded as the adverse event. 
 Clinically significant laboratory abnormalities presen t at the pre-study (baseline) visit will be 
recorded as pretreatment signs  and symptoms. After study treatme nt administration, laboratory 
abnormalities will not be recorded as adverse events  unless considered clini cally significant by the 
Investigator, and clinically signi ficant laboratory abnormalities will  not be recorded as serious 
adverse events unless the event m eets the definition of serious. 
 Each Investigator is responsible for assessing the clinical signifi cance of all abnormal laboratory 
values using the NCI CTCAE Scale version 4.0 (see http://ctep.cancer.gov/reporting/ctc.html), 
where applicable. It is also the responsibility of the Investigator to assess the clinical significance of 
all abnormal laboratory values as  defined by the list of normal values provided  by the local 
laboratory. All abnormal laboratory te sts that are judged to be at least possibly drug related, or 
clinically relevant abnormal labor atory tests of uncertain causalit y, must be repeated. Any abnormal 
values that persist should be followed at the discre tion of the Investigator. In  some cases, significant 
changes within the range of normal va lues will require similar judgment. 
 
5.1.1 Screening and Pre-study Assessments 
                      
The following evaluations and procedures will be performed within 28 days prior to Day 1:  • Signed informed consent  • Clinical evaluations  
• Medical and surgical history (including dem ographics and prior can cer therapy history) 
 • Complete physical examination         • Vital Signs: Height, weight, pulse, blood pressure, respiratory rate, and temperature 
 •ECOG performance status (see Appendix A)  • Concurrent medications: Reco rd all concurrent medications  administered within the 28 
days preceding Day 1  • Laboratory assessments  
Hematology: hemoglobin, hematocrit, plat elet count, red bl ood cell (RBC) count, 
white blood cell (WBC) count, and perc ent and absolute differential count 
(neutrophils, bands, eosinophils, lymphocyt es, monocytes, basophils, other cells) 
 
Serum chemistries (glucose, BUN, crea tinine, sodium, potassium, magnesium, 
bicarbonate, calcium, total protein, albumin, serum total bilirubin, alkaline 
phosphatase, LDH, phosphorus, Chloride, AST, AST, and ALT ) 
Protocol Amendment 12, date December 4, 2014 31 
Complete Urinalysis  Coagulation: PT, PTT, INR 
 
Pregnancy Testing.  Women of childbearing po tential are required to have a negative 
serum pregnancy test (with a sensitivity of at least 25 mIU/mL) within 10-14 days 
and within 24 hours prior to the first dos e of GDC-0449 (serum or urine).  A 
pregnancy test (serum or urin e) will be administered ever y 4 weeks if their menstrual 
cycles are regular or every 2 weeks if thei r cycles are irregular  while on study within 
the 24-hour period prio r to the administration of GDC -0449.  A positive urine test 
must be confirmed by a serum pregnancy test.  Prior to dispensing GDC-0449, the 
investigator must confirm and document the patient’s use of two contraceptive 
methods, dates of negative pregnancy test, and confirm the patient ’s understanding of 
the teratogenic potential of GDC-0449. 
 
• 12-lead ECG  • Tumor assessment (per RECIST 1.1; see section 11). The method used for a patient 
must be the same throughout the study.  CT scan  of chest, abdomen and pelvis (or MRI if 
patient allergic to contrast agent).   • Consent to obtain tissue biopsy by ultrasound or ct guided biopsy  
 • Pretreatment biopsy for correlative studie s, must be obtained w ithin 14 days before 
cycle 1, day 1 
 
5.1.2 Assessments during the study period 
 
The study period begins on Day 1 of Cycle 1 and continues until documented disease 
progression. A window of ± 3 days will be allowed for all visits and radiographic 
assessments performed during the study period.  All assessments and procedures should 
be performed prior to study treatment on th e scheduled treatment day, unless otherwise 
specified. 
 
• Response assessments : Response assessment CT scans should be performed at Baseline, 
Cycle 1 Day 1 (only if Baseline CT scan not done within 14 days prior to Cycle 1 Day 1), 
every 8 weeks (at any time during that week ), and EOS (if required per the defined study 
imaging schedule). The same mode of imaging fo r target lesions must be used at Baseline 
and throughout the study. CT image preparation will follow the specifications provided in 
the RECIST 1.1 response guidelines. CT im aging should include contrast unless 
medically contraindicated and conventional CT should be performed with contiguous 
cuts of 10 mm or less in slice thickness. If spiral CT is used, it should be performed by 
use of a 5 mm contiguous r econstruction algorithm. 
 
• Drug related toxicities : If the investigator suspects a drug-related toxicity, an extra-
Protocol Amendment 12, date December 4, 2014 32unscheduled visit with additional laboratory tests may be performed. 
 • GDC-0449, nab paclitaxel and gemcitabine shoul d be administered as specified in 5.2 
and study calendar in section 10.  
 
5.1.3 Beginning of each cycle 
 
The following assessments will be performed on Day 1 of each treatment cycle: 
 
• GDC-0449 drug accountability. The first dose of GDC-0449 will be taken on Day 1 of 
Cycle 2 while the patient is at the site. Drug will be dispensed to the patient on this day. GDC-0449 drug accountability and review of the Medication Diary will occur at the 
beginning of each subsequent visit. GDC-0449 will be dispensed every 4 weeks. Unused 
medication should not be re-dispensed.  • Clinical evaluations: Weight, pulse, blood pressure, respiratory rate, and temperature 
 • BSA calculations (Day 1 of cycle 1, and then subsequently if there is a weight change 
of more than 10%)  • Concurrent procedures  • Adverse event evaluation  • Peripheral neuropathy assessment  
• Cycle 1, Day 1 CT scan (only if baseline CT  not done within 14 days prior to Cycle 1, 
Day 1)  • Serum CA19-9 (Day 1 of Cycle 1, Cycle 2, Cycle 4 and every even cycle onward) 
 • Plasma SPARC (Day 1 of Cycle 1, Cycle 2, Cycle 4 and every even cycle onward) 
 • Local laboratory assessments  • Day 1 evaluations may be omitted if Baseline evaluations are performed within 72 hours of Cycle 1, Day 1. 
 
Hematology: hemoglobin, hematocrit, plat elet count, red bl ood cell (RBC) count, 
white blood cell (WBC) count, and perc ent and absolute differential count 
(neutrophils, bands, eosinophils, lymphocyt es, monocytes, basophils, other cells) 
 
Serum chemistries (glucose, BUN, crea tinine, sodium, potassium, magnesium, 
bicarbonate, calcium, total protein, albumin, serum total bilirubin, alkaline 
phosphatase, AST, and ALT ) 
 
Protocol Amendment 12, date December 4, 2014 33Serum or urine pregnancy test (for women of childbearing potential). If a urine test is 
positive should be confirmed with serum pregnancy test. For all other women, documentation must be present in their medi cal histories confirmi ng that the patient 
is not of childbearing po tential (see Appendix B). 
 • Record concurrent medications.  • Record cancer-related medical or surgical procedures.  • Record adverse events. 
 
 
5.1.4 Follow up assessments 
 
Efficacy Response Assessments 
 
The following efficacy response assessments will be performed: 
 • CT scan (or MRI if patient is allergic to  contrast agent) ever y 8 weeks at any time 
during that week, starting from  Cycle 1 Day 1. In order to confirm objective response, an 
unscheduled CT scan will be allowed 4 week s (a minimum of 28 days) from the initial 
documented complete or partial response. Fo r such patients, all subsequent CT scans 
should return to the original schedule perfor med every 8 weeks starting from the date of 
first dose of study therapy. An unscheduled CT scan for suspected progression may be performed at any time;  
Per Cycle Evaluations 
 
On Days 8 and 15 of each cycle, the fo llowing assessments will be performed: 
 • Concomitant medication evaluation  • Vital signs (prior to dosing)  • CBC, differential and platelet count 
 • Adverse event evaluation.  
At the beginning of each cycle 
 
Note: The following procedures should be performed during the entire study period.  
 • Brief physical examination  • Clinical evaluations (performed at be ginning of each chemotherapy cycle or, if 
chemotherapy has been stopped, every 3-4 weeks): Weight, pulse, blood pressure, 
Protocol Amendment 12, date December 4, 2014 34respiratory rate, and temperature 
 • Local laboratory assessments (performed at  beginning of each chemotherapy cycle or, if 
chemotherapy has been stopped, every 3-4 weeks)  
Hematology: hemoglobin, hematocrit, pl atelet count, RBC c ount, WBC count, and 
percent and absolute differential c ount (neutrophils, bands, eosinophils, 
lymphocytes, monocytes, basophils, other cells)  Serum chemistries (glucose, BUN, crea tinine, sodium, potassium, magnesium, 
bicarbonate, calcium, total protein, albumin, serum total bilirubin, alkaline 
phosphatase, AST, and ALT) 
 • ECOG performance status (see Appendix A)  • Serum or urine pregnancy test every 4 w eeks (for women of childbearing potential) 
 • Record concurrent medications.  • Record cancer-related medical or surgical procedures.  • Record adverse events. 
 
Every 8 weeks 
Note: The following procedures should be pe rformed during the en tire study period. If 
chemotherapy has been stopped every 8 weeks 
 
• Tumor assessment (per RECIST 1.1; see section 11). The method used for a patient 
must be the same throughout the study  • Record concurrent medications.  • Record cancer-related medical or surgical procedures.  • Record adverse events.  
End-of-Study (EOS) Evaluations 
 
An EOS evaluation should be performed for all patients who end treatment. The 
following procedures will be completed at the EOS Visit:  • Physical examination  • Weight assessment  • Concomitant medication evaluation 
Protocol Amendment 12, date December 4, 2014 35 
• Concurrent procedures  • Vital signs  • ECOG performance status scale  • Clinical chemistry panel  • CBC, differential and platelet count 
 • CT scan (or MRI if patient is allergic to contrast agent) only if required per the defined 
study imaging schedule;  • Adverse event evaluation.  The Investigator must follow all SAEs obser ved during the study until these events have 
resolved or stabilized, the patient is lost  to follow-up, or the events are otherwise 
explained. The Investigator should report these SAEs in accordance with the procedures described in Section 7. Clinical laborator y tests may be repeated during the post-
treatment period if clinically indicated. 
 
Follow-up for Adverse Events 
 
Any AE or SAE whose onset occurred between the first administration of study drug to 
30 days after the last dose of study drug or EO S (whichever is later) will be collected. 
The Investigator should report SAEs in accordance with the procedure described in 
Section 7. Adverse event follow-up will be conducted as follows:  • Non-serious adverse events, other than ne uropathy, will be followed for 30 days after 
the patient’s last dose of study drug.  • Neuropathy will be followed until improvement to Grade 1 occurs, or at least 3 months have elapsed without improvement or wors ening, or the patient initiates any other 
anticancer therapy during follow-up.  • All serious adverse events (regardless of relationship to study dr ug) will be followed 
until resolution. Clinical laboratory tests may be repeated during follow-up if clinically 
indicated. Follow-up evaluations include studies necessary to  document the resolution or 
persistence of any unresol ved AEs and could include: 
 • Physical examination, weight; 
• Concomitant medication evaluation; • Concurrent procedures; • Vital signs; 
Protocol Amendment 12, date December 4, 2014 36• ECOG Performance Status scale; 
• CBC, differential, platelet count, and clinical chemistries; • Peripheral neuropathy assessment.  
Follow-up for Disease Progression 
 
Patients who are discontinued from treatment in the absence of disease progression (e.g., 
patients removed for unacceptable toxicity or  patient/investigator discretion) should 
undergo repeat imaging and tumor response a ssessments until disease progression is 
documented. Imaging studies (CT scans) should be continually performed into follow-up every 8 weeks (at any time during that week),  regardless of regimen. It is recommended 
that subsequent therapy not be instituted until disease progression is documented. Ideally 
this repeat imaging should be done  at the treating  institution.  
 
Follow-up for Overall Survival 
 
Post-study, overall survival status will be m onitored on a monthly basis for 6 months and 
then every 3 months thereafter for 12 months. Patients will be followed for a total of 18 
months. This evaluation may be by reco rd review and/or telephone contact.  
  
5.2  Agent Administration 
 
Patients will be treated on an outpatient basis. Pa tients receiving nab-Paclitaxel +gemcitabine will 
receive 125 mg/m2 nab-Paclitaxel as a 30-minut e infusion followed by 1000 mg/m2 gemcitabine as 
a 30-minute infusion for 3 weeks followed by a week  of rest. Supportive care per the institution’s 
normal standard of care can be provided  at the Investigat or’s discretion. 
   
 
REGIMEN DESCRIPTION 
 
Agent Premedications; 
Precautions   
Dose  
Route  
Schedule Cycle 
Length  
Gemcitabine Dexamethasone 
12 mg PO or IV 30-60 min prior 
to Gemcitabine 
 1000 mg/m
2 IV  Days 1, 8 
and 15 
4 weeks 
(28 days) 
 Nab-paclitaxel Not required 125 mg/m
2 IV  Days 1, 8 
and 15 
GDC-0449 Morning or PM.  150 mg tablet PO in the a.m.  Daily 
starting on 
cycle 2 
 
5.2.1 GDC-0449 
 
Protocol Amendment 12, date December 4, 2014 37Administration  
 
GDC-0449 150 mg will be administered beginning on Cycle 2, Day 1 once daily by oral dosing, in combination with gemcitabine and nab-paclitaxe l as described in section 5.1. Therapy should 
continue until one of the conditions  specified in section 5.4 occurs. 
 
Drug should be taken at approximately the same tim e each day, with or wit hout food. If a patient 
misses a dose (e.g., due to emesis), he or she should be instructed not to take or make up that dose 
and to resume dosing with the ne xt scheduled dose. Missed doses wi ll not be made up. Patients will 
be instructed to bring all unus ed capsules and their medication diary to each study visit for 
assessment of compliance.  The terminal half-life of GDC-0449 is currently unknown, but is expect ed to be longer than 1 week, 
and may be as high as 2 to 3 weeks. If plasma levels of GDC-0449 need to be lowered emergently, 
animal studies suggest that oral administration of  activated charcoal may lower drug plasma levels 
more quickly than dose cessation alone. 
 
5.2.2 nab-paclitaxel 
 
nab-Paclitaxel Premedication 
 Patients do not require premedication pr ior to nab-Paclitaxe l administration,  
as hypersensitivity reactions are not expect ed, though initial antiemetic prophylaxis  
is recommended due to administration of ge mcitabine following nab-Paclitaxel treatment. 
 
Hypersensitivity reactions are not expected with either nab-paclitaxel or gemcitabine. If they do 
occur, minor symptoms such as flushing, skin reactions, dyspnea, hypotension, or tachycardia may 
require temporary interruption of  the infusion. However, severe  reactions, such as hypotension 
requiring treatment, dyspnea requiring bronchodilators , angioedema, or genera lized urticaria require 
immediate discontinuation of st udy drug administration and aggr essive symptomatic therapy. 
Patients who develop a severe hypersensitivity reaction to nab-paclitaxel should not be re-
challenged.  If a hypersensitivity reaction occurs, the infusion shoul d be stopped and not restarted. If felt to be in 
the patient’s best interests, at the investigator’s discretion, treat ment may continue on subsequent 
cycles using the premedication regimen the institution typically uses for Taxol. 
 
Chemotherapy Dose 
 The cycle length is 4 weeks (28 days). Treatment w ith protocol therapy will continue until one or 
more of the criteria listed in Section 5.4 are met. 
 
5.2.3 Gemcitabine 
 
Gemcitabine Premedication 
 
Protocol Amendment 12, date December 4, 2014 38Please see gemcitabine prescribing informati on for recommended premedication strategies. 
 
 
5.2.4      Other Modality (ies) or Procedures 
 
Administration of other chemothe rapy, immunotherapy, or anti-tum or hormonal therapy during the 
study is not allowed. All concomitant treatment s, including blood and blood products, must be 
reported on the case report form ( CRF). Erythropoietin may be admini stered at the discretion of the 
Investigator, consistent with in stitutional guidelines. Guidelines  for administration of GCSF are 
described in Table 5 but will be to the discretion of the investigator and according to institutional 
guidelines. 
       Planned Surgical Procedures 
 
If, during the course of therapy, a planned surg ical procedure is anticipated, chemotherapy, GDC-
0449 may be stopped 4 weeks prior to minimize su rgical complications. Patients may restart 
chemotherapy as appropriate. GDC-0449 must be rest arted within 8 weeks of stopping in order to 
continue treatment with GDC-0449. 
  
5.3 General Concomitant Medication and Supportive Care Guidelines 
  
5.3.1 GDC-0449 
 
 
 GDC-0449 inhibits CYP2C8, CYP2C9, a nd CYP2C19 drug metabolism enzymes 
in vitro at clinically relevant concentr ations. There is a potential for GDC-0449 to 
also inhibit CYP1A2 and 2D6. Caution s hould be exercised and dose reduction of 
the concomitant substrate drug should  be considered when dosing GDC-0449 
concurrently with medications with narrow therapeutic windows that are 
substrates of CYP2C8, CYP2C9, CYP2 C19, CYP1A2 and 2D6  because their 
concentrations may become elevated a nd their effects increased or prolonged. 
 
 GDC-0449 did not significan tly inhibit CYP3A4 at clinically relevant 
concentrations in vitro; however, the c linical impact of GD C-0449 on substrates 
of CYP3A4 is unknown. GDC-0449 is a subs trate of CYP3A4; however, the in 
vitro metabolic conversion of GDC-0449 is  low. Effects of CYP inducers (i.e., 
carbamezepine, phenobarbital, phenytoin, ri fabutin, rifampin, St John’s wort, and 
troglitazone) on clinical c oncentrations of GDC-0449 are unknown, it is possible 
that these drugs could re duce concentrations of GDC -0449. Likewise, the effects 
of strong inhibitors of CYP3A4 (i.e., clarithromycin, erythr omycin, itroconazole, 
ketoconazole, nefazodone, and telithromycin) on GDC-0449 clinical concentrations are unknown; it is possibl e that these drugs could increase the 
concentrations of GDC-0449. Use of these drugs with GDC-0449 should be 
documented in the eCRFs.  
Protocol Amendment 12, date December 4, 2014 39 
 The following table lists clinically signi ficant substrates of  CYP2C8, CYP2C9, 
CYP2C19, CYP1A2 and 2D6.  This is not necessarily a complete list; other 
medications may also interact with GDC-0449. 
 
2C8 2C9 2C19 
Miscellaneous 
 Repaglinide 
 Rosiglitazone 
       Paclitaxel        Torsemide 
       Cerivastatin 
       Amiodaquine NSAIDs 
 Diclofenac 
 Ibuprofen 
 Piroxicam  Naproxen 
 Celecoxib 
 
Oral hypoglycemic agents 
 Glipizide 
 Tolbutamide 
 
Angiotensin II blockers 
 Irbesartan 
 Iosartan 
 NOT candesartan  NOT valsartan 
 
Miscellaneous 
 Fluvastatin 
 Phenytoin 
 Sulfamethoxazole  Tamoxifen 
 Torsemide 
 Warfarin Proton-pump inhibitors 
 Omeprazole 
 Lansoprazole  Pantoprazole  Rabeprazole  Esoprazole  Anti-epileptics 
 Diazepam  Phenytoin  Phenobarbitone  Miscellaneous 
 Amitriptyline  Clomipramine  Clopidogrel  Cyclophosphamide 
 NSAIDs = Non-steroidal anti-inflammatory drugs 
   
1A2 2D6  
Amitriptyline 
Clomipramine 
Clozapine 
Cyclobenzaprine 
Estradiol 
Fluvoxamine 
Haloperidol 
Imipramine  
Mexiletine 
Naproxen 
Olanzapine 
Ondansetron 
Phenacetin 
Acetaminophen NAPQI
Propanolol Tamoxifen 
 BBlockers   Carvedilol   S-metoprolol   Propafenone   Timilol  Antidepressants     Amitriptyline   Clomipramine   Desipramine   Fluoxetine   Imipramine   Paroxetine Atomoxetine 
Bufuralol Chlorpheniramine Chlorpromazine Codeine Debrisoquine Dexfenfluramine Dextromethorphan Donepezil Duloxetine Encainide Flecainide Fluvoxamine Lidocaine Metoclopramide 
Protocol Amendment 12, date December 4, 2014 40Riluzole 
Ropivicaine 
Tacrine 
Theophylline 
Tizanidine 
Verapamil  
Warfarin 
Zileuton 
Zolmitriptan 
 
  
Antipsychotics   Haloperidol   Perphenazine   Risperidone   Thioridazine   Zuclopenthixol  Alprenolol Amphetamine Aripiprazole   Methoxyamphetamine 
Mexiletine Minaprine Nebivolol Nortriptyline Ondansetron Oxycodone Perhexiline Phenacetin  
 Because there is a potential for interaction of GDC-0449 with other 
concomitantly-administered drugs through the cytochrome P450 system, the case 
report form must capture the concurrent use of all other drugs, over-the-counter 
medications, or alternative therapies.  Th e Principal Investigat or should be alerted 
if the patient is taking any agent known to affect or with the potential to affect 
selected CYP450 isoenzymes (refer to A ppendix C for a list of drugs that may 
potentially interact with CYP3A4).  
 
 Use of medications or food that may in terfere with the metabolism of GDC-0449 
is prohibited, including ketoconazole and fresh-squeezed grapefruit juice. 
 
 If plasma levels need to be lowered em ergently, animal studies have suggested 
that oral administration of activated charcoal may lower drug plasma levels more 
quickly than drug cessation alone. 
 
 Women of childbearing potenti al (defined in Appendix B) are required to have a 
negative serum pregnancy test  (with a sensitivity of at  least 25 mIU/mL) within 
10-14 days and within 24 hours prior to the first dose of GDC-0449 (serum or urine).  A pregnancy test (s erum or urine) will be ad ministered every 4 weeks if 
their menstrual cycles are regular or ever y 2 weeks if their cycles are irregular 
while on study within the 24-hour period prior to the administration of GDC-
0449.  Prior to dispensing GDC-0449, the investigator must confirm and 
document the patient’s use of two cont raceptive methods, dates of negative 
pregnancy test, and confirm the patient ’s understanding of the teratogenic 
potential of GDC-0449. 
 
Female patients are required to use two forms of acceptable contraception (refer 
to Appendix B), including one barrier method during participation in the study 
and for the 7 months following the last dose .  Women of chil dbearing potential 
are also advised to have monthly pregnancy tests for 12 months after 
discontinuation of GDC-0449.  All patie nts should receive contraceptive 
counseling either by the investigator, or  by an obstetrician(OB)/gynecologist or 
Protocol Amendment 12, date December 4, 2014 41other physician who is qualified in this area of expertise.  If a woman of 
childbearing potential believes that her contraceptive method has failed, 
emergency contraception should be considered. 
 
If a patient is suspected to be pregnant, GDC-0449 s hould be immediately 
discontinued.  In addition, a positive ur ine test must be confirmed by a serum 
pregnancy test.  If it is confirmed that th e patients is not pregnant, the patient may 
resume dosing with GDC-0449.   
 
If a female patient becomes pregnant during therapy or within 7 months 
after the last dose of GDC-0449, or if the female partner of a male patient exposed to the drug becomes pregnant while the male patient is receiving 
GDC-0449 or within 7 months a fter the last dose of GDC-0449 , the 
investigator must be notified in or der to facilitate outcome follow-up. 
 Abortion, whether accidental, therapeuti c, or spontaneous, should always be 
classified as serious.  Any congenital a nomaly/birth defect in a child conceived 
during the study or within 7 months afte r the last dose of GDC-0449 to a female 
patient or to a female partner of a ma le patient exposed to the agent during 
treatment or within 7 mont hs after the last dose of GDC-0449 should be recorded 
and reported as an SAE. 
 
 Female patients should not breastf eed a baby while on this study.   
 
 Female patients must NEVER donate ova while being treated with GDC-0449. 
 
 All sexually active male subjects (i ncluding those who have undergone 
vasectomy) should utilize a barrier form of contraception during study 
treatment and for 7 months after the last dose  as it is not known whether 
GDC-0449 that may be present in seminal fl uid would cause tera togenic effects in 
a fetus born to the female partner of a ma le subject.  Males should also not donate 
sperm during treatment or up to 3 months after the last dose. 
 
 All patients are prohibited from donating bl ood for 7 months after the last dose of 
GDC-0449. 
  
5.3.2 Other Considerations 
 
5.3.2.1  Concomitant and Excluded Therapies 
 
For information regarding other drugs that ma y interact with either nab-paclitaxel or 
gemcitabine and affect their metabolism, pha rmacokinetics, or excretion, please see the 
gemcitabine and nab-paclit axel package inserts. 
 5.3.2.2  Supportive Care and administration of additional therapies 
Protocol Amendment 12, date December 4, 2014 42 
Over the course of this trial, additional medi cations may be required to manage aspects of the 
disease state of the patients; including side  effects from trial treatments or disease 
progression Supportive care not othe rwise specified in th is protocol may be administered per 
institutional standard of care. Supportive car e, including but not limited to anti-emetic 
medications, may be administered  at the discretion of the Inve stigator. Irradiation is not 
allowed during the study.  Colony stimulating factors may be given accord ing to institutional guidelines for the 
treatment of neutropenic fever or infections a ssociated with neutropenia. References on use 
of granulocyte colony-stimula ting factors can be used as recommended by the American 
Society of Clinical On cology (ASCO) guidelines. 
 
 
5.4 Duration of Therapy 
 
In the absence of treatment delays due to ad verse events, treatment may continue for   
indefinitely or until  one of the following criteria applies: 
 
• Disease progression • Intolerable (Grade 3 or 4) t oxicity most probably attributab le to GDC-0449 or other agents 
• Intercurrent illness that prevents  further administration of treatment 
• Require palliative radiotherapy • Withdrawal from the study • Initiation of other anticancer therapy. • The physician feels it is not longer in thei r best interest to continue on treatment 
• If the patient becomes pregnant 
• Noncompliance (e.g., missed doses, visits) 
  
5.5 Duration of Follow Up 
 
Patients will be followed for 18 months after removal from study or until death, whichever 
occurs first.  Patients removed from study fo r unacceptable adverse even ts will be followed 
until resolution or stabilization of the adverse event. 
 
 5.6 Criteria for removal from Study 
 
Patients will be removed from stud y when any of the criteria lis ted in Section 5.4 applies.  
The reason for study removal and the date the patient was rem oved must be documented in 
the Case Report Form. 
 
 
6. DOSING DELAYS/DOSE MODI FICATIONS/DOSE OMISSIONS 
 
Protocol Amendment 12, date December 4, 2014 43      6.1 GDC-0449 
 
Dose modifications of GDC-0449 are not planne d. Treatment with GDC-0449 may be interrupted 
for up to 4 weeks for evaluation of a toxicity finding or up to 8 weeks for a planned surgical 
procedure. If a treatment interruption occurs and it is determined that GDC-0449 will be restarted, 
the original dose will be maintained. Ther e are no planned dose reductions of GDC-0449. 
 
     6.2 Gemcitabine and nab-Paclitaxel 
 
Rules for Dose Omissions and Modified Schedules 
 
Day 1 dose missed: 
If the dose held or missed was to be given on Day 1 of the next cycl e, that next cycle will not be 
considered to start until the day the first dose is ac tually administered to th e patient (i.e., 1-2-3-Rest, 
X-1-2-3-Rest, etc.)  
Day 8 dose is missed: 
Cycle continues per protocol, with one dose not gi ven (i.e., 1-2-3-Rest, 1- X-3-Rest, 1-2-3- Rest, 
etc.). Day 15 is administered as per cycl e calendar if counts and chemistries permit. 
 
Day 15 dose missed: 
That week becomes the week of rest. Next dose (i f counts and chemistries permit) becomes Day 1 of 
a new cycle, and the patient is c onsidered to have had a x2q3 (21-day) cycle (i.e ., 1-2-3-Rest, 1-2-X, 
1-2-3-Rest, etc). 
 
Doses will be reduced for hematologic and other non- hematologic toxicities. Dose adjustments are to 
be made according to the system showing the great est degree of toxicity. T oxicities will be graded 
using the NCI CTCAE Version 4.0. Two dose modifications are permit ted according to the criteria 
below. If a toxicity requiring dose modification occurs followi ng the second dose reduction, further 
treatment should be discontinued.   
Dose Level 
 nab- Paclitaxel 
(mg/m2)  Gemcitabine 
(mg/m2)a  
    
Study Dose 125  1000 
-1 100  800 
- 2b 75  600 
aDose reductions may or may not be concomitant. Please refer to Tables 4-6 for specific 
recommendations regarding dose reductions 
 
bAdditional 25% dose modifications are permissible to establish the tolerable dose for an individual 
patient 
 
 If patients experience st udy drug-related toxicities th at require a delay in sc heduled nab-paclitaxel 
and gemcitabine dosing for ≥ 28 days will be discontinued from further participation in this study. 
Protocol Amendment 12, date December 4, 2014 44When a dose reduction is required for Day 1 of any cycle, no dose re-escalation will be permitted for 
the duration of study treatment.  
DOSE MODIFICATIONS AT DAY 1 
In the event dose modifications are required at the beginning of a cycle due to AEs or hematologic 
toxicities, doses of nab-paclitaxel  and gemcitabine may be adjusted as detailed in Table 3 and Table 
4 below: 
 
 
Table 3. Dose Modifications for Hematolo gic Toxicities (Day 1 of Each Cycle) 
 
Absolute Granulocytes  Platelets Timing 
≥ 1.5 x 109/L  AND ≥ 100 x 109/L  Treat on time 
< 1.5 x 109/L  OR 
<100 x 109/L  Delay by one week 
intervals until 
recovery  
 
 
   
Table 4. Dose Modifications for Non-Hemato logic Toxicity (Day 1 of Each Cycle) 
 
 
Non Hematologic Toxicity and/ or Dose Hold with Previous Cycle 
 
Toxicity/ dose held 
 Gemcitabine/ Gemcitabine + nab-paclitaxel 
dose this cycle 
Grade 0, 1 or 2 Same as day 1 previous cycle 
Grade 3 toxicity Decrease gemcitabine and nab-Paclitaxel to next 
lower dose levela  
Grade 4 toxicity Off protocol treatmentb 
Dose held in 2 previous consecutive cycles Decrease gemcitabine to next lower dose level 
and continue throughout the rest of treatment 
a  If the toxicity only affects neuropathy, then  only nab-Paclitaxel  should be reduced 
b  Pulmonary embolism (a Grade 4 toxicity in CT CAE tables) if mild or asymptomatic, will be 
exempt from this requirement. 
 
 
DOSE ADJUSTMENTS WITHIN A TREATMENT CYCLE 
In the event that patients must have treatment de layed within a treatment cycle due to toxicities, 
those doses held during a cycle w ill not be made up. Dose modificati ons due to hematologic toxicity 
(as represented by the blood counts and toxicities, below) within a treatment cycle should be 
adjusted as outlined in Table 5. 
 
Protocol Amendment 12, date December 4, 2014 45 
Table 5. Dose Modifications for Hema tologic Toxicity within a Cycle 
 
     Day 8 
BloodCount         Day 8      
Nab-
Paclitaxel       Day 8 
Gemcitabine   Day 15        
Blood Count     Day 15         
Nab-
Paclitaxel       Day 15 
Gemcitabine 
ANC > 1000     
and             
Platelets           
≥ 75,000          100%  100% ANC > 1000    
and           
Platelets        
≥ 75,000        100%  100% 
ANC 500-1000   
or              
Platelets       
50,000-74,999 Full 
Dose(treat on 
time) 
+GCSF* Full 
Dose(treat on 
time) 
+GCSF* 
ANC < 500      
or             
Platelets        
< 50,000 Hold+GCSF* Hold+GCSF* 
ANC 500-1000a    
or                
Platelets        
50,000-74,999 Decrease 
dose by 1 
level (treat 
on time) Decrease 
dose by 1 
level (treat 
on time) ANC > 1000    
and           
Platelets        
≥ 75,000        Return to Full 
Dose(treat on 
time) + GCSF* Return to Full 
Dose(treat on 
time) + GCSF* 
ANC 500-1000   
or              
Platelets       
50,000-74,999 Same 
Dose(as Day 
8, treat on 
time) +GCSF*
††† Same 
Dose(as Day 
8, treat on 
time) +GCSF*
††† 
ANC < 500      
or              
Platelets        
< 50,000 Hold+GCSF* Hold+GCSF* 
ANC < 500a        
or                
Platelets           
< 50,000 Hold  Hold ANC > 1000    
and           
Platelets        
≥ 75,000        Decrease Day 
8 dose by 1 
level (treat on 
time)+GCSF* Decrease Day 
8 dose by 1 
level (treat on 
time)+GCSF* 
ANC 500-1000   
or              
Platelets       
50,000-74,999 Decrease Day 
8 dose by 1 
level (treat on 
time)+GCSF* Decrease Day 
8 dose by 1 
level (treat on 
time)+GCSF* 
ANC < 500      
or              
Platelets        
< 50,000 Hold+GCSF* Hold+GCSF* 
 
    
Protocol Amendment 12, date December 4, 2014 46 
Febrile 
Neutropenia (Grade 3 or 4)
b Hold. Upon 
resuming dosing, 
decrease to 
next lower level and do 
not re-
escalate throughout 
the rest of 
treatment Hold. Upon 
resuming dosing, 
decrease to 
next lower level and do 
not re-
escalate throughout 
the rest of 
treatment 
  Hold. Upon 
resuming dosing, 
decrease to 
next lower level and do 
not re-
escalate throughout 
the rest of 
treatment Hold. Upon 
resuming dosing, 
decrease to 
next lower level and do 
not re-
escalate throughout 
the rest of 
treatment 
Recurrent Febrile neutropenia 
(Grade 3 or 4)
 b  Decrease to 
next lower 
dose level 
and do not  re- escalate 
throughout 
the rest of treatment Decrease two 
dose levels 
(to 600 
mg/m2) and do not re-
escalate  
throughout the rest of 
treatment   Decrease to 
next lower 
dose level 
and do not  re- escalate 
throughout 
the rest of treatment Decrease two 
dose levels 
(to 600 
mg/m2) and do not re-
escalate  
throughout the rest of 
treatment 
a  If patient do not experience resolution of neut ropenia within 21 days, despite  uninterrupted  
   G-CSF treatment, study treatment will be discontinued 
 
b Febrile patient (regardless of neut rophil count) should have their chem otherapy treatment interrupted.  
  A full sepsis diagnostic work- up should be performed while conti nuing  broad spectrum antibiotics. 
  If cultures are positive, the antibiotic may or ma y not be changed, depending on the sensitivity profile 
  of the isolated organism. Patien ts with persisting fever after 3 week s, despite uninterrupted antibiotic 
  treatment, will discontinue study treatment. Febrile neutropenic patients can also receive G-CSF, in    addition to antibiotic treatment, to hasten the resolution of their febrile neutropenia (following current    institutional guidelines). In all cases, blood counts must have returned to baseline levels before resuming  
  chemotherapy treatment. 
 
 
* G-CSF to the investigator discretion . It is optional if 
descent only affects platelets  
††† If episode of myelosuppression 
occurred starting day 15 of this cycle decrease day 8 dose by 1 level
 
   
 Dose modifications may also be made for non-hemato logical toxicity within a cycle as specified in 
Table 6.   
Protocol Amendment 12, date December 4, 2014 47 
Table 6. Dose Modifications for Non-He matological Toxicity within a Cycle 
CTC Grade   
CTC Grade 
 Percent of Day 1  
 
0-2   (and Grade 3 nausea/ vomiting and alopecia) 100% 
3      (except nausea/vomiting and alopecia) 50% or Holda 
4 Holda 
a  This decision as to which drug should be modified w ill depend upon the type of non-hematologic toxicity seen and 
which course is medically most sound in  the judgment of the physician/investig ator. Treatment may be reinstated on 
Day 1 of the next cycle. 
 
 
 
Peripheral Neuropathy 
 
Nab-Paclitaxel treatment should be w ithheld in patients who experience ≥ Grade 3 peripheral 
neuropathy. Gemcitabine administration can conti nue during this period at the discretion of the 
investigator.  Nab-Paclitaxel trea tment may be resumed at the next lower dose level in subsequent 
cycles after the peripheral neuropathy improves to ≤ Grade 1, regardless of suspected cause . Patients 
experiencing peripheral neuropat hy that requires a delay in sc heduled nab-Paclitaxel dosing for  28 
days will be discontinued from fu rther participation in this study. Additionally patients receiving a 
reduced dose of nab-Paclitaxel who experience ≥ Grade 3 peripheral neuropathy at that dose level 
requiring a dose delay  28 days without resolvi ng to < Grade 1 will be discontinued from further 
participation in this study. 
 Similarly, GDC-0449 should be held in the event that patients experience ≥ Grade 3 peripheral 
neuropathy. GDC-0449 may be resumed at the same  dose of 150 mg daily after the peripheral 
neuropathy improves to ≤ Grade 1. 
 As observed in other clinical trials, ≥ Grade 3 neuropathy related to nab- Paclitaxel is usually seen in 
later phases of the treatmen t (cycle 6 and beyond). If ≥ Grade 3 neuropathy occu rs in early treatment 
cycles, other factors predisposing the patient to neuropathy might be  present (eg. diabetes, alcohol 
consumption, concomitant medications). To mainta in dose intensity during the first 6 treatment 
cycles, careful consideration shoul d be exercised when these pred isposing factors are present.  
    
Cutaneous Toxicity 
 
Patients who develop Grade 2 or 3 cutaneous toxicity should have their dose reduced to the next 
lower dose level of both drugs. If the patient continues to experien ce these reactions, nab-paclitaxel 
despite dose reduction, treatment should be discontinued. Patients who develop Grade 4 cutaneous 
Protocol Amendment 12, date December 4, 2014 48toxicity should have treatment discontinued.  
 
Gastrointestinal Toxicity 
 
If Grade 3 mucositis or diarrhea occurs, st udy drug should be withheld until resolution to ≤ Grade 1, 
then reinstituted at the next lower dose level of both drugs. Patients who develop Grade 4 mucositis 
or diarrhea should have treatment discontinued. 
 
7. ADVERSE EVENTS 
 
These adverse event management guidelines are inte nded to ensure the safety of each patient while 
attempting to characterize the safety and tolerability of the test products. In agreeing to the provisions 
of this protocol, the Investigator accepts all legal responsibilities for prompt  notification of SAEs 
to the Coordinating Center (Johns Hopkins), Genentech, Cancer Research and Biostatistics 
(CRAB) and IRB.  
 
7.1 Adverse Events (AE) definition 
 
An adverse event is any untoward medical occurrence in a patient receiving a marketed 
pharmaceutical product or in a patien t who is participatin g on a clinical trial who is receiving an 
investigational or non-investigational pharmaceutical agent. The AE does not necessarily have a 
causal relationship with the patient’s treatment. Therefore, an advers e event can be any 
unfavorable and unintended sign, sy mptom, or disease temporally associated with the use of a 
medicinal product, whether or not considered to be  related to the medicinal product. In cancer 
clinical trials, many AEs are in fact related to  progression of the pati ent’s underlying malignancy. 
 
This includes the following: 
• AEs not previously observed in the subject that emerge dur ing the protocol -specified AE 
reporting period, including signs or  symptoms associated with pa ncreatic cancer that were not 
present prior to the AE reporting period. • Complications that occur as a result of pr otocol-mandated interven tions (e.g., invasive 
procedures such as cardiac catheterizations).  If applicable, AEs that occur prior to assignment of study treatment associated with medication washout, no treatment run-in, or othe r protocol-mandated intervention. 
 Preexisting medical conditions (other than the cond ition being studied) judged by the investigator to 
have worsened in severity or frequency or cha nged in character during th e protocol-specified AE 
reporting period.  
An adverse event includes: 
• an exacerbation of a pre-existing illness; 
 • an increase in frequency or intensity of a pre-existing episodic event or condition;  • a condition detected or diagnosed after study drug administration even though it may 
Protocol Amendment 12, date December 4, 2014 49have been present prior to  the start of the study 
 
• continuously persistent disease or symptoms that were present at Baseline and worsen following 
the start of the study. 
An adverse event does not include: 
• medical or surgical proce dures (e.g., surgery, endoscopy, toot h extraction, or transfusion); 
however, the condition that leads to the procedure is an adverse event.  
 • pre-existing diseases, conditions, or laborat ory abnormalities present or detected at the 
start of the study that do not worsen; 
 • hospitalizations or procedures that are done for elective purposes not related to an 
untoward medical occurrence (e .g., hospitalizations for cosme tic or elective surgery or 
social/convenience admissions);  • the disease being studied or signs/symptom s associated with the disease unless more 
severe than expected fo r the patient's condition; 
 
• overdose of study drug without a ny clinical signs or symptoms. 
 
7.2 Serious Adverse Events (SAE) Definition  
 
A serious adverse event (SAE) is defined as any untoward medical occurrence at any dose 
that:  • is fatal ; 
• is life-threatening (defined as an immediate risk of deat h from the event as  it occurred);  
• results in persistent or significan t disability or incapacity ; 
• requires in-patient hospitalization or prolon gs an existing hospitalization. (Exception: 
Hospitalization for elective treatme nt of a pre-existing condition that  did not worsen during the study 
is not considered an adverse event. NOTE: Co mplications that occur during hospitalization are 
adverse events and if a compli cation prolongs hospitalization, then the event is serious); 
• is a congenital anomaly/birth defect in the offspring of a patient who received medication ; 
• conditions not included in th e above definitions that may jeopardize the patient or may 
require intervention to prevent one of the out comes listed above unless clearly related to 
the patient’s underlying disease.  The Investigator should exercise  medical and scientific judgment  when deciding whether expedited 
reporting is appropriate in other s ituations not strictly meeting the criteria outlined above. Examples 
of important medical events which may also m eet the definition of a SAE include: intensive 
treatment in an emergency room or at home for a reversible condition that did not result in 
hospitalization (e.g., allergic bronchospasm or convul sions), certain laboratory abnormalities (e.g., 
blood dyscrasias), or development of drug dependency or  drug abuse. If there is any question, please 
consult the relevant Medical Monitor.  
Protocol Amendment 12, date December 4, 2014 507.3 Grading and Assessing Causality 
 
Adverse events occurring during the study will be graded according to the NCI CTCAE Scale 
version 4.0 (see http://ctep.cancer.go v/reporting/ctc.html ), where applicable. Adverse events that are 
not included on the toxicity scale will be designat ed as Grade 1 = mild, Grade 2 = moderate, Grade 3 
= severe, Grade 4 = life-threa tening, and Grade 5 = death.  
 The Investigator should evaluate all adverse ev ents and should make an immediate effort to 
determine their etiology. Adverse events that are determined not to be possibly, probably, or 
definitely related to stud y drug may not require further evaluation but will need to be recorded on the 
CRAB eCRFs. Study medications may be interrupted for an adverse event at the discretion of the 
Investigator. Patients requiring t oxicity management should be assessed and evaluated at least 
weekly as indicated by the severity of the event. 
 
 Attribution  of the AE: 
- Definite – The AE is clearly related  to the study treatment. 
- Probable – The AE is likely related to the study treatment. 
- Possible – The AE may be related  to the study treatment. 
- Unlikely – The AE is doubtfully related to the study treatment. 
- Unrelated – The AE is clearly NOT related  to the study treatment. 
 
Assessment of Adverse Events 
 
All AEs and SAEs whether vol unteered by the subject, disc overed by study personnel during 
questioning, or detected through phys ical examination, laboratory test , or other means will be reported 
appropriately. Each reported AE or SAE will be de scribed by its duration (i.e., start and end dates), 
regulatory seriousness criteria if applicable, suspected relationship to the {study drug} (see following 
guidance), and actions taken. 
 
To ensure consistency of AE and SAE causality  assessments, investigat ors should apply the  
following general guideline: 
 
Yes 
 
There is a plausible temporal re lationship between the onset of th e AE and administration of the  
{study drug}, and the AE cannot be readily explained by the subject’s clinical state, intercurrent  
illness, or concomitant therapies; and/or the AE follows a known pattern of response to the  {study drug}; and/or the AE abates or resolves  upon discontinuation of th e {study drug} or dose  
reduction and, if applicable, reappears upon re -challenge. 
 
No 
 
Evidence exists that the AE has an etiology othe r than the {study drug} (e .g., preexisting medical  
condition, underlying disease, interc urrent illness, or concomitant medication); and/or the AE has  
no plausible temporal relationshi p to {study drug} administration (e.g., cancer diagnosed 2 days  
after first dose of study drug). 
Protocol Amendment 12, date December 4, 2014 51 
Expected adverse events are those adverse events th at are listed or characterized in the Package  
Insert or current Investigator Brochure.  
 
Unexpected adverse events are thos e not listed in the Package Insert (P.I.) or current Investigator  
Brochure (I.B.) or not identified. This includes adverse events for which the specificity or  
severity is not consistent with  the description in the P.I. or  I.B. For example, under this  
definition, hepatic necrosis would be unexpected if  the P.I. or I.B. only referred to elevated  
hepatic enzymes or hepatitis. 
 
[Insert additional unexpected adverse events applicable to this disease state]  
PROCEDURES FOR ELICITING, RECORD ING, AND REPORTING ADVERSE  
EVENTS 
 
Eliciting Adverse Events 
A consistent methodology for eliciting AEs at a ll subject evaluation time points should be  
adopted. Examples of non-di rective questions include:  
• “How have you felt since your last clinical visit?” • “Have you had any new or changed health  problems since you were last here?”  
 
Specific Instructions for Recording Adverse Events 
 
Investigators should use correct medical termi nology/concepts when repo rting AEs or SAEs.  
Avoid colloquialisms and abbreviations.  
a.  Diagnosis vs. Signs and Symptoms 
 
If known at the time of reporting, a diagnosis should be reported rather than  individual signs and  
symptoms (e.g., record only liver failu re or hepatitis rather than ja undice, asterixis, and elevated  
transaminases). However, if a constellation of signs and/or symptoms cannot be medically  
characterized as a single diagnosis or syndrome at  the time of reporting, it is ok to report the  
information that is currently available. If a di agnosis is subsequently established, it should be  
reported as follow-up information.  
b.  Deaths 
 
All deaths that occur during the protocol-spe cified AE reporting period (see Section 5.1.2),  
regardless of attribution, will be reported to the appropriate parties. When recording a death, the  
event or condition that caused or contributed to the fatal outcome should be reported as the single  
medical concept. If the cause of death is unknow n and cannot be ascertained at the time of  
reporting, report “Unexplained Death”. 
 
c.  Preexisting Medical Conditions 
 
A preexisting medical condition is one that is present at the star t of the study. Such conditions  
Protocol Amendment 12, date December 4, 2014 52should be reported as medical and surgical histor y. A preexisting medical condition should be re- 
assessed throughout the trial and reported as an AE or SAE only if the frequency, severity, or  
character of the condition worsen s during the study. When reporting such events, it is important  
to convey the concept that th e preexisting condition has chan ged by including applicable  
descriptors (e.g., “more frequent headaches”). 
 
d.  Hospitalizations for Medical or Surgical Procedures 
 
Any AE that results in hospitalization or prol onged hospitalization shou ld be documented and  
reported as an SAE. If a subject is hospitalized to undergo a medica l or surgical procedure as a  
result of an AE, the event responsible for the pr ocedure, not the procedure itself, should be  
reported as the SAE. For example, if a subjec t is hospitalized to unde rgo coronary bypass  
surgery, record the heart condition that  necessitated the bypass as the SAE. 
 
Hospitalizations for the following re asons do not require reporting: 
• Hospitalization or prolonged hospi talization for diagnostic or elec tive surgical procedures for  
 preexisting conditions • Hospitalization or prolonged hospitalization requ ired to allow efficacy measurement for the  
 study or • Hospitalization or prolonged hospitalization for sche duled therapy of the target disease of the study. 
   
Protocol Amendment 12, date December 4, 2014 53e.   Pregnancy 
 
If a female subject becomes pre gnant while receiving investigati onal therapy or within [insert  
time period (e.g., 90 days)] after th e last dose of study drug, a repor t should be completed and  
expeditiously submitted to the Genentech, Inc. Follow-up to obtain the outcome of the pregnancy  should also occur. Abortion, whet her accidental, therapeutic, or s pontaneous, should always be  
classified as serious, and e xpeditiously reported as an SA E. Similarly, any congenital  
anomaly/birth defect in a child born to a fema le subject exposed to th e {study drug} should be  
reported as an SAE.   
f. Post-Study Adverse Events 
 
The investigator should expeditio usly report any SAE occurring af ter a subject has completed or 
discontinued study participation if a ttributed to prior {study drug} expo sure. If the inve stigator should 
become aware of the development of cancer or a congenital anomaly in a subsequently conceived 
offspring of a female subject w ho participated in the study, this should be reported as an SAE.  
 
g. Reconciliation 
 
The Sponsor agrees to conduct reconciliation for th e product. Genentech and the Sponsor will agree to 
the reconciliation periodicit y and format, but agree at minimum to exchange monthly line listings of 
cases received by the other party.  If discrepancies are identifie d, the Sponsor and Genentech will 
cooperate in resolving the discrepancies. The responsible individua ls for each party shall handle the 
matter on a case-by-case basis until satisfactory resolution. 
 
h. AEs of Special Interest (AESIs) 
 
AEs of Special Interest are defined as a potential safety problem, identified as a result of safety monitoring of the Product    The [study drug] Events of Special Interest are:  [List of Events of Special Interest HERE] 
 
7.4 Potential Risks for Study Drugs  
 
The following adverse events has been reported in previous clinical trials  with the drugs that 
are used in the current study (GDC-0449, nab- Paclitaxel and Gemcita bine) and can be  
expected during the study. 
 
7.4.1 Adverse Event List(s) for GDC-0449 
 
The toxicities possibly related to GDC-0449 repor ted in previous phase 1 clinical trial 
included:  
 
• Constitutional:  Fatigue, weight loss 
 
Protocol Amendment 12, date December 4, 2014 54• Cardiovascular : atrial fibrillation 
 • Gastrointestinal:  anorexia, dyspepsia (heartburn or stomach upset), nausea, vomiting 
 
• Metabolic:  hyponatremia, hypomagnesemia 
 
• Neurologic:  hypoesthesia (sensory neuropathy), dysge usia (taste alteration), hypogeusia 
(decrease taste), ageusia (loss of taste),  numbness 
 • Musculoskeletal:  arthralgia, muscle spasms 
 • Skin and subcutaneous tissue disorders: skin exfoliation, al opecia (scalp, body, 
eyelashes and face), dermatitis acneiform  GDC-0449 has been administered in a limited number of clin ical studies. The following 
adverse events had been observed in animal studies . The adverse events of GDC-0449 
with other combinations chemotherapy ar e not known. Several studies in humans 
combining GDC-0449 with other chemothe rapy agents are currently underway. 
 
 Dogs: 
Decreased platelets; prolonge d QTc; increased salivation;  increased cholesterol; 
proteinuria; weight loss; weight gain; foamy vomitus; orange mucoid feces; alopecia, increased male germ cell degeneration in seminiferous tubules and epididymides, 
decreased sperm motility and decreased number of corpora lutea. 
 
Rats: 
Hunched appearance; increased stomach we ight; weight gain; weight loss; rough 
haircoat; dehydration; few feces; increased incidence of malocclusion; microscopic 
lesions on incisors; hyperalbuminemia; in creased cholesterol; decreased alkaline 
phosphatase; decreased grip strength; decrea sed motor activity; re versible mild body 
tremors (male), twitching, ataxia.  
 Note : GDC-0449 in combination with other agen ts could cause an exacerbation of any 
adverse event currently known to be caused by the other agent, or the combination may 
result in events never previously associated with either agent. 
 
Teratogenic Effects of GDC-0449 
Studies have demonstrated that inhibition of the Hh pathway in embryos results in brain, 
facial, and other midline defects, includi ng holoprosencephaly or microencephaly, 
cyclopia, absent nose, cleft palate, tooth abnormalities, and bone development 
abnormalities.  While the effects of GDC-0449 on the developing human fetus at the recommended therapeutic dose are unknown, wo men of childbearing potential and men 
must agree to use two methods of contracep tion (i.e., barrier contraception and another 
method of contraception) prior to study entr y, for the duration of study participation, and 
for 7 months following treatment. 
Protocol Amendment 12, date December 4, 2014 55 
Women of childbearing potenti al are defined as follows: 
 Patients with regular menses 
 Patients with amenorrhea, irregular cycles , or using a contraceptive method that 
precludes withdrawal bleeding 
 Women who have ha d a tubal ligation 
 
Women are considered not to be of childbe aring potential for th e following reasons: 
 The patient has undergone hysterectom y and/or bilateral oophorectomy. 
 The patient is post-menopausal defined by ame norrhea for at least 1 year in a woman > 
45 years old.  Women of childbearing potential are re quired to use two forms of acceptable 
contraception (refer to Appendix B), includi ng one barrier method during participation in 
the study and for the 12 months following the la st dose.  Women of childbearing potential 
are also advised to have monthly pregnancy tests for 7 months after discontinuation of 
GDC-0449.  All patients should receive c ontraceptive counseling either by the 
investigator or by an OB/gyneco logist or other physician who is qualified in this area of 
expertise.  If a woman of childbearing poten tial believes that he r contraceptive method 
has failed, emergency contrace ption should be considered. 
 If a patient is suspected to be pr egnant, GDC-0449 should be IMMEDIATELY 
discontinued and the study physic ian contacted.  A positive ur ine test must be confirmed 
by a serum pregnancy test.  If it  is confirmed that the patients is not pregnant, the patient 
may resume dosing with GDC-0449.    
If a female patient becomes pregnant durin g therapy or within 7 months after the 
last dose of GDC-0449, or if the female pa rtner of a male patient exposed to the 
drug becomes pregnant while the male pa tient is receiving GDC-0449 or within 7 
months after the last dose of GDC-0449 , the investigator must be notified in order to 
facilitate outcome follow-up.  Abortion, whether accidental, therapeutic, or sp ontaneous, should always be classified as 
serious.  Any congenital anomal y/birth defect in a child co nceived during the study or 
within 7 months after the la st dose of GDC-0449 to a female patient or to a female 
partner of a male patient exposed to the agen t during treatment or w ithin 7 months after 
the last dose of GDC-0449 should be r ecorded and reported as an SAE. 
 In addition, it is not know n whether GDC-0449 that may be present in seminal fluid 
would cause teratogenic effects in a fetus born to the female partner of a male subject.  
Sexually active male subjects should utilize a barrier form of contraception, even those 
who have had a vasectomy, during study treatment and for 7months after the last dose.  Male patients should advise their partners to use an addi tional method of contraception 
during the study and for at least 7 months  after discontinuation of GDC-0449.  Male 
subjects should also not donate sperm during treatment or up to 7 months after the last 
dose. 
Protocol Amendment 12, date December 4, 2014 56 
   Risk of Male Germ Cell Degeneration 
Effects on testes and epididymides charact erized by mild to moderate germ cell 
degeneration in seminiferous tubules, relati ve paucity of spermatozoa, and increased 
cellular debris in epididymides were observed in male dogs at all dose levels tested and 
were consistent with the pharmacologic activ ity of the drug.  There were no changes in 
Leydig or Sertoli cells in any animal.  Eviden ce of partial recovery was noted after a 4-
week recovery period.  Germ cell degeneration in male patients is likely to occur at pharmacologically active 
doses.  There is no specific mitigation st rategy for this GDC-0449 toxicity; however, 
male patients should be made aware of it duri ng the consent process.  Although this effect 
is expected to be reversible with discon tinuation of dosing, long-term effects on male 
fertility cannot be excluded at this time.   
7.4.2 Adverse Event List(s) for nab-Paclitaxel 
 
The most common toxicities reported in pr evious clinical trials included:  
 
•  Myelosuppression, predominantly neutropenia . Grade 4 neutropenia was reported 
and typically resolved in < 7 days and did not  require colony stimul ating factor support.  
 
•  Peripheral neuropathy, predominantly sensory . Grade 3 peripheral neuropathy 
was reported and typically improved to Grade 1 or 2 within 21 days of interrupting the 
nab-Paclitaxel dose. Following resolution of  the peripheral neuropathy to acceptable 
levels, clinicians were able to restart na b-Paclitaxel dosing at a lower dose levels.  
 
•  Nausea and vomiting . Nausea and vomiting were see n, typically at Grade 1 or 2 
levels. This AE responded well to standard anti-emetic regimens.  
 
•  Myalgias and arthralgias . Myalgias and arthralgias were reported and typically 
were Grade 1 or 2; these were respons ive to standard acetaminophen-containing 
medication.  •  Mucositis . Mucositis was reported typically Gr ade 1 or 2. It was not dose limiting 
 •  Alopecia . Alopecia was reported by most patien ts and was similar to that seen 
with Taxol. 
 
7.4.3 Adverse Event List(s) for Gemcitabine 
 
The most common toxicities reported with gemcitabine are: 
 
• Hematologic  - In studies in pancreatic cancer, myelosuppression is the dose-
limiting toxicity with Gemzar®, but <1% of  patients discontinued therapy for anemia, 
Protocol Amendment 12, date December 4, 2014 57leukopenia, or thrombocytopenia. Red blood cell  transfusions were required by 19% of 
patients. The incidence of sepsis was le ss than 1%. Petechiae or mild blood loss 
(hemorrhage), from any cause, was reported in 16 % of patients; less than 1% of patients 
required platelet transfusions. Patients s hould be monitored for myelosuppression during 
Gemzar therapy and dosage modified or suspended according to the degree of 
hematologic toxicity    • Gastrointestinal  - Nausea and vomiting were co mmonly reported (69%) but were 
usually of mild to moderate severity. Se vere nausea and vomiti ng (WHO Grade 3/4) 
occurred in <15% of patients. Diarrhea was reported by 19% of pati ents, and stomatitis 
by 11% of patients.   
 
 • Hepatic - In clinical trials, Gemzar was associ ated with transient elevations of one 
or both serum transaminases in approximately 70% of patients, but there was no evidence 
of increasing hepatic toxicity with either longer duration of exposure to Gemzar or with 
greater total cumulative dose. Serious hepato toxicity, including liver failure and death, 
has been reported very rarely in  patients receiving Gemzar.   
 • Renal  - In clinical trials, mild proteinuri a and hematuria were commonly reported. 
Hemolytic Uremic Syndrome (HUS) has been  reported rarely (0.25%) with the use of 
Gemzar. Renal failure may not be reversible even with discontinuation of therapy and 
dialysis may be required.  
 
 • Fever  - The overall incidence of fever wa s 41%. This is in contrast to the 
incidence of infection (16%) a nd indicates that Gemzar may cause fever in the absence of 
clinical infection. Fever was frequently asso ciated with other flu-like symptoms and was 
usually mild and clinically manageable.    • Rash  - Rash was reported in 30% of patients.  The rash was typically a macular or 
finely granular maculopapular pruritic eruption of mild to moderate severity involving 
the trunk and extremities. Pruritus was reported for 13% of patients.   • Pulmonary - In clinical trials, dyspnea, unrelat ed to underlying di sease, has been 
reported in association with Gemzar therapy.  Dyspnea was occasion ally accompanied by 
bronchospasm. Pulmonary toxicity has been  reported with the use of Gemzar. The 
etiology of these effects is  unknown. If such effects develop, Gemzar should be 
discontinued. Early use of supportive care  measures may help ameliorate these 
conditions. • Neurotoxicity  - There was a 10% incidence of mild  paresthesias and a <1% rate of 
severe paresthesias  • Edema : Edema (13%), peripheral edema (20%) %), and generalized edema (<1%) 
were reported. Less than 1% of pa tients discontinued due to edema. 
 
• Flu-like Symptoms  - “Flu syndrome” was reported for 19% of patients. Individual 
Protocol Amendment 12, date December 4, 2014 58symptoms of fever, asthenia, anorexia, headache, cough, chills, and myalgia were commonly 
reported. Fever and asthenia were also reported frequently as isolated symptoms. Insomnia, 
rhinitis, sweating, and malaise were reported infrequently. Less than 1% of patients 
discontinued due to flu-like symptoms.   
 
• Infection  - Infections were reported for 16% of patients. Sepsis was rarely reported.   
 
• Alopecia - Hair loss, usually minimal, was reported by 15% of patients 
 
Please see gemcitabine prescribing info rmation for more details on the known 
precautions, warnings, and adverse reactions of gemcitabine (current version of 
Prescribing Information is provided in the Study Manual).  
 
7.5 Reporting Adverse Events 
 
The Investigator is responsible for recording, re porting and following all adverse events, regardless  
of causality, observed during the study period,  starting with initial st udy drug administration and 
ending at the time the patient goes off study or 30 days after patient’s last dose of study drug, 
whichever is later. Events occurr ing within 30 days prior to st udy drug administration should be 
recorded as pre-treatment signs and symptoms.  The investigator is responsible for ensuring that all AEs and SAEs that ar e observed or reported 
during the study, are collected and re ported to the FDA, appropriate IRB(s), and Genentech, Inc. in 
accordance with CFR 312.32 (IND Safety Reports).  “Lack of efficacy” (progressive disease) is not cons idered an adverse event. The signs and symptoms 
or clinical sequelae resulting from lack of efficacy should be reported if they fulfill the adverse event or SAE definitions.  
Laboratory Results as Serious Adverse Events 
 
According to the NCI CTCAE system of adverse ev ent grading, laboratory va lues of Grade 3 or 4 
are described as “severe” or “ life-threatening.” For example, a neutrophils count <500/mm3 would 
meet laboratory criteria as Grad e 4 (“life-threatening”). This de scription is not always synonymous 
with the assessment of the “serious” crit eria of an AE as “life threatening”. 
 In order for adverse events to be considered seri ous by “life-threatening”  c r i t e r i a ,  i t  m u s t  b e  
medically judged as possessing “an immediate risk of death from the event as it occurred,” not 
because of the theoretical potenti al for life-threatening consequen ces. In the case of a neutrophil 
count <500/mm3, the AE would be captured as an AE of Grade 4 neutropenia, but it would not 
automatically be considered a SAE unless the inve stigational physician determined this represented 
an immediately life-threate ning event for the patient. 
 Specifically, uncomplicated Grade 4 neutr openia should not be reported as a SAE. 
Neutropenia associated with fe ver, infection, or hospitalizati on should be reported as a SAE. 
 
Protocol Amendment 12, date December 4, 2014 59Investigator Reporting of AEs and SAEs 
 
The Investigator or designee must completely a nd promptly record each adverse event using the 
eCRF, regardless of relationship to study drug as determined by the Investigator. The Investigator 
must assess AE/SAE causality for any patients treated at his/her site. The Investigator should 
attempt, if possible, to establ ish a diagnosis based on the pati ent's signs and symptoms. When a 
diagnosis for the reported signs or  symptoms is known, the Investigat or should report the diagnosis, 
not the symptoms, as the adverse event.  Clinically significant laboratory abnormalities presen t at the Baseline visit wi ll be recorded as pre-
treatment signs and symptoms. After study trea tment administration, laboratory abnormalities will 
not be recorded as adverse events unless consider ed clinically significant by the Investigator, and 
clinically significant laboratory abnormalities will not  be recorded as serious AEs unless the event 
meets the definition of serious.  AEs and SAEs should be reported on the elect ronic Case Report Forms provided by CRAB.  
 
Reporting Serious Adverse Events (SAEs) 
 
The study period during which all AEs and SAEs must be reported begins after informed consent is 
obtained and initiation of study trea tment [or “initiation of any study procedures”] and ends 30 days 
[or insert other time period] following the la st administration of study treatment or study 
discontinuation/termination, whichever is earlier. After this period, inves tigators should only report 
SAEs that are attributed to prior study treatment.  
ALL sites should report ALL Serious adverse ev ents, regardless of causality, to ALL of the 
following: 
 1. Coordinating Site (Joh ns Hopkins Hospital) 
2. Genentech Safety Group 
3. Cancer Research and Biostatistics (CRAB) 
4. Institution IRB 
 
Timelines for reporting SAE’s 
 1. Participating sites are responsib le for reporting SAE’s to the Coordinating Site (Johns 
Hopkins) within 24 hours of becoming aware of the event occurrence.  All SAEs should be 
recorded on the Serious Adverse Event Reporting Form accessible on the website. This 2 page 
form must be completed and faxed to:  Study Coordinating Site 
Daniel Laheru MD (Prinicipal Investigator) Yvette Cetasaan, CCRP  Fax: 443-287-6566 
 
Protocol Amendment 12, date December 4, 2014 602. Participating sites are responsible  for reporting to their Instituti on IRB in accordance with their 
institution guidelines.  
 
3. Participating sites are responsible for reporting to the Genentech Safety Group  by facsimile 
within 24 hours of becoming aware of the event occurrence.   All SAEs should be recorded on 
CRAB eCRF and faxed to: 
 Genentech Drug Safety 
 
Fax: (650) 225-4682 or (650) 225-5288 
 
4. Participating sites are responsib le for reporting to Cancer Res earch and Biostatistics (CRAB ) 
within 24 hours  of becoming aware of the event occurrence.   All SAEs should be recorded on 
CRAB eCRF.  
 
The Johns Hopkins Investigators will report all SAEs on CRAB eCRF and faxed to all the following 
agencies: 
 
1. IRB- within 3 days if the SAE is  related to the study dr ug. If the SAE is not considered related to 
the study drug within 10 days.  
  
Johns Hopkins Medicine IRB Reed Hall B-130 1620 McElderry St. Baltimore, MD 21205-1911 Phone: 410-955-3008 
 
2. Genentech Drug Safety- within 24 hrs  
Fax: (650) 225-4682 or (650) 225-5288 
 
3. FDA- .  As per section 7.6 
 
4. CRAB- within 24 hrs  
 
Follow up on SAE reports should also be send to all the above agencies within  two weeks of receipt 
of information at the site.  Investigators must report all SAEs to Genentech within the timelines described below. The completed Medwatch/case report should be faxe d immediately upon completion to Genentech Drug 
Safety at:  (650) 225 4682 OR (650) 225 5288  • Relevant follow-up information should be su bmitted to Genentech Drug Safety as soon as it 
Protocol Amendment 12, date December 4, 2014 61becomes available. 
• Serious AE reports that are rela ted to the [study drug] and AEs of Special Interest (regardless of 
causality)  will be transmitted to Genentech within  fifteen (15) calendar days of the Awareness Date. 
• Serious AE reports that are unrelated to the [s tudy drug] will be transmitted to Genentech within 
thirty (30) calendar days of the Awareness Date. • Additional Reporting Requirements to  Genentech include the following: 
• Any reports of pregnancy following the start of  administration with the [study drug] will be 
transmitted to Genentech within thirty (30)  calendar days of the Awareness Date.  
• All Non-serious Adverse Events originating fr om the Study will be forwarded in a quarterly 
report to Genentech.  Note: Investigators should also repor t events to their IRB as required. 
 MedWatch 3500A Reporting Guidelines In addition to completing appropriate patient de mographic and suspect medication information, the 
report should include the following information w ithin the Event Description (section 5) of the 
MedWatch 3500A form: • Protocol description (a nd number, if assigned) 
• Description of event, severit y, treatment, and outcome if known 
• Supportive laboratory results and diagnostics • Investigator’s assessment of the relationship of the adverse event to each  investigatio nal product 
and suspect medication  
Follow-up Information 
 
Additional information may be added to a previ ously submitted report by any of the following 
methods: 
• Adding to the original MedWatch 3500A report and submitting it as follow-up • Adding supplemental summary information and submitting it as follow-up with the original 
MedWatch 3500A form  
  
Protocol Amendment 12, date December 4, 2014 62• Summarizing new information and faxing it with a cover letter including patient identifiers (i.e. 
D.O.B. initial, patient number), protocol descri ption and number, if assigned, brief adverse event 
description, and notation that additional or follo w-up information is being submitted (The patient 
identifiers are important so that the new inform ation is added to the correct initial report) 
 Occasionally Genentech may contact the reporter for additional inform ation, clarification, or current 
status of the patient for whom and adverse event was reported. For questions regarding SAE 
reporting, you may contact the Genentech Drug Safe ty representative noted above or the MSL 
assigned to the study. Relevant follow-up informati on should be submitted to Genentech Drug Safety 
as soon as it becomes available and/or upon request.  MedWatch 3500A (Mandatory Reporting) form is available at http://www.fda.gov/AboutFDA/Report sManualsForms/Forms/default.htm 
 
 
7.6  Safety Reporting Requirements for IND Holders 
 
For Investigator Sponsored IND Studies , there are some additional reporting requirements for the 
FDA in accordance with the guidance set forth in 21 CFR 212.32. Sponsor-investigators of studies 
conducted under an IND must comply with th e following safety repor ting requirements:  
 
a. Expedited IND Safety Reports: 
 
7 Calendar-Day Telephone or Fax Report :   
The Sponsor-Investigator is  required to notify the FDA of any fatal or life- threatening adverse event 
that is unexpected and assessed by the investigator  to be possibly related to the use of GDC-
0449.  An unexpected adverse event is one that is not already described in the Investigator Brochure.  
Such reports are to be telephoned or faxed to the F DA and Genentech within 7 calendar days of first 
learning of the event.  Each te lephone call or fax transmission (see fax number below) should be 
directed to the FDA new drug review division in th e Center for Drug Evaluation and Research or in 
the product review division for the Center for Biologics Evaluation and Research, whichever is 
responsible for the review of the IND. 
 
15 Calendar-Day Written Report :   
The Sponsor-Investigator is also required to notify the FDA and all participating investigators, in a 
written IND Safety Report, of any serious, unexpected AE that is c onsidered possibly related to the 
use of GDC-0449.  An unexpected adverse event is  one that is not already described in the 
Investigator Brochure.  Written IND Safety Reports should include an Analysis of Similar Events in accordance with regulation 21 CFR § 312.32.  All safety reports pr eviously filed with th e IND concerning similar 
events should be analyzed.  The new report shoul d contain comments on the significance of the new 
event in light of the prev ious, similar reports.   
 Written IND safety reports with Analysis of Similar Events are to be submitted to the FDA, Genentech Drug Safety, and all participating investig ators within 15 calendar days of first learning 
Protocol Amendment 12, date December 4, 2014 63of the event.   In this study electronic CRF will be used. 
 FDA fax number for IND Safety Reports: 1 (800) FDA - 0178 
 
All written IND Safety Reports submitted to the FDA by the Sponsor-Investigator must also be 
faxed to:  
1. Genentech Drug Safety 
 
Fax: (650) 225-4682 or (650) 225-5288 
For questions related to safety reporting, contact: 
 Genentech Drug Safety Tel: 1-888-835-2555  (Please use the safety reporting fa x cover sheet attached to this document for your fax transmission) 
 
b. IND Annual Reports 
In accordance with the regulation 21 CFR § 312.32, th e Sponsor-Investigator shall within 60 days of 
the anniversary date that the IND went into eff ect submit a brief report of the progress of the 
investigation.  Please refer to Code of Fede ral Regulations, 21 CFR § 312.32 for a list of the 
elements required for the annual report.  All IND annual reports submitted to the FDA by the Sponsor-Investigator should be copied to Genentec h.  Copies of such reports should be mailed to: 
 Genentech, Inc. ATTN: GDC-0449 IST Coordinator  
1 DNA Way, Mailstop 445-A 
South San Francisco, CA 94080-4990  
Tel: (650) 225-7121 (Oncology Hotline)  
STUDY CLOSE-OUT 
 
Any study report submitted to the FDA by the Sponsor-Investigator should be copied to Genentech. This includes all IND annual reports and the Clin ical Study Report (final study report). Additionally, 
any literature articles that are a result of the study should be sent  to Genentech. Copies of such 
reports should be mailed to the assigned Clinical Operations contact for the study: 
  Vismodegib (GDC0449) Protocols Email: hedgehog-gsur@gene.com Fax: 866-741-3639 
7.7 Data and Safety Monitoring Plan 
 
This is a Level II study under the SKCCC Data Safe ty Monitoring Plan (DSMP).  Data Monitoring 
of this study will occur after the first three patients  are enrolled and every six months thereafter.   
 The study will be monitored internally by the Prin cipal Investigator and externally by CRO in 
Protocol Amendment 12, date December 4, 2014 64accordance with SKCCC guidelines.   
 7.7.1     Internal review in all participating centers  
The PI in each participating center will have a regular internal monitoring. 
 
The internal review should occur after the first three patients are enrolled and have completed two cycles 
of therapy. The process should occur every six months thereafter. The PI at each institution will review 
data to assure the validity of data, as well as, the safety of the subjects. The PI will also monitor the progress of the trial. The PI will  review safety reports and clini cal trial efficacy endpoints and to 
confirm that the safety outcomes favor continuation of the study.  
  
The PI will be responsible for maintaining the clinical protocol, reporting adverse events, assuring that consent is obtained and docum ented, reporting of unexpected outco mes, and reporting the status 
of the trial in the annual report submitted to the I RB. Content of the report will include year-to-date 
and full trial data on: accrual and eligibility, protocol compliance, treatment administration, toxicity 
and adverse events, response, survival, regula tory compliance, complia nce with prearranged 
statistical goals. 
The following will be reviewed: 
 
- Original, signed consent forms to ensure that one is available for each subject.  
 - Case report forms and source documentation for valid ity and consistency in the completed entries, 
as well as, accuracy, legibili ty, signatures and dates.  
 - Treatment administration records to ensure co ncurrence between dispensing records and CRFs as 
to subject identity, and dosage  of study drug administered.  
 - Compliance with the protocol will also be checked.   - Pharmacy drug accountability records for accuracy  and completeness, and study drug storage to 
ensure proper maintenance and supply levels.  
 7.7.2  External review in all participating centers 
 
Johns Hopkins SKCCC: The protocol  will be monitored externally  by the SKCCC CRO in accordance 
with SKCCC guidelines.  Trial monitoring and re porting will be done through the Safety Monitoring 
Committee (SMC) at SKCCC.   Participating sites: The protocol will be monitored by an external CRO (TD2). A report of the reviews 
will be submitted to Johns Hopkins prin cipal investigator and SKCCC CRO.  
  
8. PHARMACEUTICAL INFORMATION 
 
A list of the adverse events and potential risks asso ciated with the investig ational or commercial 
agents administered in this study can be found in Section 7.1. 
 
Protocol Amendment 12, date December 4, 2014 658.1 GDC-0449 
 
Route  of Administration: Oral 
 
Mode of Action:   GDC-0449 provides anticancer responses by inhibiting the 
Hedgehog pathway.  The He dgehog signaling pathway 
controls cell differentiation, growth, and proliferation.  It is most active during embryogenesis but may also play a role in 
the regulation of adult stem cel ls involved in the maintenance 
and regeneration of adult tissues. 
 
How Supplied:   GDC-0449 is supplied by Genentech/ JHH Investigational 
Drug Services (IDS). It is available as:  
 25-mg orange, size 3 capsules containing 
microcrystalline cellulose, sodium lauryl sulfate, talc, sodium 
glycolate and magnesium stea rate as excipients.   
 150-mg grey and pink, size 1 capsules containing 
microcrystalline cellulose, lactose monohydrate, sodium 
lauryl sulfate, povidone, talc, sodium glycolate, and magnesium stearate.  Capsules are packaged in 75-mL round, white, high-density polyethylene (HDPE) bottles an d closed with 38/400 two-
piece HDPE child-resistant caps.  Each bottle contains 32 
capsules. 
                       Clinical Formulation: For the clinical studies, hard gelatin capsules containing 150 
mg vismodegib are available.  For the 150 mg strength, 
placebo capsules ar e also available. 
 
The 150-mg vismodegib drug product is a hard gelatin capsule formulation for oral administration. The capsule fill 
consists of vismodegib and the following excipients: 
microcrystalline cellulose PH101, lactose monohydrate, 
sodium lauryl sulfate, povidone K29/32, sodium starch  glycolate, talc, magnesium 
stearate, and purified water. All of these excipients are 
compendial (USP/NF-EP) grade.  The capsule shell consists 
 of gelatin, red iron oxi de, black iron oxide, and 
titanium dioxide. A compendial-grade black printing ink may 
be used. 
 
The placebo for the 150-mg drug product is a hard gelatin capsule formulation for oral administration. The capsule fill 
consists of the following ex cipients, without the active 
pharmaceutical ingredient (API ): microcrystalline cellulose 
PH102, lactose monohydrate, sodi um lauryl sulfate, sodium 
Protocol Amendment 12, date December 4, 2014 66starch glycolate, talc, and ma gnesium stearate. All of these 
excipients are compendial (U SP/NF-EP) grade. The capsule 
shell consists of gelatin, red ir on oxide, black iron oxide, and 
titanium dioxide. A compendial-grade black printing ink may 
be used. 
 Storage:   GDC-0449 capsules should be stored in the recommended 
storage conditions at 59°F an d 86°F (15°C and 30°C) and 
should be protected from excessive exposure to light. Information on the shelf life of the capsules is provided on the label. 
 
Drug Administration:            Patients should ta ke GDC-0449 at approximately the  
                        sa me time each day, with or wi thout food.  If a patient  
                       misses a dose (e.g., due to emesis ), he or she should  
                        be instru cted not to take or make up that dose and to  
                         resume  dosing with the next scheduled dose.  Missed  
                       doses should not be made up.  
 
Patient Care Im plications:  The terminal half-life of GDC -0449 is currently unknown, 
but is expected to be longer th an 1 week, and ma y be as high 
as 2 to 3 weeks.  If plasma levels of GDC-0449 need to be lowered emergently, animal studies suggest that oral administration of activated ch arcoal may lower drug plasma 
levels more quickly than  dose cessation alone. 
 
Drug Interactions :   Avoid any concurrent drug metabolized by  
                         cy tochrome P450 that has a narrow therapeutic index. 
 
Supply:                                  GDC-0449 will be obtained from JHH IDS. 
  
 
8.2 nab-Paclitaxel 
 
Route  of Administration: Intravenous 
 
Packaging, Labeling, and Storage of Study Drug :     
 
Nab-Paclitaxel will be supplied by Abraxis BioScience (Abraxis) /JHHIDS, in single-use vials. Each single-use 50 mL vial will contain paclitaxel (100 mg) and approximately  900 mg human albumin (HA) as a 
stabilizer. Each vial will be la beled according to country-specific 
regulatory requirements for labeli ng of investiga tional products. 
Unreconstituted nab-paclitaxel shoul d be stored at controlled room 
temperature (25°C or 77°F; excursions permitted to 15- 30ºC [See USP 
Protocol Amendment 12, date December 4, 2014 67controlled room temperature]). Reconstituted nab-paclitaxel should be 
used immediately. If not used immediately, the vial of reconstituted Nab-Paclitaxel must be placed in its carton and be placed in a refrigerator at 2° to 8°C (36° to 46°F) for a maximum of 8 hours. Both forms should be stored in an area free of environmental extremes and must be accessible only to study personnel. Temperature records for nab-paclitaxel must be 
made available to the Abraxis or other sponsor nominated monitoring 
teams for verification of pr oper study drug storage.  
    
Administration 
 
NOTE: It is not a requirement to use filter needles in the preparation 
of, or in-line filters during the admini stration of nab-paclitaxel. In any 
event, filters of pore-size less than  15 micrometers must not be used. 
 
nab-paclitaxel will be reconstituted by appropriate study personnel and 
administered to the patient at the study site. The Investigator will calculate the body surface area (BSA) of the patient  in order to determine the total 
amount of paclitaxel to be administered. 
 
Reconstitution and use of nab-paclitaxel: 
 
1. Calculate the patient’s BSA according to standard institutional methods. 
BSA will be calculated at Baseline and recalculated only if body weight 
changes by more than 10%. Dosing BS A may be capped if the treating 
physician believes it is in the best interest of an obese patient. 
 2. Calculate the total dose (in mg) to be administered by: 
Total Dose (mg) = BSA x (study dose mg/m2) 
 
3. Calculate the total numb er of vials required by: 
Total Number of Vials = To tal Dose (mg) 100 (mg/vial) 
Round up the number of vials to be r econstituted to the next higher whole 
number when a fractional number of  vials is obtained by the above 
formula (e.g., if the total number of vials = 4.05 or 4.5, th en 5 vials would 
be reconstituted).  4. Using sterile technique, prepar e the vials for reconstitution. 
 5. Swab the rubber stoppers with alcohol.  6. Reconstitute each nab-paclitaxel vi al by using a 50 or 60 cc sterile 
syringe to inject 20 mL of 0.9% Sodium  Chloride Injection or equivalent 
Protocol Amendment 12, date December 4, 2014 68into each vial over a period of not less than 1 minute (Note: Change the 
syringes after reconsti tuting every 3 vials). 
 ◦ Slowly inject the 20 mL of 0.9% Sodi um Chloride Injection, over a 
minimum of 1 minute, using the sterile  syringe directing the solution flow 
onto the inside wall of the vial. 
 ◦ DO NOT INJECT the 0.9% Sodium Chloride In jection solution directly 
onto the lyophilized cake as th is will result in foaming. 
 ◦ Once the injection is complete, allow the vial to sit for a minimum of 5 
minutes to ensure proper wetting of the lyophilized cake/powder. 
 ◦ Gently swirl and/or invert the vial slowly for at least 2 minutes until 
complete dissolution of any cake/powder occurs. Avoid generation of 
foam.  ◦ If foaming or clumping occurs, sta nd solution for at least 15 minutes 
until foam subsides.  ◦ Each mL of reconstituted product will contain 5 mg of paclitaxel. 
 7. Calculate the exact total dosi ng volume of 5 mg/mL suspension 
required for the patient: 
Dosing volume (mL) = Total dose (mg) / 5 (mg/mL) 
 
8. The reconstituted sample should be milky and homogeneous without 
visible particulates. If unsuspended pow der is visible, the vial should be 
gently inverted again to ensure comple te resuspension, prior to use. 
 9. Use immediately following reconsti tution. If not used immediately, 
replace the reconstituted vial in the carton and store reconstituted nab-Paclitaxel in a refrigerator for not more than 8 hours. 
 10. Using a new, sterile 50 or 60 cc syringe, withdraw the reconstituted 
nab-Paclitaxel solution. Do  not remove the rubber  stopper from the nab-
Paclitaxel vials as this can comp romise the sterility of the drug 
preparation.  11. Inject the calculated dosing volum e of reconstituted nab-Paclitaxel 
suspension into an empty sterile, st andard PVC IV bag, using an injection 
port. Inject perpendicularly into the center of the injection port to avoid dislodging plastic material into the IV bag. Repeat steps 9 and 10 until the patient’s entire required dose is  injected into the IV bag. 
 12. Remove the injection port. 
Protocol Amendment 12, date December 4, 2014 69 
13. Once the exact volume of reconstituted nab-Paclitaxel has been withdrawn from the vials, discar d any excess solution left over in 
accordance with standard operating procedures for cytotoxic drugs.  14. Administer the calculated dosing volume of reconstituted nab-Paclitaxel suspension by IV infusi on over 30 minutes. The use of in-line 
filters is not necessary; if used, in-line filters with pore sizes of < 15 microns (15 μm) should not be used. 
 
Supply:            nab-Paclitaxel will be obtained from JHH IDS. 
 
 
8.3  Gemcitabine 
 
Route  of Administration: Intravenous 
 
Description: 
For complete details on drug admi nistration, storage, clinical 
pharmacology, and the human pharmacokinetics of gemcitabine, please see the gemcitabine package insert (current version of Prescribing 
Information is provided in the Study Manual). 
 
Formulation: 
Gemcitabine (difluorodeoxycy tidine) is a pyrimidine  
antimetabolite, which is an analogue of deoxycytidine. It was initially 
synthesized as a potential antiviral drug but selected for anticancer 
development because of its activity in in-vivo and in vitro tumors. 
Gemcitabine is approved for the trea tment of patients with pancreatic 
cancer and will be obtained commercially. Gemcitabine should be 
stored, reconstituted and administered  according to the manufacturer’s 
recommendation  
Packaging, Labeling, and St orage of Gemcitabine :     
 
Instructions for Storing Gemcitabine Store at controlled room temperatur e (20° to 25°C) (68° to 77°F). The 
USP has defined controlled room temperature as “A temperature 
maintained thermostatically that encompasses the usual and customary working environment of 20° to 25°C (68°  to 77°F); that results in a mean 
kinetic temperature calculated to be not  more than 25°C; and that allows 
for excursions between 15° and 30°C ( 59° and 86°F) that are experienced 
in pharmacies, hospitals, and warehouses.” 
 
Administration: 
 
Protocol Amendment 12, date December 4, 2014 70Preparation and administration of  gemcitabine should be per the 
gemcitabine package insert (current ve rsion of Prescribing Information is 
provided in the Study Manual).  Instructions for Use/Handling of Gemcitabine The recommended diluent for reconsti tution of gemcitabine is 0.9% 
Sodium Chloride Injection without preservatives. Due to solubility 
considerations, the maximum con centration for gemcitabine upon 
reconstitution is 40 mg/mL. Reconstituti on at concentrations greater than 
40 mg/mL may result in incomplete di ssolution, and should be avoided. 
To reconstitute, add 5 mL of 0.9% S odium Chloride Injection to the 200-
mg vial or 25 mL of 0 .9% Sodium Chloride Inje ction to the 1-g vial. 
Shake to dissolve. These dilutions each yield a gemcitabine concentration of 38 mg/mL which includes accounting for the displacement volume of 
the lyophilized powder ( 0.26 mL for the 200-mg vial or 1.3 mL for the 1-g 
vial). The total volume upon recons titution will be 5.26 mL or 26.3 mL, 
respectively. Complete withdrawal of the vial contents will provide 200 
mg or 1 g of gemcitabine, respective ly. The appropriate amount of drug 
may be administered as prepared or  further diluted with 0.9% Sodium 
Chloride Injection to concentrations as low as 0.1 mg/mL. Reconstituted 
gemcitabine is a clear, colorless to light straw-colored solution. After reconstitution with 0.9% Sodium Ch loride Injection, the pH of the 
resulting solution lies in the range of 2.7 to 3.3. The solution should be 
inspected visually for particulate matter and discoloration, prior to 
administration, whenever solution or  container permits. If particulate 
matter or discoloration is found, do not administer.  
 
When prepared as directed, gemcitabine solutions are stable for 24 hours at controlled room temperature 20° to 25°C (68° to 77°F) [ See USP]. 
Discard unused portion. Solutions of r econstituted gemcitabine should not 
be refrigerated, as crystallization may occur. The compatibility of gemcitabine with other drugs has not been studied. No incompatibilities 
have been observed with infusion bottles or polyvinyl chloride bags and administration sets. Unopened vials of  gemcitabine are stable until the 
expiration date indicated on the packag e when stored at controlled room 
temperature 20° to 25°C (68° to 77°F) [ See USP]. 
 Supply:            Will be obtained by commercial means 
 
      
Protocol Amendment 12, date December 4, 2014 718.3  Study Medication Accountability and Destruction  
(GDC-0449 and nab-Paclitaxel) 
 
All study drug required for completion of this study will be provided by Johns Hopkins Hospital (JHH) 
Investigational Drug Services (IDS).   The recipient will acknowledge r eceipt of the drug by returning the appropriate documentation form 
indicating shipment content and conditi on. Damaged supplies will be replaced. 
 Accurate records of all study drug re ceived at, dispensed from, returned to and disposed of by the study 
site should be recorded by using the Drug Inventory Log. Inspections of the study drug supply for 
inventory purposes and assurance of proper storage will be conducte d as necessary. Any significant 
discrepancy will be recorded and reported to JHH ID S or their designee and a plan for resolution will be 
documented.  Study drugs will not be loaned or dispensed by the I nvestigator to another Investigator or site, unless 
specifically requested by  JHH IDS in writing. 
 Temperature records for nab-Paclitaxel must be ma de available to the J HH IDS or other Sponsor 
nominated monitoring teams for verifi cation of proper study drug storage. 
 Only completely unused study drug vials (nab-Pacl itaxel) should be retained by the site until a 
representative from JHH IDS or other JHH IDS- designated personnel have completed an inventory. 
Partially used and completely used vials should be de stroyed according to the site’s guidelines, and their 
disposition should be recorded on the Invest igational Drug Accountability Record Form. 
 
Study drug will either be disposed of at the study s ite according to the study site’s institutional standard 
operating procedure or returned to JHH IDS with the appropriate documentation. JHH IDS or someone 
else designated by the JHH IDS will personally inspec t the study drug inventorie s before returning or 
destroying supplies of either  medication . If the study site chooses to destroy study drug, the method of 
destruction must be documented and JHH IDS mu st evaluate and approve  the study site’s drug 
destruction standard operating pr ocedure prior to the in itiation of drug destru ction by the study site. 
 
 
9. CORRELATIVE/SPECIAL STUDIES 
 
9.1 Laboratory Correlative Studies  
 
We will evaluate two sources of patient material (tumor core biopsies and blood) in order to evaluate the effects of GDC-0449 on the tumor-ini tiating CSC compartment in treated tumors.  
We will also evaluate the effects combination therapy with nab-paclitaxel on circulating biomarker levels, including CA 19-9 and SPARC .  Tumor core biopsies and blood samples will 
be obtained pre- and post- treatment in patients.  
 Biopsies :  Pre-treatment biopsies will be done at scr eening within 14 days before starting cycle 
1. The second post-treatment biopsy will occur after two months of being on the study.  
Protocol Amendment 12, date December 4, 2014 72 
Patients who  have response to therapy (partial res ponse or complete response) but then subsequently 
develop disease progression while on treatment may be asked to provide an optional third biopsy. 
This will be utilized to evaluate the hedgehog sign aling pathway markers (sec tion 9.1.5.3) or tests to 
evaluate for mechanisms of acquired resistance.  
 
9.1.1 Specimen collection techniques 
 
9.1.1.1. Core biopsy of tumor tissue 
 
9.1.1.1.1 Patient preparation instructi ons for core biopsy procedure 
 Detailed instructions may be provided to patie nts who are planning to have a tumor biopsy and 
their health care providers. A tumor biopsy eligib ility checklist will be completed prior to the 
tumor biopsies by a member of the clinical study team. 
 
Medication and Supplement Restrictions: 
 Must be off Plavix, Coumadin, aspirin and aspiri n-containing medications, herbal, fish oil based 
(omega 3), and vitamin E supplements for 7 days prior to procedure 
 Must be off all non-steroidal an ti-inflammatory drugs (NSAIDs) for 4 days prior to procedure 
(this includes but is not limited to ibupro fen, naproxen, celecoxib, indomethacin, etodolac 
 Must be off Heparin for 6 hours prior to procedure. 
 
Labwork: 
 PT/PTT, and the platelet level must be within normal ranges within 7 da ys of the procedure. 
 
Day of Procedure Restrictions: 
 If procedure is in the morning, NPO after 12 midnight, 
 If procedure is in the afternoon, may have a liquid breakfast only 
 
9.1.1.1.2. Biopsy Procedure Biopsies will be done by routine U/S or CT- guided procedures depending on the imaging 
characteristics of the area to be biopsied. 18-22 G core biopsy needles will be used, and 2-4 
samples will be obtained from the lesion.  Prio r to biopsy, potential bi opsy "targets" will be 
evaluated by a radiologist, to assess whet her the lesion can be safely biopsied.  
 
Analgesia and Anesthesia 
Local anesthesia will be achieved with lidocaine  2% injection. Post-pro cedure analgesia, which 
is rarely needed, will consist of acetaminophen (<3 gm total in any 24-hour period), NSAID’s 
(for patients with platelet count > 50,000 mm3 w ithout overt bleeding), or oxycodone as needed. 
Unexpectedly severe post-procedure pain will be immediately evaluated by the study subject’s 
primary oncologist or research personnel.  
Anatomical sites to be biopsied 
Biopsies will be obtained only from sites that c onstitute minimal risk to the subject. The biopsy 
service will make the final decision independent of the principal investigator or co-investigators.  
Protocol Amendment 12, date December 4, 2014 73It is not possible to designate every con ceivable site, but accept able areas include:  
 liver metastasis (not immediately adjacent to major vessels) 
 peripheral accessible lym ph nodes (cervical, axillary, inguinal, extremities) 
 Primary pancreatic mass by Endosc opic ultrasound and core biopsy 
 
Of these, the liver is the most commonly biopsi ed site in patients with  advanced pancreatic 
cancer, in our experience.  Sites that will not be biopsied for research purposes only include: 
- lung - brain - mediastinum - intra-pelvic viscera - any site deemed by the patient’s primary onc ologist, study investigator , or radiologist to 
represent greater than minimal risk to the subject. 
 
JHH/JHU and Published Experience 
At Johns Hopkins, the following data is available regarding biopsy complication rates. This data 
was compiled by the biopsy service for fiscal year 2002: 
-     There were 0 complications of 89 lymph node biopsies -     There were 0 complications of 479 liver core biopsies. 
 Published literature on the complications of tumo r biopsies is typically organ-specific. For study 
subjects with colorectal cancer, it is expected that the liver will be the most common site of 
tumor biopsies. For liver biopsies, published reviews quote a complication rate of 0.06 – 
0.32%.The complication rate does not appear to be affected by peri -hepatic ascites. Extrapolation 
to an oncology study population is somewhat probl ematic given that the indication for such 
biopsies in the general population is often severe liver disease or dysfunction; such patients 
would not be candidates fo r oncology clinical trials. 
 9.1.1.1.3. Fine needle aspiration biopsy (FNAB) as an alternative procedure to core biopsy 
 
In the unlikely event that no sites amenable to core biopsy are available, we will obtain tumor 
material via ultrasound-guided FNA of the prim ary tumor, a routine diagnostic procedure for 
establishing the diagnosis of pancreatic adenocar cinoma.  An FNAB will  be performed using a 
standard technique using 22 to 27 G needle, per standard radiologic pract ice, including on-site 
microscopic evaluation by a cytopa thologist, or a specially trai ned cytotechnologist. A maximum 
of four FNA “passes” will be performed. The first pass will be used for on-site examination of the material, to determine presence and quality of lesional tissue. The subsequent passes will be performed either for tissue procurement for the e nd-point assays, or to guide the radiologist to 
the appropriate area of the lesion.  The first F NA pass will be examined on air-dried, DiffQuik-
stained slides, as well as ethanol-fixed for Papanicolaou staining. Second and third FNA pass 
will be used for mRNA collection in RNAlater bu ffer (Ambion, Inc.).  The fourth pass will be 
used for suspension in 10% neutral buffered form alin, then processed us ing the thrombin clot 
technique, and embedded in paraffin.  The FNAB material collected in RNALater will be used 
for the real time quantitative PCR assays, as described subsequently (see section 9.1.5.), and the formalin fixed “cytospin” sample will be used  for immunohistochemical assessment of the CSC 
compartment using a panel of biomarkers.   
Protocol Amendment 12, date December 4, 2014 74 
9.1.1.2. Blood Blood samples for the biomarkers CA19-9 and SPARC  will be collected at the beginning of the 
first two cycles and every eight weeks afterwards. CA19-9 is cons idered standard  of care. Blood 
samples for circulating stem cells will be collect ed twice during the study. The first sample will 
be obtained at the beginning of treatment (cycle  one day 1). The second sample will be obtained 
at the beginning of cycle 3. We will collect a pproximately 150mL of blood (20mL of serum for 
banking in order to perform biomarker studies,  and 120mL of PBMCs fo r circulating CSCs.) 
 
9.1.2. Handling of specimens 
 
9.1.2.1. Core biopsy  Samples of core biopsy will be equally divided into containers marked as “formalin” (containing 
10% neutral buffered formalin), or “RNA” (contai ning RNAlater, Ambion, Inc.).  Samples fixed 
in formalin will be processed as per routine prot ocols for archival samples, and 5µM recuts from 
the paraffin-embedded blocks will be obtained as  follows: one reference hematoxylin and eosin 
slide, and five serial unstained slides on Chem Mate (Ventana Medical Systems, Inc).  One or 
more of the latter sections will be utilized  for immunohistochemical analysis of the CSC 
compartment using a panel of biomarkers, in cluding aldehyde dehydr ogenase (ALDH), CD24, 
CD44, and CD133.  Samples fixed in RNAlater will undergo total mRNA extraction using the 
RNEasy Mini Kit (Qiagen, In c.), followed by reverse tran scription to cDNA using the 
SuperScript II cDNA Synthesis k it (Invitrogen).  Real time quantitative PCR (qRT-PCR) 
analysis will be performed for transcript levels of Gli1, Ptch,  Aldh, CD24  and CD44 in the 
samples, using SDHA  as a housekeeping gene control. Fu rther details on these assays are 
indicated in section 9.1.5. 
 
9.1.2.2. Blood PBMCs will be separated from  whole blood using the Ficoll Hypaque density gradient 
centrifugation method, and used for flow cytometry for circulating CSCs as described in section 
9.1.5.  The residual serum will be stored at -80
0C, and used for measurement of circulating 
CA19-9 and SPARC levels.  
 
  
9.1.3. Shipping of Specimens  
All samples collected for laboratory corre lative studies will be shipped to: 
 Anirban Maitra, MBBS Associate Professor of Pathology and Oncology The Sol Goldman Pancreatic Cancer Research Center Johns Hopkins University School of Medicine Room 345, CRB II 1550 Orleans Street, Baltimore, MD 21212 
Protocol Amendment 12, date December 4, 2014 75Ph 410 955 3511 / Fax 410 614 0671 
Email: amaitra1@jhmi.edu  
 
9.1.4. Sites performing correlative studies 
 
Johns Hopkins University 
Translational Genomics (TGEN), Inc. University of Pennsylvania  (Note: Only archival core biopsy specimens will be obtained from patients recruited in Spain due to logistics and restrictions on intern ational shipping of fresh human tissues). 
 
9.1.5. Specific laboratory assays  
 
9.1.5.1. Immunohistochemical analysis of the CSC compartment  Multiple lines of evidence suggest that Hh anta gonists impact the surviv al of tumorigenic CSC 
populations in solid tumors, includi ng pancreatic cancer.  Studie s in orthotopic xenograft models 
of pancreatic cancer demonstrate that Hh inhibitors significantly  reduce the proportion of CSCs.  
We hypothesize that the addition of  GDC-0449 in the treatment cock tail (beginning at cycle 2) 
will similarly diminish the proportion of tumorige nic CSCs in pancreatic  cancer lesions, and 
thereby, improve PFS by limiting subsequent metastat ic events.  To test this hypothesis, we will 
obtain pre-and post-treatment biopsie s in patients enrolled in this trial, and interrogate the CSC 
compartment in matched biopsies using a divers e panel of immunohistochemical markers.  The 
biomarkers included are ALDH, CD24, CD44, and CD133, which have all been shown to label 
distinct, and partially non-overla pping, subsets of CSCs in solid tumors.  These CSC markers are 
routinely used, and published, in the Maitra laboratory.  Unstai ned 5µM thick Ch emMate slides 
will be stained with antibodies against thes e markers (all obtained from Cell Signaling 
Technologies, Ltd), and chromogenic detect ion performed using the Catalyzed Signal 
Amplification kit (Dako).  Quantitative Image Analysis for CSC markers will be performed 
using the Frida Image Analysis Software ( http://bui2.win.ad.jhu.edu/frida/ ).  The percentage of 
cells staining for each CSC marker will be ut ilized for calculating the mean and standard 
deviation in pre- and post-biopsy cohorts, and an y statistical significance in difference calculated 
using Chi-square analysis.  Patients enrolled in the trial will be stratified as “progressors” versus  
“non-progressors” based on defined criteria, and differences in CSC amelioration between these 
two cohorts compared as a potential measure of treatment response to Hh antagonists.  In a 
subset of ~10 patients, we will also determine if anti-metabolite therapy increases the proportion 
of CSCs at the culmination of cycle 1 of therapy, based on previ ous preclinical data in xenograft 
models.  We anticipate these correlative st udies will establish a framework for judging the in 
vivo efficacy of CSC-directed therapies in futu re trials with this class of antagonists. 
 9.1.5.2. Quantitative real time PCR analysis for CSC markers 
 The rationale for analyzing CSC-related transcripts ( ALDH , CD24  and CD44 ) remains identical 
to that of immunohistochemical analysis, but provi des an additional layer of internal validation.  
Moreover, in the event that adequate material is not obtained from core  biopsies, qRT-PCR will 
be the assay of choice in FNAB material.  E xpression analysis will be performed on cDNA 
Protocol Amendment 12, date December 4, 2014 76synthesized from total mRNA obtained from sample s preserved in RNAlater  buffer.  All of the 
qRT-PCR primers are routinely used in the Maitra  laboratory, and the assay will be performed on 
a ABI 7500 Fast real-Time PCR mach ine (Applied Biosystems), using SDHA  as a housekeeping 
gene.  Relative fold expression of various transcripts will be calculated using the 2-ΔΔCt method 
(Schmittgen and Livak, 2001).  All of the assa ys will be performed in triplicate.   
 9.1.5.3. Quantitative real time PCR an alysis for Hh gene targets 
 In addition to evaluation of the CSC compartment,  we will also evaluate expression of key Hh 
gene targets, Gli1 and Ptch, which are known to be downregulated in the tumor tissues 
secondary to Hh inhibitor therapy.  While recent studies have shown that bulk of these Hh targets are expressed in the stromal (rather than epithelial) compartment in pancreatic cancer, this will not be differentiated in the assa ys performed.  The rationale for these assays is to establish a 
tissue-specific pharmacodynamic measure of drug av ailability to the tumor site, and to correlate 
with pharmacokinetic analysis of GDC-0449.  All of  the qRT-PCR primers are routinely used in 
the Maitra laboratory, and the assay will be performed on a ABI 7500 Fast real-Time PCR 
machine (Applied Biosystems), using SDHA  as a housekeeping gene.  Relative fold expression 
of various transcripts will be calculated using the 2
-ΔΔCt method (Schmittgen and Livak, 2001).  
All of the assays will be performed in triplicate.   
 
9.1.5.4. Flow cytometry for circulating CSCs  The published data correlating circulating tumor ce lls (CTCs) with prognosis is uneven, with a 
wide range of correlation (or l ack thereof) in various solid tumors.  The underlying hypothesis 
for this correlative study is that only circulat ing CSCs (rather than the entire complement of 
CTCs) is responsible for metastat ic seeding and colonization at secondary sites, and therefore 
likely to be a more reliable measure of PFS.  Gradient centrifuged PBMCs will be analyzed for 
the fraction of circulating CSCs using the Al defluor reagent (Stem Cell Technologies), which 
provides a quantitative measure of enzyme activity  in viable cells.  Cells with highest ALDH 
activity will be gated.  Additionally, surface co -expression of CD24/CD44 will be analyzed in 
order to further enrich for the population of ci rculating CSCs.  Normal peripheral blood cells 
(i.e., B and T cells) may also express the CD44 and CD24, but they do not appear to express 
ALDH, and we would not expect  to detect CD24+CD44+ALDH+ cells in normal individuals. 
Furthermore, cells will also be stained with  a monoclonal antibody against ESA that is not 
expressed by lymphocytes, but is expressed by pancreatic CSC.  For further confirmation of 
epithelial origin, CD24+CD44+ALDH+ cells will be isolated by FACS, cytocentrifuged onto 
glass slides then stained for the expression of  epithelial-specific cytokeratins CK9 and CK19 by 
standard immunohistochemical tec hniques.  It is anti cipated that in patie nts with advanced 
pancreatic cancer, there will be a reduction in the proportion of circulating CSCs upon treatment 
with GDC-0449, especially in patients that have a tangible improvement in subsequent PFS.   
 
9.1.5.5. Circulating CA19-9 and SPARC  ELISA will be performed on plasma samples for circulating CA19-9 and SPARC levels.  Standard assay formats for ELISA will be utiliz ed, including kits for CA19-9 (Calbiochem, Inc.) 
and SPARC (Hematologic Technologi es, Inc).  CA19-9 is the stan dard-of-care tumor marker for 
Protocol Amendment 12, date December 4, 2014 77pancreatic cancer, and measuremen t of this analyte will be used  as a surrogate tumor response 
measure to therapy.  CA19-9 should be analyzed local ly at each participati ng site using standard 
laboratory measures.  SPARC (secreted protein acidic and rich in cyst eine, a.k.a. osteonectin) is abundantly expressed 
in the stroma of pancreatic cancers, and is an  albumin-binding protein th at is responsible for 
enrichment of nab-paclitaxel in the peritumoral milieu.  Recent preclinical data have shown that 
nab-paclitaxel therapy ameliorates the tumor stro ma, and enhances delivery of gemcitabine to the 
site of cancer.  Thus, it is anticipated that reduction in circulating SPARC levels post-therapy 
with nab-paclitaxel will be a surrogate measur e for stromal depletion at the tumor site.  
Reduction in pre-treatment circulating SPARC levels will be correlated with PFS. In this protocol we wish to obtain data on a poten tial correlation between  plasma SPARC protein 
expression and response to albumin-bound drugs therapy. This method will become a potential means of following treatment res ponse of nab-Paclitaxel drugs.  
 
Patient plasma will be extracted at different time points during the course of the treatment and used as the analyte for SPARC ELISA (enzym e-linked immunosorbent a ssay). To obtain the 
analyte, collect 10cc of blood in a vacutainer containing sodium heparin. The use of a heparin-
based anticoagulant containing pl atelet inhibitors is required to minimize the contribution of 
osteonectin in plasma due to platelet activat ion during phlebotomy. Plasma processed from the 
blood should be frozen at -20oC and shipped to the Alta Analytical for analysis.  
     
ALTA Analytical Laboratory  
Attention: Trang Le  Project Manager/Principal Investigator  Immunochemistry Services  Intertek Chemicals and Pharmaceuticals  3985 Sorrento Valley Blvd., Suite C  San Diego, CA-92121  Tel: 858-558-2599  Fax: 858-558-2600  Email: trang.le@intertek.com  
  
Protocol Amendment 12, date December 4, 2014 78 
10. STUDY CALENDAR      
Cycle 1   
Cycle 2   
Cycle 3 on    
    
Pre- 
Study  
Day 
1 Day 
8 Day 
15 Day 
22 Day 
1 Day 
8 Day 
15 Day 
22 Day 
1  
Day 
8  
Day 
15  
Day 
22 Every  
8 weeks End of 
Studyc 
 
GDC-0449  
  
     
X --------------------------------------------------- X  
 
Gemcitabine  
  
X X X  X X X  X  
X  
X  
   
 Nab-Paclitaxel  
  
X X X  X X X  X  
X  
X  
   
 
Informed consent  
X  
          
  
  
   
 
Demographics  
X  
          
  
  
   
 Medical history  
X  
          
  
  
   
 
Concurrent meds  
X  
X-------------------------------------------------------------------------------------------------X X 
 
Concurrent procedures  
X  
X-------------------------------------------------------------------------------------------------X X 
 Adverse event evaluation  
  
X-------------------------------------------------------------------------------------------------X X 
 
Peripheral Neuropathy 
Evaluation  
  
X-------------------------------------------------------------------------------------------------X X 
 
Physical exam  
X  
X    X    X  
  
  
  X 
 Vital signs  
X  
X X X  X X X  X  
X  
X  
 X X 
 
Weight  
X  
X    X    X  
  
  
   
 
BSA calculation  
X  
X    X    X  
  
  
  X 
 ECOG Performance  
X  
X    X    X  
  
  
  X 
 
CBC w/diff, plateletsg  
X  
X X X  X X X  X  
X  
X  
  X 
Serum chemistrya,Mg, 
phosphate g  
X  
X    X    X  
  
  
  X 
 Com plete Urinal ysisg     X     
 
PT, PTTg  
X  
          
  
  
   
 
EKG (as indicated)  
X  
          
  
  
   
 Radiologic evaluation  
CT scan or MRI  
X  
Radiologic measurements should be  performed every 8 weeks.   Xc 
 
Pregnancy Testg  
Xb  
Every 4weeks if regular menstrual cycles. Every 2 weeks if irregular menstrual cycles Xc 
 
Biopsy for correlative studies  
Xf  
        X   
  
  
   
 Serum CA 19-9g and SPARC  
  
X    X      
  
  
 X  
 
Blood Circulating CSCg  
  
X        X   
  
  
   
 
Phone f/u for Survival  
  
          
  
  
  X 
 Taste Questionnaire     XX        
a: Albumin, alkaline phosphatase, total bilirubin, bicarbonate, BUN, calcium, chloride , creatinine, glucose, LDH, phosphorus, p otassium, total protein,  
          SGOT [AST], SGPT [ALT], sodium. b: Pregnancy test (women of childbearing potential)., at screening , within 10-14 days and within 24 hrs prior to first dose of GDC-0449    
c  End of-study evaluation,   f . pretreatment biopsy within 14 days before first treatment day         g.   All blood tests and biopsies will be done within +/- 3 days 
 
Protocol Amendment 12, date December 4, 2014 79 
Baseline evaluations are to be conduc ted within 1 week prio r to start of protocol  therapy.  Scans and 
x-rays must be done 14 days prior to the start of th erapy.  In the event that the patient's condition is 
deteriorating, laboratory evaluations  should be repeated within 48 hours prior to initiati on of the next 
cycle of therapy. 
 
             
11. MEASUREMENT OF EFFECT 
 
 11.1 Antitumor Effect – Solid Tumors  
 For the purposes of this study, patients s hould be re-evaluated for response every  8 weeks.  In 
addition to a baseline scan, confirmatory s cans should also be obtained 4 weeks following 
initial documentation of objective response. 
 Response and progression will be evaluated in th is study using the new international criteria 
proposed by the revised Respons e Evaluation Criteria in Solid Tumors (RECIST) guideline 
(version 1.1) [ Eur J Ca  45:228-247, 2009].  Changes in the la rgest diameter (unidimensional 
measurement) of the tumor lesions and the shor test diameter in the case of malignant lymph 
nodes are used in the RECIST criteria.  
  11.1.1 Definitions 
 Evaluable for toxicity.  All patients will be ev aluable for toxicity from the time of their 
first treatment. 
 
Evaluable for objective response.  Only t hose patients who have measurable disease 
present at baseline, have receiv ed at least one cycle of therap y, and have had their disease 
re-evaluated will be considered evaluable fo r response.  These patients will have their 
response classified according to the definitions st ated below.  (Note:  Patients who exhibit 
objective disease progression prior to the en d of cycle 1 will also be considered 
evaluable.)  Evaluable Non-Target Disease Response.  Pa tients who have lesions present at baseline 
that are evaluable but do not meet the definitions of measurable disease, have received at 
least one cycle of therapy, and have had thei r disease re-evaluated will be considered 
evaluable for non-target disease.  The response assessment is based on the presence, absence, or unequivocal progr ession of the lesions.  
 
  11.1.2 Disease Parameters 
 Measurable disease.  Measurable lesions ar e defined as those that can be accurately 
measured in at least one dimension (longest diameter to be recorded) as >20 mm by chest 
x-ray, as >10 mm with CT s can, or >10 mm with calipers by clinical exam.  All tumor 
measurements must be recorded in millimeters (or decimal fractions of centimeters). 
 
Protocol Amendment 12, date December 4, 2014 80Note:  Tumor lesions that are situated in a pr eviously irradiated area might or might not 
be considered measurable.    Malignant lymph nodes.  To be considered pathologically enlarged  and measurable, a 
lymph node must be >15 mm in short axis when assessed by CT scan (CT scan slice 
thickness recommended to be no greater than 5 mm).  At baseline and in follow-up, only 
the short axis will be measured and followed.  Non-measurable disease.  All other lesions (o r sites of disease), in cluding small lesions 
(longest diameter <10 mm or pathological lymph nodes with ≥ 10 to <15 mm short axis), 
are considered non-measurable disease.  Bone  lesions, leptomeningeal disease, ascites, 
pleural/pericardial effusions, lymphangitis cutis/pulmonitis, inflammatory breast disease, and abdominal masses (not followed by CT or MRI), are considered as non-measurable. 
 Note:  Cystic lesions that meet the criteri a for radiographically defined simple cysts 
should not be considered as malignant lesi ons (neither measurable nor non-measurable) 
since they are, by definition, simple cysts.  ‘Cystic lesions’ thought to represent cystic me tastases can be considered as measurable 
lesions, if they meet the definition of meas urability described above. However, if non-
cystic lesions are present in the same patient, these are preferred for selection as target lesions.  Target lesions.  All measurable lesions up to a maximum of 2 lesions per organ and 5 
lesions in total, representa tive of all involved organs , should be identified as target 
lesions  and recorded and measured at baseline.  Target lesion s should be selected on the 
basis of their size (lesions with  the longest diameter), be re presentative of all involved 
organs, but in addition should be those that lend themselves  to reproducible repeated 
measurements.  It may be the case that, on o ccasion, the largest lesion  does not lend itself 
to reproducible measurement in which circum stance the next largest lesion which can be 
measured reproducibly should be selected.  A sum of the diameters (longest for non-
nodal lesions, short axis for nodal lesions) fo r all target lesions will be calculated and 
reported as the baseline sum diameters.  If lymph nodes are to be included in the sum, 
then only the short axis is added into the su m.  The baseline sum diameters will be used 
as reference to further characterize any objective tumor regression in the measurable 
dimension of the disease.  Non-target lesions.  All other lesions (or s ites of disease) including any measurable 
lesions over and above the 5 target lesions should be identified as non-target lesions and 
should also be recorded at ba seline.  Measurements of thes e lesions are no t required, but 
the presence, absence, or in rare cases une quivocal progression of each should be noted 
throughout follow-up.   
  11.1.3 Methods for Evaluati on of Measurable Disease 
 
All measurements should be taken and record ed in metric notation using a ruler or 
Protocol Amendment 12, date December 4, 2014 81calipers.  All baseline evalua tions should be performed as closely as possible to the 
beginning of treatment and never more th an 4 weeks before th e beginning of the 
treatment.  The same method of assessment and the same technique should be used to characterize 
each identified and reported lesion at ba seline and during follow-up. Imaging-based 
evaluation is preferred to evaluation by clin ical examination unless the lesion(s) being 
followed cannot be imaged but ar e assessable by clinical exam. 
 Clinical lesions   Clinical lesions will only be considered measurable when they are 
superficial (e.g., skin nodules and palpable lymph nodes) and 10 mm diameter as 
assessed using calipers (e.g., skin nodules).  In the case of skin  lesions, documentation by 
color photography, including a ruler to estima te the size of the lesion, is recommended.  
 Chest x-ray   Lesions on chest x-ray are acceptable as  measurable lesions when they are 
clearly defined and surrounded by aerated lung.  However, CT is preferable.  
 Conventional CT and MRI  This guideline ha s defined measurability of lesions on CT 
scan based on the assumption that CT slice th ickness is 5 mm or less.  If CT scans have 
slice thickness greater than 5 mm, the mini mum size for a measurable lesion should be 
twice the slice thickness.  MR I is also acceptabl e in certain situations (e.g. for body 
scans).    Use of MRI remains a complex issue.  MRI ha s excellent contrast, sp atial, and temporal 
resolution; however, there are many image acquisition variables involved in MRI, which greatly impact image quality, lesion conspi cuity, and measurement.  Furthermore, the 
availability of MRI is variab le globally.  As with CT, if  an MRI is performed, the 
technical specifications of the scanning se quences used should be optimized for the 
evaluation of the type and site of disease.  Furthermore, as with CT, the modality used at 
follow-up should be the same as was used at baseline and the lesions should be 
measured/assessed on the same pulse sequence.   It is beyond the scope of the RECIST 
guidelines to prescribe specifi c MRI pulse sequence paramete rs for all scanners, body 
parts, and diseases.  Ideally, the same type of scanner sh ould be used and the image 
acquisition protocol should be fo llowed as closely as possible to prior scans.  Body scans 
should be performed with breath-hold scanning techniques, if possible. 
 PET-CT  At present, the low dose or atte nuation correction CT portion of a combined 
PET-CT is not always of optimal diagnostic CT quality for use with RECIST 
measurements.  However, if the site can doc ument that the CT performed as part of a 
PET-CT is of identical diagnostic quality to a diagnostic CT (with IV and oral contrast), 
then the CT portion of the PET-CT can be used for RECIST measurements and can be 
used interchangeably with conventional CT in accurately measuring cancer lesions over 
time.  Note, however, that the PET portion of  the CT introduces additional data which 
may bias an investigator if it is no t routinely or seri ally performed.   
 Ultrasound  Ultrasound is not usef ul in assessment of lesion si ze and should not be used 
Protocol Amendment 12, date December 4, 2014 82as a method of measurement.  Ultrasound ex aminations cannot be reproduced in their 
entirety for independent review at a later da te and, because they are operator dependent, it 
cannot be guaranteed that the same techniqu e and measurements will be taken from one 
assessment to the next.  If new lesions are identified by ultrasound in the course of the 
study, confirmation by CT or MRI is advise d.  If there is concern about radiation 
exposure at CT, MRI may be used inst ead of CT in selected instances. 
 Endoscopy, Laparoscopy  The utilization of these techniques for objective tumor 
evaluation is not advised.  However, such t echniques may be useful to confirm complete 
pathological response when biopsies are obtaine d or to determine relapse in trials where 
recurrence following complete response (CR) or surgical resection is an endpoint. 
 Tumor markers  Tumor markers alone cannot be used to assess respons e.  If markers are 
initially above the upper normal limit, they must  normalize for a patient to be considered 
in complete clinical response.    Cytology, Histology  These tech niques can be used to diffe rentiate between partial 
responses (PR) and complete responses (CR) in rare cases (e.g., resi dual lesions in tumor 
types, such as germ cell tumors, where known residual benign tumors can remain).  The cytological confirmation of the neoplastic  origin of any effusion that appears or 
worsens during treatment when the measurab le tumor has met criteria for response or 
stable disease is mandatory to differentia te between response or stable disease (an 
effusion may be a side effect of th e treatment) and progressive disease. 
 FDG-PET  While FDG-PET response assessments  need additional study, it is sometimes 
reasonable to incorporate the use of FDG-P ET scanning to complement CT scanning in 
assessment of progression (particularly possible 'new' disease).  New lesions on the basis 
of FDG-PET imaging can be identified according to the following algorithm:  
a) Negative FDG-PET at baseline, with a pos itive FDG-PET at follow-up is a sign of 
PD based on a new lesion. 
b) No FDG-PET at baseline and a positive FDG-PET at follow-up:  If the positive 
FDG-PET at follow-up corresponds to a new s ite of disease conf irmed by CT, this 
is PD.  If the positive FDG-PET at follo w-up is not confirmed as a new site of 
disease on CT, additional follow-up CT  scans are needed to determine if there is truly progression occurring at that site (if s o, the date of PD will be the date of the 
initial abnormal FDG-PET scan).  If the positive FDG-PET at follow-up corresponds to a pre-existing si te of disease on CT that  is not progressing on the 
basis of the anatomic im ages, this is not PD. 
c) FDG-PET may be used to upgrade a respon se to a CR in a manner similar to a 
biopsy in cases where a re sidual radiographic abnormality  is thought to represent 
fibrosis or scarring.  The use of F DG-PET in this circumstance should be 
prospectively described in the protocol and supported by disease-specific medical 
literature for the indication.  Howeve r, it must be acknowledged that both 
approaches may lead to false positive CR due to limitations of FDG-PET and biopsy resolution/sensitivity. 
Protocol Amendment 12, date December 4, 2014 83  
Note:  A ‘positive’ FDG-PET scan lesion means one which is FDG avid with an uptake greater than twice that of the surroundi ng tissue on the attenuation corrected image.  
 
  11.1.4 Response Criteria 
 
   11.1.4.1  Evaluation of Target Lesions 
 Complete Response (CR): Disappearan ce of all target lesions.  Any 
pathological lymph nodes (whether target or non-
target) must have reduction in short axis to <10 mm. 
 Partial Response (PR): At least a 30% decrease in the sum of the diameters 
of target lesions, taking as reference the baseline 
sum diameters. 
 Progressive Disease (PD): At least a 20 % increase in the su m of the diameters 
of target lesions, taking as reference the smallest 
sum on study (this includes the baseline sum if that is the smallest on study).  In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.  (Note:  the appearance of one or more  new lesions is also 
considered progressions). 
 
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor 
sufficient increase to qualify for PD, taking as 
reference the smallest sum diameters while on study. 
 
   11.1.4.2 Evaluation of Non-Target Lesions 
 Complete Response (CR): Disappearan ce of all non-target lesions and 
normalization of tumor marker level.  All lymph 
nodes must be non-pathol ogical in size (<10 mm 
short axis).  Note:  If tumor markers ar e initially above the upper 
normal limit, they must normalize for a patient to be considered in complete clinical response.  
Non-CR/Non-PD: Persistence of one  or more non-target lesion(s) 
and/or maintenance of tumo r marker level above the 
normal limits. 
 
Protocol Amendment 12, date December 4, 2014 84Progressive Disease (PD): Appearance of one or more new lesions and/or 
unequivocal progression  of existing non-target 
lesions.  Unequivocal progression  should not 
normally trump target lesion status.  It must be representative of overall di sease status change, not a 
single lesion increase.     
 Although a clear progression of “non-targ et” lesions only is exceptional, the 
opinion of the treating physician should pr evail in such circumstances, and the 
progression status should be confirmed at  a later time by the review panel (or 
Principal Investigator).  
   11.1.4.3  Evaluation of Best Overall Response 
The best overall response is the best response recorded from the start of the 
treatment until disease progr ession/recurrence (taking as reference for progressive 
disease the smallest measurements record ed since the treatment started).  The 
patient's best response assignment will depend on the achievement of both measurement and confirmation criteria.  
 
     
For Patients with Measurable Disease (i.e., Target Disease) 
 
Target 
Lesions Non-
Target 
Lesions New 
Lesions Overall 
ResponseBest Overall Response 
when Confirmation is 
Required* 
CR CR No CR >4 wks. Confirmation** 
CR Non-
CR/Non-
PD No PR 
>4 wks. Confirmation** CR Not 
evaluated No PR 
PR Non-
CR/Non-
PD/not 
evaluated No PR 
SD Non-
CR/Non-
PD/not 
evaluated No SD documented at least once 
>4 wks. from baseline** 
PD Any Yes or 
No PD no prior SD, PR or CR 
Any PD*** Yes or PD 
Protocol Amendment 12, date December 4, 2014 85No 
Any Any Yes PD 
*  See RECIST 1.1 manuscript for furthe r details on what is evidence of 
a new lesion. 
**  Only for non-randomized trials with response as primary endpoint. 
*** In exceptional circumstances, une quivocal progression in non-target 
lesions may be accepted as disease progression. 
 Note: Patients with a global deterior ation of health status requiring 
discontinuation of treatment without  objective evidence of disease 
progression at that time should be reported as “ symptomatic deterioration.”  
Every effort should be made to document the objective progression even after discontinuation of treatment. 
 
       
 
  
For Patients with Non-Measurable Di sease (i.e., Non-Target Disease) 
 
Non-Target Lesions New Lesions Overall Response 
CR No CR 
Non-CR/non-PD No Non-CR/non-PD* 
Not all evaluated No not evaluated 
Unequivocal PD Yes or No PD 
Any Yes PD 
* ‘Non-CR/non-PD’ is preferred over ‘sta ble disease’ for non-target disease 
since SD is increasingly used as an endpoint for assessment of efficacy in 
some trials so to assign this category when no lesions can be measured is not 
advised 
   11.1.5 Duration of Response  
 
Duration of overall response:  The duration of overall response is measured from the time 
measurement criteria are met for CR or PR (w hichever is first recorded) until the first 
date that recurrent or progressive disease is objectively documented (taking as reference 
for progressive disease the smallest measurem ents recorded since the treatment started). 
 The duration of overall CR is measured from the time measurement criteria are first met 
for CR until the first date that progressive disease is objectively documented.   
Protocol Amendment 12, date December 4, 2014 86 
Duration of stable disease:  Stable disease is measured from the start of the treatment 
until the criteria for progression are met, taking as reference the smallest measurements 
recorded since the treatment started, including the baseline measurements.  
   11.1.6 Response Review 
 Response on imaging studies will be assess ed by expert radiol ogists based on above 
RECIST 1.1 criteria. 
  
Protocol Amendment 12, date December 4, 2014 87 
12. STATISTICAL CONSIDERATIONS 
 
12.1 Study Design/Endpoints  
 
This is an open-label, single arm, multi-center, Phase II trial.  
Primary Endpoints(s)  
 
 PFS as defined by the time from first therapy received to the earlier documented disease 
progression or death from  any cause. PFS will be determined by the investigator.  Imaging 
studies to assess response will be evaluated by ex pert radiologists usi ng RECIST 1.1 criteria. 
 
Secondary Endpoint(s) 
 
Efficacy endpoints 
 Overall survival from the time of cycle 1, day 1 until death from any cause 
 Objective tumor response (partial  response, complete response) or stable disease based on CT 
scans (or MRI scans if patient is allergic to cont rast agent or has some other contraindication to a 
CT scan). These will be evaluate d according to RECIST 1.1 criteria. 
 
Safety endpoints 
 Number of grade 3 and 4 toxicities according to  National Cancer Ins titute Common Toxicity 
Criteria for Adverse Events (NCI CTCAE; Ve rsion 4.0) that occur after Cycle 1, day 1 
 Incidence, nature and severity  of all adverse events that occur on or after Cycle 1, Day 1 
 
Correlative studies endpoints 
 Quantitative pancreatic cancer stem cell identification using functional assays and phenotypic 
assays. Functional assays include immunohistoche mistry or RT-PCR for ALDH bright cells. 
Phenotypic assays include immunohistochemistry or  flow cytometry for pa ncreatic cancer stem 
cell markers (CD24+/CD44+/ESA+ and CD133+)  in tissue biopsy and peripheral blood.  
 Semi-quantitative measurement of hedgehog lig and expressions in pre-post biopsies and 
hedgehog signaling pathway downregulati on as measured by Gli 1 and Patch 
 Biomarker changes as measured by serum CA19-9 and plasma SPARC levels 
 
12.2 Statistical Considerations 
This is a single-arm, Phase II trial of Gemcita bine, nab-Paclitaxel and GDC-0449 in patients with 
previously untreated metastatic adenocarcinoma of the pancreas.  Progression-free survival (PFS) is 
the primary endpoint.  Eight y patients will be accrued. 
 
 
12.2.1 Primary Endpoint Analysis Plan 
PFS will be timed from the first treatment received  (cycle 1, day 1) until the earlier of disease 
progression or death due to any cause.  The product- limit (Kaplan-Meier) that  estimate the specific 
Protocol Amendment 12, date December 4, 2014 88survival functions will be calculated.  Median su rvival will be calculated from the Kaplan-Meier 
estimate, along with a 80 % confid ence interval.  The proportion surv iving to one year will be 
calculated, along with a 80 % exac t binomial confidence interval. 
The null hypothesis that the median survival is less th an or equal to 7.9 months will be tested using a 
one-sided test at a 0.1 significance level. 
 
12.2.2 Secondary Endpoint Analysis Plans 
1 Overall survival will be summarized using th e product-limit (Kaplan-Meier) estimator.  Median 
OS and 1-year surviving proportion will be estimated as in the primary objective. 
2 Objective tumor response will be summarized by the proportion of patients (with 95% exact 
binomial confidence intervals) that achieve a c onfirmed complete or partial response based on 
radiology assessment of response using RECIST 1.1 response guidelines. Confirmation will be at 
least 4 weeks after th e initial response. 
3 The number and attribution of Grade 3 and 4 adve rse events will be tabulated. Safety will also be 
assessed through summaries of all adverse events , including serious advers e events and adverse 
events leading to discontinuation of chemothe rapy or GDC-0449. All treatment-emergent adverse 
events will be graded by NCI CTCAE, Version 4.0. 
4 Hematology parameters: In order to investigat e the maximal degree of myelosuppression, the 
NCI CTCAE grade for WBC, ANC, platelet count  and hemoglobin will be summarized by the most 
severe grade in each treatment cycl e and by the most severe grade du ring the study. The incidence of 
patients with NCI CTCAE hematology values of Grad e 3 or 4 that occurred after the first dose of 
study drug also will be presented. Data for patients with Grade 3 or 4 hematology values will be 
listed. The nadir of each of these parameters will be presented in each cycle and overall. For ANC 
and WBC, time to overall nadir and time to rec overy will be analyzed using the Kaplan-Meier 
method. 
5 Clinical chemistry: Liver and renal function will be summarized us ing the NCI CTCAE for 
alkaline phosphatase, serum glutamate oxaloacetate transaminase (SGOT), total bilirubin, and creatinine. The number and percen tage of patients that have  each NCI CTCAE grade will be 
summarized using the most severe grade for the first cycle of therapy and for anytime during the 
study. The incidence of patients with NCI CTCAE chem istry values of Grade 3 or 4 that occurred 
after the first dose of study drug also will be presen ted. Data for patients with Grade 3 or 4 chemistry 
values will be listed. 
6 The percent of cancer stem cells measured in primary tissue and peripheral blood will be 
determined. The percent change from the pre to the post-treatment biopsies will be calculated for  the clinical outcomes (PFS, OS, and response ra te).  These endpoints will be summarized using 
means, standard deviations, medians and ranges.   
7 Hh- ligand expression in tissue by IHC or flow cytometry will be quantified as either continuous 
or semi-quantitative measurement. The effect of Hh expression and/or pathway signaling on primary 
and secondary endpoints may be ex amined using proportional hazards 
regression (for PFS, OS and other time-to-event-endpoi nts) or logistic regr ession (for dichotomous 
endpoints, such as objective response). 
8 SPARC and CA19-9: Logistic re gression will be used to asse ss the relationship between SPARC 
Protocol Amendment 12, date December 4, 2014 89and CA19-9 and objective response.  Product-limit (C ox) regression will be  used to assess the 
relationship between these markers as predictors of response, PFS and OS. 
 
12.2.3  Justification of Design  
This Phase II trial is designed to make a preliminary assessment of the efficacy of treatment, as 
measured by PFS.  In previous trials the use of chemotherapy with gemcitabine and nab-paclitaxel, 
the median PFS was 7.9 months. We have powere d our study with the assumption of 24 months 
accrual with 12 months follow up. Based upon these a ssumptions, a sample size of 80 patients will 
have an 80% power to detect an increase in th e median progression free survival to 10.4 months 
from the null rate of 8 months us ing a one sided type 1 error of 0.10.  The one-sided test with 0.10 
significance level is a ppropriate for an early Phase II pr oof-of-principle study designed to 
accumulate evidence motivating a la ter multi-center confirmatory Phas e III study with stricter test 
criteria. 
This trial is hypothesis-generating and is only ab le to detect a relatively large benefit (30% 
increases) of GDC-0449 added to chemotherapy us e with gemcitabine and nab-paclitaxel. In 
particular, this trial will not ha ve adequate power to detect minimum clinically meaningful 
differences between current treatment and historical  control (gemcitabine and nab-paclitaxel). Thus, 
formal hypothesis testing is limited in that statisti cally negative outcomes do not necessarily rule out 
clinically significant treatment effects. 
 
12.2.4 Safety Monitoring 
This trial will combine three agents and we must a llow for the possibility of an interaction between 
the treatments in terms of toxicity as well as e fficacy. In phase 1 and 2 st udies, the combination of 
gemcitabine and nab paclitaxel were  associated with grade 3 or highe r toxicities in at most 36% of 
patients (the most significant bei ng neutropenia).  No neutropenia or myelosuppression was reported 
with GDC-0449.  Therefore, we set the upper boundary  for an acceptable level of grade 3 or higher 
hematologic toxicity at 50%.  Toxicities will be recorded and evaluated for se verity according to the National Cancer Institute 
Common Toxicity Criteria for Adverse Events  (NCI CTCAE; Version 4.0).  The number of 
individuals with any toxicities of grad e 3 or higher will be tabulated.   
 Toxicity and adverse events will be closely moni tored by the study statisti cian and the principal 
investigators throughout the study. Afte r the first 10 patients have been accrued and treated on to this 
study accrual will be temporarily halted until these patients have been assessed for toxicity for one 
cycle of treatment with GDC . If five or more of the first ten patients experience grade 3 hematologic 
toxicities that are possibly, probabl y or definitely related to study tr eatment, safety of this study will 
be re-evaluated by the principal investigators to determine whethe r they are unexpected and pose an 
excessive safety risk and whether the study needs to  be permanently closed to accrual. In addition, 
accrual to the trial will be halted if unexpected, significant, or un acceptable risk to patients occurs at 
any time during this study.  A thorough safety re view by the principal in vestigators will then 
determine whether the trial needs to be terminated.  
12.2.5 Futility Monitoring 
 
Protocol Amendment 12, date December 4, 2014 90An interim futility analysis will be performed once 66% of the patients (53) have completed 6 
months of follow-up.   At that time, we will construct 99.5% confidence intervals for progression 
free survival.  If the upper bound of the CI does  not contain the altern ative PFS (7.05) months 
and the other efficacy outcomes do not show benefit then  we will halt the trial for futility.  This test 
is equivalent to "spending"  0.0025 of the type I error   
 
12.3 Sample Size/Accrual Rate 
 We have powered our study with the assumption of 24 months accrual w ith 12 months follow up. 
Based upon these assumptions, a sample size of 72 pa tients will have an 80% power to detect an 
increase in the median progression free survival to  7.15 months from the null rate of 5.5 months (HR 
= 1.3) using a one sided type 1 error of 0.10.  Up to  an additional 10% will be accrued in order to 
control for loss to follow-up.  The expected accr ual rate is between 4- 5 patients per month.  
Rationale: We have decided to decrease the sample size based on the following points:  
-New data presented at ASCO GI and now published at NEJM demonstrated the PFS of gem/abraxane based on 
phase 3 study is 5.5 mo (MPACT study, Von Hoff NEJM 2014). Given these findings reducing the sample size will 
not alter the power initially planned fo r the study. Our study woul d still have 80% power with N=72 if PFS of 5.5 
months (as per MPACT study)  were known at study design, and study planned to detect a 30% increase in median 
PFS from 5.5 months to 7.15 months at the 1-sided 10 % significance level, upper bound used for futility should 
have been 7.15.  
-Accrual has been significantly slow over the past two years as new standard treatments have become available 
(gem/abraxane and FOLFIRINOX) and less patients are participating in our first line clinical trials.  
-New data (one study) has become available demonstrating that hedgehog inhibitors have not increased progression 
free survival in patients with pancreatic cancer (Kim et al. CCR Oct 2014) 
-We have evaluated our data in every six months basis at the AACR SU2C meetings (planned to review the trial) 
and our mPFS remains 5.5 mo with upper limit CI not including 7.15 
 
 
 
Rationale for changing th e statistical analysis 
 When the study was originally designed, previous  trials using gemcitabi ne and nab-paclitaxel 
reported a PFS of 7.9 months.  A sample size of 80 participants recruited over a 2 year period and 
followed for a minimum of 1 year would provide 80%  power to detect an increase in PFS from a 
median of 8 months to 10.4 months using a one side d type I error rate of 10%.  An interim futility 
analysis was included to enable us to halt the trial if the efficacy after 50% of the patients completed 
6 months of follow-up was much lower than expect ed, specifically if th e upper bound of the 99.5% 
confidence interval did not incl ude the alternative ( 10.4 months).  The interim analysis was 
completed and the estimated median was 5.0 months  with a 99.5% confidence  interval of 4.4 to 7.2 
months.  Since the upper bound was much lower than  the hypothesized alternative, recruitment of 
the trial was halted.  Participants already enrolled in the trial continued follow-up. 
 On previous phase 2 PFS was 7.9 months. On January 25, 2013 the results of a large (N = 861) 
phase III trial of gemcitabine and nab-paclitaxel were reported. This is the data  that would have been 
used if these results were available at the time of  design of this clinical trial. The median PFS was 
5.5 months, which a much lower value than was previously reported.  In light of the new 
information, we re-ran our power calculations and interim analysis  guidelines to see if the new 
reference value would have impacted our decision to halt the trial.  Using the same accrual and 
Protocol Amendment 12, date December 4, 2014 91follow-up assumptions outlined above, we would have 80% power to detect an increase in median 
PFS from 5.5 months (the new refe rence) to 7.05 months (HR = 1.28) with a one-sided type I error 
rate of 10%.  The interim stopping rule therefor e changed to comparing the upper boundary of the 
99.5% confidence interval to 7.05.  In this case the observed upper boundary was 7.2 months; hence 
the stopping criteria would not be met. Given the updated phase III da ta and we believe that it is 
appropriate to re-open accrual.   
 
12.4    Stratification Factors  
None 
 
12.5    Reporting and Exclusions  
 
         12.5.1 Evaluation of toxicity.  All patients will be evaluable for toxicity from the time of 
their first treatment with GDC-0449, gemcitabine and nab-paclitaxel 
   12.5.2 Evaluation of response.   All patients included in the study must be assessed for 
response to treatment, even if there are major protocol treatme nt deviations or if they 
are ineligible.  Each patient will be a ssigned one of the following categories:  1) 
complete response, 2) partial response, 3) st able disease, 4) progressive disease, 5) 
early death from malignant disease, 6) ear ly death from toxicity, 7) early death 
because of other cause, or 9) unknown (not as sessable, insufficient data).  [Note:  By 
arbitrary convention, category 9 usually desi gnates the “unknown” status of any type 
of data in a clin ical database.] 
All of the patients who met the eligibility  criteria (with the po ssible exception of 
those who received no study medication) should be included in the main analysis of 
the response rate.  Patients in response categ ories 4-9 should be considered to have a 
treatment failure (disease progression).  T hus, an incorrect treatment schedule or drug 
administration does not result in exclusion from the analysis of the response rate.  
Precise definitions for categories 4-9 will be protocol specific.   
  
Protocol Amendment 12, date December 4, 2014 92 
References 
          
1. Jemal, A., et al., Cancer statistics, 2009.  CA Cancer J Clin, 2009. 59(4): p. 225-49. 
2. Burris, H.A., 3rd, et al., Improvements in survival and clinical  benefit with gemcitabine as first-
line therapy for patients with advanced  pancreas cancer: a randomized trial.  J Clin Oncol, 1997. 
15(6): p. 2403-13. 
3. D. D. Von Hoff, R.R., M. Borad, D. Laheru, L. Smith, T. Wood, R. Korn, N. Desai, J. Iglesias, 
M. Hidalgo; TGen, Scottsdale, AZ; Mayo Clin ic, Scottsdale, AZ; Johns Hopkins, Baltimore, 
MD; South Texas Oncology and Hematology, Sa n Antonio, TX; University of Alabama, 
Birmingham, AL; Scottsdale Medical Imagi ng, Scottsdale, AZ; Abraxis BioScience, Los 
Angeles, CA SPARC correlation with response to gemc itabine (G) plus nab-paclitaxel (nab-P) 
in patients with advanced metastatic pancreatic cancer: A phase I/II study.  J Clin Oncol 2009. 
27:15s, 2009 (suppl; abstr 4525)  
4. Ingham, P.W. and A.P. McMahon, Hedgehog signaling in animal development: paradigms and 
principles.  Genes Dev, 2001. 15(23): p. 3059-87. 
5. Thayer, S.P., et al., Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis.  
Nature, 2003. 425(6960): p. 851-6. 
6. Berman, D.M., et al., Widespread requirement for Hedgehog ligand stimulation in growth of 
digestive tract tumours.  Nature, 2003. 425(6960): p. 846-51. 
7. Tian, H., et al., Hedgehog signaling is restricted to the stromal compartment during pancreatic 
carcinogenesis.  Proc Natl Acad Sci U S A, 2009. 106(11): p. 4254-9. 
8. Curran, T. and J.M. Ng, Cancer: Hedgehog's other great trick.  Nature, 2008. 455(7211): p. 293-
4. 
9. Yauch, R.L., et al., A paracrine requirement for hedgehog signalling in cancer.  Nature, 2008. 
455(7211): p. 406-10. 
10. Martin, S.T., et al., Aberrant methylation of the Human Hedgehog interacting protein (HHIP) 
gene in pancreatic neoplasms.  Cancer Biol Ther, 2005. 4(7): p. 728-33. 
11. Feldmann, G., et al., Hedgehog inhibition prolongs survival in a genetically engineered mouse 
model of pancreatic cancer.  Gut, 2008. 57(10): p. 1420-30. 
12. Li, C., et al., Identification of pancrea tic cancer stem cells.  Cancer Res, 2007. 67(3): p. 1030-7. 
13. Hermann, P.C., et al., Distinct populations of cancer stem  cells determine tumor growth and 
metastatic activity in human pancreatic cancer.  Cell Stem Cell, 2007. 1(3): p. 313-23. 
14. Feldmann, G., et al., Blockade of hedgehog signaling inhi bits pancreatic cancer invasion and 
metastases: a new paradigm for comb ination therapy in solid cancers.  Cancer Res, 2007. 67(5): 
p. 2187-96. 
15. Feldmann, G., et al., An orally bioavailable small-mol ecule inhibitor of Hedgehog signaling 
inhibits tumor initiation and meta stasis in pancreatic cancer.  Mol Cancer Ther, 2008. 7(9): p. 
2725-35. 
16. P. M. LoRusso, C.M.R., M. J. Borad, L. Vernill et, W. C. Darbonne, H. Mackey, J. F. DiMartino, 
F. de Sauvage, J. A. Low, D. D. Von Hoff, A first-in-human, first-in-clas s, phase (ph) I study of 
systemic Hedgehog (Hh) pathway antagonist, GDC- 0449, in patients (pts) with advanced solid 
tumors.  2008 ASCO Annual Meeting, Abstract No: 3516. 
17. Von Hoff, D.D., et al., Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.  N 
Engl J Med, 2009. 361(12): p. 1164-72. 
18. Jimeno, A., et al., A direct pancreatic cancer xenograft mode l as a platform for cancer stem cell 
Protocol Amendment 12, date December 4, 2014 93therapeutic development.  Mol Cancer Ther, 2009. 8(2): p. 310-4. 
19. Olive, K.P., et al., Inhibition of Hedgehog signaling enhances  delivery of chemotherapy in a 
mouse model of pancreatic cancer.  Science, 2009. 324(5933): p. 1457-61. 
20. D. D. Von Hoff, R.R., M. Borad, D. Laheru, L. Smith, T. Wood, R. Korn, N. Desai, J. Iglesias, 
M. Hidalgo; TGen, Scottsdale, AZ; Mayo Clin ic, Scottsdale, AZ; Johns Hopkins, Baltimore, 
MD; South Texas Oncology and Hematology, Sa n Antonio, TX; University of Alabama, 
Birmingham, AL; Scottsdale Medical Imagi ng, Scottsdale, AZ; Abraxis BioScience, Los 
Angeles, CA SPARC correlation with response to gemc itabine (G) plus nab-paclitaxel (nab-P) 
in patients with advanced metastatic pancreatic cancer: A phase I/II study.  J Clin Oncol, 2009. 
27:15s, 2009 (suppl; abstr 4525)  
21. Ivanova, A., B.F. Qaqish, and M.J. Schell, Continuous toxicity monitoring in phase II trials in 
oncology.  Biometrics, 2005. 61(2): p. 540-5. 
22. Pocock S: Group sequential methods in the design  and analysis of clinical trials. Biometrika: 
191-199. 
    
  
Protocol Amendment 12, date December 4, 2014 94 
Appendices 
 
 APPENDIX A 
 
Performance Status Criteria 
 
 
 
ECOG Performance Status Scale 
  
Karnofsky Performance Scale 
Grade Descriptions Percent Description 
0 Normal activity.  Fully active, able 
to carry on all pre-disease 
performance without restriction. 100 Normal, no complaints, no evidence 
of disease. 
90 Able to carry on normal activity; 
minor signs or symptoms of disease. 
1 Symptoms, but ambulatory.  
Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature (e.g., light housework, office work). 80 Normal activity with effort; some 
signs or symptoms of disease. 
70 Cares for self, unable to carry on 
normal activity or to do active work. 
2 In bed <50% of the time.  
Ambulatory and capable of all self-care, but unable to carry out any work activities.  Up and about more than 50% of waking hours. 60 Requires occasional assistance, but 
is able to care for most of his/her 
needs. 
50 Requires considerable assistance and 
frequent medical care. 
3 In bed >50% of the time.  Capable 
of only limited self-care, confined to bed or chair more than 50% of waking hours. 40 Disabled, requires special care and 
assistance. 
30 Severely disabled, hospitalization 
indicated.  Death not imminent. 
4 100% bedridden.  Completely 
disabled.  Cannot carry on any self-care.  Totally confined to bed or chair. 20 Very sick, hospitalization indicated. 
Death not imminent. 
10 Moribund, fatal processes 
progressing rapidly. 
5 Dead. 0 Dead. 
         
Protocol Amendment 12, date December 4, 2014 95 
APPENDIX B   
Definition of Women of Childbearing Potential and  
Acceptable and Unacceptable Forms of Contraception 
 
Women of childbearing potenti al are defined as follows: 
 Patients with regular menses 
 Patients with amenorrhea, irregular cycles, or  using a contraceptive method that precludes 
withdrawal bleeding 
 Women who have ha d a tubal ligation 
Women are considered not to be of childbe aring potential for th e following reasons: 
 The patient has undergone hysterect omy and/or bilateral oophorectomy. 
 The patient is post-menopausal defined by am enorrhea for at least 1 year in a woman  45 years 
old. 
Women of childbearing potential are required to  use two forms of acceptable contraception, 
including one barrier method with spermicide, dur ing their participation in the study and for 12 
months following discontinuation of GDC-0449. 
The following are acceptable forms of barrier contraception: 
 Latex condom (always used with spermicide) 
 Diaphragm (always used with spermicide) 
 Cervical cap (always used with spermicide) 
 Male subject must use condoms at all tim es, even after a vasectomy, during sexual 
intercourse with female part ner of reproductive potential during treatment with GDC-0449, 
and for 2 months after the last dose to avoid exposing a pregnant partner and unborn fetus to 
GDC-0449. 
 
The following are acceptable forms of secondary c ontraception, when used with a barrier method: 
 Tubal ligation  
 Partner’s vasectomy 
 Combination hormonal contraceptives includi ng birth control pills, patches, rings, 
or injections ,medroxyprogesterone acetate depot,  with the exception of the progesterone-only 
“minipill”   
Protocol Amendment 12, date December 4, 2014 96 Intrauterine device (non–progesterone T) 
 Vaginal sponge (containing spermicide) 
In addition, 100% commitment to abstinence is c onsidered an acceptable form of contraception.he 
following are unacceptable  forms of contraception for wome n of childbearing potential: 
 IUD progesterone T  
 Progesterone-only “minipill” 
 Female condom 
 Natural family planning (rhyt hm method) or breastfeeding 
 Fertility awareness 
 Withdrawal 
 Cervical shield  
 
Protocol Amendment 12, date December 4, 2014 1 
  
 
 
APPENDIX C 
 
LIST OF CYP3A4 INHIBITORS AND INDUCERS 
 
  CYP3A4 Inhibitors 
Acetominophen 
Acetazolamide 
Amiodarone 
Amlodipine Amprenavir 
Anastrozole 
Aprepitant Atazanavir 
Atorvastatin 
Azelastine Azithromycin 
Betamethasone 
Bortezomib Bromocriptine 
Caffeine 
Cerivastatin Chloramphenicol 
Chlorzoxazone 
Cimetidine Ciprofloxacin 
Cisapride 
Clarithromycin Clemastine 
Clofazimine 
Clotrimazole Clozapine Cocaine 
Conivaptan 
Cyclophosphamide Cyclosporine 
Danazol 
Dasatinib (1) Delavirdine 
Desipramine 
Dexmedetomidine Diazepam Diclofenac 
Dihydroergotamine 
Diltiazem 
Disulfiram Docetaxel 
Doxorubicin 
Doxycycline Drospirenone 
Efavirenz 
Enoxacin Entacapone 
Ergotamine 
Erythromycin Ethinyl estradiol 
Etoposide 
Felodipine Fentanyl 
Fluconazole 
Fluoxetine Fluvastatin 
Fluvoxamine 
Fosamprenavir Glyburide 
Grapefruit juice (2) 
Haloperidol Hydralazine Ifosfamide 
Imatinib 
Indinavir Irbesartan 
Isoniazid 
Isradipine Itraconazole 
Ketoconazole 
Lansoprazole Lidocaine Lomustine 
Losartan  
Lovastatin 
Mefloquine Mestranol 
Methadone 
Methimazole Methoxsalen 
Methylprednisolone 
Metronidazole Miconazole 
Midazolam 
Mifepristone Mirtazapine 
Mitoxantrone 
Modafinil Nefazodone 
Nelfinavir 
Nevirapine Nicardipine 
Nifedipine 
Nisoldipine Nizatidine 
Norfloxacin 
Olanzapine Omeprazole Orphenadrine 
Oxybutynin 
Paroxetine Pentamidine 
Pergolide 
Phencyclidine Pilocarpine 
Pimozide 
Pravastatin Prednisolone Primaquine 
Progesterone 
Propofol  
Propoxyphene Quinidine 
Quinine 
Quinupristin Rabeprazole 
Ranolazine 
Risperidone Ritonavir 
Saquinavir 
Selegiline Sertraline 
Sildenafil 
Sirolimus Sulconazole 
Tacrolimus 
Tamoxifen Telithromycin 
Teniposide 
Testosterone Tetracycline 
Ticlopidine 
Tranylcypromine Trazodone Troleandomycin 
Valproic acid 
Venlafaxine Verapamil 
Vinblastine 
Vincristine Vinorelbine 
Voriconazole 
Zafirlukast Ziprasidone 
 
  CYP3A4 Inducers 
Aminoglutethimide Carbamazepine 
Fosphenytoin 
Nafcillin  Nevirapine 
Oxcarbazepine 
Pentobarbital 
Phenobarbital  Phenytoin 
Primidone 
Rifabutin 
Rifampin  Rifapentine 
St. John’s wort (3) 
When GDC-0449  is co-administered with compounds classified as ‘inhibitors’, increased plasma concentrations of GDC-0449 is 
the potential outcome. The co-administration of ‘inducers’  would potentially lower plasma GDC-0449 concentrations. 
 
Note: Adapted from Cytochrome P450 Enzymes: Substrates, Inhi bitors, and Inducers. In: Lacy CF, Armstrong LL, Goldman MP, 
Lance LL eds. Drug Information Handbook 15TH ed. Hudson, OH; LexiComp Inc. 2007: 1899-1912.   
Only major substrates and effective inducers are listed.   
Additional information for drug interactions with cytochro me P450 isoenzymes can be found at CYTOCHROME P450 DRUG 
INTERACTION TABLE (Version 5.0 released on January 12, 2009)  http://medicine.iupui .edu/clinpharm/ddis/  
 
(1)   Investigator’s Brochure: Dasatinib (BMS 354825). Bristol-Myers Squibb. October 2006. 
(2)  Malhotra et al. (2001). Clin Pharmacol Ther. 69:14-23. 
(3)  Mathijssen et al. (2002). J Natl Cancer Inst. 94:1247-1249. 
      Frye et al. (2004). Clin Pharmacol Ther. 76:323-329. 
 
Updated on May 1, 2007 
  
 7.3.5 
 2 
APPENDIX D  
PATIENT’S MEDICATION DIARY  
 
Today’s date  _____________________ Agent:   GDC-0449  
Patient Name _____________________( initials acceptable)    Patient Study ID  __________________________ 
INSTRUCTIONS TO THE PATIENT: 
1. Complete one form for each cycle of treatment. 2. You will take GDC-0449 150mg (___ capsule(s)) once daily.  You should take  the capsule(s) at approximately the 
same time each day with a full glass of water (200mls) with or without food. 
3. Record the date, the number of cap sules of each size of capsule that you  took, and when you took them.   
4.      If you forget to take you daily dose or vomit  a dose you will not need to make up missed dose. 
5. If you have any comments or notice any side effect s, please record them in the Comments column.   
6. Please bring this form and your bottles of GDC-0449  capsules when you retu rn for each appointment. 
 
Day  
Date  
Time of dose  # of capsules taken Comments
 
150 mg  
1     
2     
3     
4     
5     
6     
7     
8     
9     
10     
11     
12     
13     
14     
15     
16     
17     
18     
19     
20     
21     
22     
23     
24     
25     
26     
27     
28     
 
Patient’s signature_______________________________________________________________________ 
 
 
Physician’s Office will complete this section: 
1. Date patient started protocol treatment _______________________________________________________________  
2. Date patient was re moved from study ________________________________________________________________  
3. Patient’s planned total daily dose ___________________________________________________________________  
4. Total number of capsules taken this month  ___________________________________________________________  5. Physician/Nurse/Data Manager’s Signature  ___________________________________________________________  
V2 -1/20/11 
 3 
  
 
APPENDIX E 
         
An eligibility form must be completed for every subject 
and must be kept in the research chart.  
 
        
 
             
 
 4Instructions: 
This eligibility checklist must be completed in its entirety.   
 
Yes        No                  ELIGIBILITY CRITERIA: (All answers must be YES) 
 _____ ____  1.         Patients has histologically or cytologically confirmed metastatic adenocarcinoma 
                                    of the pancreas. Patients with islet cells tumors are excluded. 
 
   
_____ ____     2.       Patients has measurable di sease, defined as at least one lesion that can      
                                       be accurately measured in at least one dimension (longest diameter to be 
                                       recorded) as >20 mm with conventional techniques or as >10 mm with spiral 
                                       CT scan.   
                                       _____    ____    3.        Patient has NOT received previous radiotherapy, surgery or chemotherapy or                                                      investigational drug ther apy for the treatment of metastatic disease.  
 
If the patient received radiotherapy, chemot herapy or investigational therapy in 
the adjuvant setting it should be comple ted 3 weeks prior to enrollment. If a 
patient received gemcitabine in the adjuva nt setting, tumor  recurrence must have 
occurred at least six months after completing the last dose of gemcitabine                                      
 
_____     _____ 4.         Age >18 years .   
                                       
_____     _____ 5.         Life expectancy of greater than 1 month.  _____     _____ 6.         ECOG perform ance status <1 (Karnofsky >70%; see Appendix A).
 
                                   ECOG PS:  ________ 
 
_____     _____ 7.         Patients has adequate organ and marrow function as defined below: 
 
- leukocytes      >3,000/mcL 
- absolute neutrophil count  >1,500/mcL 
- platelets      >100,000/mcL 
- total bilirubin     < 1.5 ULN 
- AST(SGOT)/ALT(SGPT)  <2.5 X in stitutional upper limit of normal, 
unless liver metastases are clearly present, then < 5X ULN is allowed 
- creatinine      within normal institutional limits 
OR 
- creatinine clearance   Creatinine clearance >50 mL/min/1.73 m
2 for 
patients. Serum creatinine < 2 mg/mL 
 
  
 5Instructions: 
This eligibility checklist must be completed in its entirety.   
 
Yes        No                  ELIGIBILITY CRITERIA: (All answers must be YES) 
 
_____    ____ 8             Patient is asymptomatic from jaundice and ascites prior to Day 1 of therapy.  
                                     Pain symptoms should be stable. 
 
_____   ____ 9             Patient is NOT pregnant or lactating. Not planning pregnancy during treatment and  
                                   for 7 months after last dose of treatment  _____   _____ 10            Patient has agreed to practice effective contraceptive measures throughout                                     
                                         the study. 
                                     
                                 Women of  childbearing potential are required to  have a negative serum pregnancy  
                                 test (with a sensitivity of at least 25 mIU/mL)                                        
      Women of childbearing potential are defined as follows: 
• Patients with regular menses 
• Patients with amenorrhea, irregular cycles, or using a contraceptive       method that precludes withdrawal bleeding • Women who have had a tubal ligation  
     Women are considered not to be of childbearing potential for the following   
      reasons: •    The patient has undergone hysterectomy and/or bilateral oophorectomy. •    The patient is post-menopausal defined by amenorrhea for at least 1 year        in a woman > 45 years old. 
      
_____     ____ 11.         For sexually active ma les: Patient is willing to use of barrier form of  
                                      cont raception, even if they have had a vasectomy, during the study and for 2    
                                      months after stopping GDC-0449.                                                                                                        
  
_____     ____ 12.         Patient agrees NOT to donate blood products fo r 7 months after stopping  
                                       GDC-0449 
 _____     ____ 13.         Patient has given wr itten informed consent to participate in this study. 
 _____     ____ 14.         Patient is NOT receiving concurrent anticancer therapy or any other 
                                   investigational agents while on study. 
 _____     ____ 15.      Patient does NOT have uncontrolled brain metastases. Patients with brain  
                                   metast ases must have been previously treated and well controlled for at least  
                                   three months (defined as clinically stable, no edema, no steroids and stable                                    in 2 scans at least 4 weeks apart)                                        
 6Instructions: 
This eligibility checklist must be completed in its entirety.   
 
____ ____    16.              History has NO histor y of allergic reactions attributed to compounds of similar 
chemical or biologic composition to GDC-0449 or other agents used in the study. 
 
____ ____    17.              Patients is NOT ta king medications with narrow therapeutic indices that are  
metabolized by cytochrome P450 (CYP450), including warfarin sodium (Coumadin®). 
 
____ ____    18.              Patient does NOT  have an uncontrolled intercurrent illness including, but  
                                    not limited to, ongoing or active infection, symptomatic congestive 
heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would lim it compliance with study requirements. 
 ____ ____    19.             Patient has NOT underg one a major surgery within the past 4 weeks, other than  
diagnostic surgery (i.e. surgery done to obtain a biopsy for diagnosis without 
removal of an organ)  
 ____ ____   20.         Patient does NOT h as history of other disease, metabolic dysfunction,  
                                   physical examination finding, or clinical laboratory fining giving reasonable 
                                      susp icion of a disease or condition that contraindicates use of an investigational 
                                   drug or  that might affect interpretation of the results of the study or render 
                                   the patient at high risk from treatment complications  _____ ____21.         Patient agrees to have two biopsies during the study                                         
                                                                          
 
 
Confirmation of Eligibility 
 
 Patient meets all Inclusion Criteria as defined by the protocol. 
  
 
______________________________                                                         
_________________________________                                 
Signature of site Study Coordinator                                                             Printed name of site Study Coor dinator  
 
Phone:  ____________________________ 
 
Fax to return registration:  _________________ 
        Email contact:  ____________________________  
  
 7 
APPENDIX F 
Registration Form Please supply the following information for all patients who sign informed consent.* 
 
Please Print Legibly  
 
Study Number:       
 
Patient’s History Number       ( o p t i o n a l )  
 
P a t i e n t ’ s  N a m e :                   
        First Name       Middle Initial   Last Name 
 
P a t i e n t ’ s  D a t e  o f  B i r t h :               
             Month  Day          Year 
 
 
    Estimated start date : ___/____/____ 
 
 
    
_________________________________________________                 _________________ 
Signature of PE/Designee Completing Form                                             Date 
 
* Note: If a subject has more than one consent form  for the same study, only complete this form ONE  
time.  
 
Attach this completed form to the eligibility  check list, consent and fax to the attention of 
Rosalind Walker, RN at 443-287-6566 
 
To be completed By Johns Hopkins University 
 Registration Confirmed: _______Yes _______ No   Patient ID Number: __ __ __ - __ __ __ 
 Johns Hopkins Representative Signature: __________________   Date:____________  
 
 Race: ( all that apply)
 Ethnicity: (  one) Gender: (  one)
 American Indian or Alaskan Native    Hispanic or Latino  Male 
 Asian  Not Hispanic or Latino  Female 
 Black or African American  Unknown  
 Native Hawaiian or Other Pacific Islander  
 White  
 Other  
 Unknown  
Patient’s USA  Zip Code:            
Foreign  Country (if does not reside in US):       
Type of Cancer:       (e.g. colon, lung, ALL, etc.) 
 8 
APPENDIX G: PROTOCOL SIGNATURE PAGE 
 
 
Protocol Number: J1013, NA_00036883 
   
A Phase II Study of Gemcitabine and nab- Paclitaxel in Combination with GDC-0449 
(Hedgehog Inhibitor) in Patients with Previo usly Untreated Metastatic Adenocarcinoma of 
the Pancreas 
 
 
Protocol Amendment 12, date December 4, 2014 
 
IND Number: 108819 
 
Sponsor: SU2C 
 
Coordinating Center: Johns Hopkins University 
 
 
I have read and understand the contents of the clinical protocol and agree to perform this 
study in accordance with the protocol and Go od Clinical Practice (GCP) 21 CFR Parts and 
applicable regulations/guidelines.   
I agree to conduct the clinical study in accordan ce with these principals and the procedures 
described in this protocol. I am aware of  my responsibilities as an investigator. 
  
PI Name:  ______________________    Title:   _______________________________   
 
Address:        _________________________________ 
 
  _________________________________    _________________________________ 
                                       
    PI Signature: _________________________________   Date:  _________________ 
 
  
 9APPENDIX H: MEDICAL MONITOR SIGNATURE PAGE 
 
Protocol Number: J1013, NA_00036883 
 
 
Medical Monitor Signature Page 
 
 
A Phase II Study of Gemcitabine and nab- Paclitaxel in Combination with GDC-0449 
(Hedgehog Inhibitor) in Patients with Previo usly Untreated Metastatic Adenocarcinoma of 
the Pancreas 
 
 
Protocol Amendment 12, date December 4, 2014 
 
 
IND Number: 108819 
 
Sponsor: SU2C 
 
Coordinating Center: Johns Hopkins University 
 
 
I have read and approved the protocol and a ppendices. My signature, in conjunction with 
the signature of the investigator, confirms th e agreement of both parties that the clinical 
trial will be conducted in accordance with the protocol and all applicable laws and 
regulations, including, but not limited to, th e ICH Guidelines for  the Good Clinical 
Practice (GCP) and US 21 CFR Pa rts and the ethical principles that have their origins in 
the Declaration of Helsinki, as well as all applicable privacy laws.  
  
Name:  ______________________    Title:   _______________________________   
 
Address:        _________________________________ 
 
  _________________________________    _________________________________ 
                                       
    Medical Monitor Signature: _________________________________   Date:  _______________  
 
 10APPENDIX I: AMENDMENTS SUMMARIES 
  
Amendment 1, June 8, 2010 
 
1. Section 3.1.10 was updated to explain that sexua lly active male patients need a barrier of 
contraception until 12 months after stopping GDC-0449.  
2. In the dose modification secti on (section 6.2), the second para graph in the portion entitled 
“Peripheral Neuropathy” was modified to cl arify that nab-Paclitaxel will be hold in 
patients with grade 3 neuropathy until resolution to ≤ grade 1 neuropathy,  regardless of 
suspected cause. In the same section the protocol now states that GDC-0449 should be 
held for grade 3 neuropathy until resolution to ≤ grade 1 neuropathy.   
 
Amendment 2, June 11, 2010 
1. The protocol was modified in section 5.3.1 to reflect there is a potential for GDC-0449 to 
also inhibit CYP1A2 and 2D 6 in addition to 2C8, 2C9, and 2C19. Caution should be 
exercised and dose reduction of the concom itant substrate drug be considered when 
dosing GDC-0449 concurrently with medicatio ns with narrow therapeutic windows that 
are substrates of CYP1A2 and 2D6. In the same section a table of drugs that may 
interfere with CYP1A2 and 2D6 was added. 
 
Amendment 3, July 6, 2010 
 
1. Section 3.1.1: Eligib ility criteria made clear to reflect that biopsy is required within 14 
days before starting treatment. 
2. Protocol Cover Page  
3. Table of contents was updated to reflect changes 
4. Version date in the protocol was changed to protocol amendment 3, date July 6, 2010 
5. Study calendar was modified. Circulating stem ce lls are collected also  at the time of the 
second biopsy. 
  
 11 
 Amendment 4, August 16, 2010 
 
1. Protocol cover page, the principal Investig ator has been changed at  Translational 
Genomics Research Institute, Scottsdale AZ site, they deleted Dan Van Hoff, MD as the  
     principal investigator  and added Ramesh K. Ramanathan, MD as the principal  
     investigator.  
  
2.  Protocol cover page, deleted Ana De Jesus-Ac osta, MD as the co-investigator. Added Ana  
De Jesus-Acosta as the Co-Principal Inve stigator. Added Pamela Johnson as the co- 
           investigator.  
3.  Protocol cover page, added Van Andel Research Institute,  MI as the new site; added 
    Timothy J. O’Rourke, M.D. as the pr incipal investigator for the site. 
 
4.  It was added to eligibility checklist that biopsies are required in  this study. Already 
     included in the inclusion cr iteria and consent forms. 
 
5. Version date in the protocol was changed to protocol amendment 4, date August 16, 2010 
 
6. Section 4 and 7.5 were modified to reflect the registration process using a centralized 
uniform database by CRAB. This includes electronic forms for adverse events and 
serious adverse ev ents reporting. 
 
7. Section 5.1 follow up for survival will be done by telephone contact 
8.  Changed fax number from 410-502-0834 to 443-287-6566 for the study 
 
9.  Added Urinalysis test at the screening.  
 
 
10.  In section 9: Amount of blood that will be obta ined for circulating cancer stem cells was   
 
decreased to 150 ml. 
 
11. Inserted Appendix G–Protocol signature page 
 
12. Inserted Appendix H- Medica l Monitor Signature page 
 
 
13. Added drug destruction accountability instruc tions for nab-Paclitaxel and GDC-0449 in 
section 8 (pharmaceutical information) 
 
 
14. Section 9.1.5 for collection of SPARC and CA19-9 was updated 
 
 
 1215. Laboratory manual for processing of corre lative studies samples was modified 
 
16. Modified statistical section 12.1.4 for prac tical purposes of multicenter trial. 
 
 
17. Updated Appendix I- Summary of changes 
 
18. Table of contents was upda ted to reflect changes. 
19. Study calendar modified Day 28 changed to day 22. 
20. Baseline CT scans will be done within 14 days  prior to starting treatment. Section 5.1.2, 
5.1.3 and Study calendar were modified to reflect this.  
21. Protocol page 60, added “JHH Investigational Drug Services (IDS)” to section How 
Supplied GDC-0449. 
22. Protocol page 61, added “Supply:    GDC-0449 will be obtained from JHH IDS.” 
23. Protocol page 61, added “JHHIDS” in section “Packaging, Labeling, and Storage of Study 
Drug:”  
24. Protocol page 63, deleted “Upon receipt of th e study drug supplies, the Investigator or 
designee will conduct an inventory and sign both copies of the study drug receipt and 
forward one copy to the address indicated on the form. One copy of the receipt and the 
packing slip must be reta ined in the Investigator '’s regulatory file records. A 
representative from Abraxis or his/her desi gnee will inspect the study drug inventory, and 
will arrange for the return of any remaining unused study drug. No study drug may be 
returned without the represen tative from Abraxis or other Abraxis-designated personnel 
first inspecting the study drug inventory.  St udy drug may be destroyed according to the 
institutional policy of study sites.  Supply:  Will be obtained from Abraxis Bioscience 
using a commercial Badge” from section “Reco nstitution and use of nab-paclitaxel #14”. 
25. Protocol page 64, added “Supply: nab-Pac litaxel will be obtain ed from JHH IDS.” 
26. Protocol page 64, added “Gemcitabine” in section “Packaging, Labeling, and Storage” 
27. Protocol page 66, added section 8.3 Study Me dication Accountability and destruction  
(GDC-0449 and nab-Paclitaxel)  
 
  
 
 13Amendment 5, February 1, 2011 
 
1. Protocol cover page, deleted princi pal investigator Manual Hidalgo, MD. 
 
2. Protocol cover page, deleted site Centro In tegral Oncology Clara Campal, Madrid Spain 
 
3. On foot section, insert  “ Protocol  amendment 5, date February 1, 2011  
4. Page 3, added “Oct 19, 2010” as the approval date for amendment 4 
5. On page 46, Table 4 modified 
6. On page 47-48, modified the “Table 5. Dose  Modifications for Hematologic Toxicity 
within a Cycle” 
7. On page 75, the shipping contacts fo r SPARC at section 9.1.5.5 was modified 
8. Apendix D: updated Patie nt Medication Diary 
9. On page 9, Table of contents wa s updated to reflect changes. 
10. On page 29, we removed second bullet 
11. On page 39, added “Guidelines for administra tion of GCSF are described in Table 5 but 
will be to the discretion of the investigator and according to institutional guidelines.” In 
section 5.2.4 
12. On page 72, deleted  “National cancer Research Cent er (CNIO), Madrid” from section 
9.1.4 
13. On page 87, added “and treated on” and “with GDC” in section 12.2.4 
 
Amendment 6, August 3, 2011 
 
1. On foot section, insert  “ Protoc ol amendment 6, date August 3, 2011  
2. Modified the name of the study dr ug on the title page and page 3 
3. Deleted principal investigator: Timothy J. O’Rourke, MD from the title page 
4. Deleted “Van Andel Research Institute, MI   ” sub site from the title page  
5. Added IRB approval date on page 3 
6. Table of Contents has been updated 
7. Table 5 modified 
 148. Section 2.4.1: The list of pot ential risks of GDC-0449 was upda ted. A list of the safety 
IND reports submitted to IND was added.  
9. Page 20, section “changed “12” to “7” months in section -–Reproductive and 
developmental Toxicity 
10. Eligibility criteria 3.1.10 was modified. Sexually active male s must use a barrier form of 
contraception during GDC-0449 treatment and fo r 7 months after last dose. Based on the 
new Investigator Brochure. Eligibility check list was modified to reflect this change. 
11. Eligibility criteria 3.1.11 was modified. The time period af ter which patients can donate 
blood or blood products following treatment  with GDC-0449 was reduced from 12 
months to 7 months. Based on new Investig ator Brochure. Eligibility checklist was 
modified to reflect this change. 
12. Page 42, changed 12 month to 7 month 
13. Eligibility criteria 3.2.8 wa s modified. Women pregna nt and nursing women are 
excluded. Women planning to become pregnant during treatment or 7 months after last 
dose of treatment are excluded. Based on new I nvestigator Brochure. Eligibility checklist 
was modified to reflect this change. 
14. Section 7.4.1 adverse events of GDC-0449 were updated. Added ageusia and hypogeusia. 
15. Section 5.3.1 CYP2C8 inhibitors updated 
16. Section 9.1: An optional biopsy upon progression for patients with previous response to 
therapy was added. 
17. Study Calendar modified to expl ain that taste questionnaire w ill be filled at the beginning 
of cycle 2 and cycle 3 
18. Taste Questionnaire added as appendix J 
 
 
  
 15Amendment 7, January 11, 2012 
 
1. On foot section, insert  “ Protoc ol amendment 7, date January11, 2012  
2. Added the IRB approval date August 30, 2011 for the amendment 6 on the page 3. 
3. Table of Contents has been updated 
4. Section 9.1 (Correlative studies ) has been modified. The second biopsy and blood sample 
collection for circulating stem cells will occur in all patients after receiving two cycles of 
treatment. Will be perform on Cycle 3, Day 1.  
5. Study Calendar (Section 10) modi fied to explain that second research biopsy and second 
blood sample for circulating stem cells will be  obtained after two cycles of treatment. 
6. Consent form modified to  reflect above changes. 
 
    
Amendment 8, February 7, 2012 
 
1. On foot section, insert  “ Protocol  amendment 8, date February 15, 2012  
2. Added the IRB approval date February 7, 2012 for the amendment 8 on the page 3. 
3. University of Pennsylvania will re-o pen enrollment. See attached letter. 
4. Table at section 6.2 was modified. Additional 25% dose modifications are permissible to 
establish the tolerable dose for an individual patient. 
5. Section 6 modified. Delays for toxicities can be permitted up to 4 weeks (28 days). If 
longer than 28 days patients will be discontinued from the study. 
 
 
Amendment 9, February 22, 2013 
 
1. Section 12.25 and 12.3 for statistics and futility analysis were modified in light of new 
data available from a large Phase III study conducted using Gemcitabine and Abraxane 
presented in ASCO GI 2013. 
2. Study reopens to enrollment. 
 
  
  
 16Amendment 10, April 16, 2013 
 
1. Eligibility 3.1.10 was modified. Male patients need to use a form of contraception for a 
period of 2 months after stopping GDC-0449. Ti me was changed from 7 months to 2 
months as per updated IB.  
2. Eligibility checklist was modified to reflect above change.  
 
 
Amendment 11, August 16, 2013 
 
1. Updated safety language and precautions 
2. Updated contraception language 
3. Updated storage language 
 
  
 
 
Amendment 12, December 4, 2014 
 
1. Revised accrual number from 80 to 72 
2. Revised on site monitoring from CRAB to CRO QA 
                 
 
 17 
 
 
 
 
 
 
 
 
 
 
APPENDIX J: GENENTECH FAX COVER SHEET 
  
 18 
SAFETY REPORTING FAX COVER SHEET GENENTECH SUPPORTED RESEARCH 
 
AE / SAE FAX No: (650) 225-4682 
 Alternate Fax No: (650) 225-5288 
 
Genentech Study Number 
 
Principal Investigator  
Site Name  
Reporter name  
Reporter Telephone #  
Reporter Fax #  
 
 
Initial Report Date [DD] / [MON] / [YY] 
Follow-up Report Date [DD] / [MON] / [YY] 
 
 
Subject Initials 
(Enter a dash if patient has no 
middle name) [ ] - [ ] - [ ] 
 
 
SAE or Safety Reporting q uestions, contact Genentec h Safety: (888) 835-2555 
 
 
PLEASE PLACE MEDWATCH REPORT or SAFET Y REPORT BEHIND TH IS COVER SHEET 
  

 19 
 
   
      
APPENDIX K: TASTE AND SMELL QUESTIONNAIRE
 20A Phase II Study of Gemcitabine and Nab- Paclitaxel in Combination With GDC-
0449 (Hedgehog Inhibitor) in Patients Wi th Previously Untreated Metastatic 
Adenocarcinoma of the Pancreas: Changes in Smell and/or Taste 
 
TASTE INFORMATION 
 
1. Since beginning this clinical trial, have you experienced a change in your 
sense of taste? Check all of the followi ng statements that apply to you now:  
 
     My sense of taste has NOT CHANGED (If not, please skip to question 
#13) 
     My sense of taste is ALTERED , that is, things taste peculiar  
 
     I experience a taste when nothi ng is there (PHANTOM TASTE) 
 
     My sense of taste is HEIGHTENED (Hypersensitive) 
 
     My sense of taste is DIMINISHED (partial loss) 
 
     My sense of taste is ABSENT (complete loss) 
 
2.  When did you notice this change?           /        /            (Month/Day/Year)  
 
3. For each type of taste problem you ex perience, indicate by a check how your  
 symptoms have changed in the past week:  
 
 Unchanged Improved Worsened 
  
TASTE LOSS    
HYPERSENSITIVITY    
TASTE ALTERED     
PHANTOM TASTE(S)    
 
4. For each of the followi ng taste qualities, indicate with a ch eck whether your 
perception of it is currentl y normal, diminished, absent, altered  or heightened:  
 Normal Diminished Absent Altered Heightened
   
   SWEET      
   SALTY      
   SOUR(e.g.,       
          lemon, vinegar)      
   BITTER(e.g.,  
    tonic water, medicine)      
 
 IF YOU DO NOT EXPERIENCE ALTERED TASTE, PLEASE SKIP TO QUESTION #7  
 
       
 21 
5.  The kinds of things that taste ALTERED  (different ) to you are (check all that 
apply):  
 FOODS/BEVERAGES (specify):           
 TOBACCO PRODUCTS (specify):          
 O T H E R  ( s p e c i f y ) :              
 EVERYTHING TASTES ALTERED 
________________________ _________________  
6.  Does everything you believe  to be altered  now taste the same to you?  
 NO, THINGS STILL TASTE DIFFERENTLY, BUT THEY DO NOT HAVE THE 
SAME QUALITY THEY USED TO. 
    YES, THEY ALL TASTE THE SAME. 
IF YOU DO NOT EXPERIENCE AN ORAL PHANTOM ( a taste when nothing is there ), 
PLEASE   SKIP TO QUESTION #13 
 7.  Do you currently experience more than one type of oral phantom?  
    NO 
    YES 
 
8.  The oral phantom(s) is  (check all that apply):  
 Not at All 
Weakly Moderately Strongly 
  
             SWEET     
             SALTY     
    SOUR     
    BITTER     
    ROTTEN     
    METALLIC     
    BURNING     
    TINGLING     
    OTHER     
 
 S p e c i f y  q u a l i t y :           
              
 22 
9.  Does the oral phantom come from your (check all that apply):  
  TONGUE (specify where) : ____________________________ _________ 
  THROAT 
  GUMS 
  DENTURES OR CAPS 
  ROOF OF MOUTH 
 SALIVA 
  WHOLE MOUTH 
  OTHER (specify):__________________ ___________________________  
 
 10.  How often do you experience the oral phantom(s)?  
    CONSTANTLY (ALWAYS PRESENT) 
    DAILY 
    AFTER EACH STUDY TREATMENT 
    ONLY OCCASIONALLY 
              OTHER (specify):____________ ________________________ _________  
 
 11.  How long does your or al phantom usually last?  
 THE PHANTOM IS ALWAYS THERE. 
 24 HOURS OR MORE 
 SEVERAL HOURS 
 MINUTES 
 BRIEF or TEMPORARY  
 
12.  How strong is your oral phantom(s) usually?  
 VERY WEAK 
 WEAK 
 MODERATE 
 STRONG 
 
    
 
 23SMELL INFORMATION 
 
13. Since beginning this clin ical trial, have you experi enced a change in your 
sense of smell? Check all of the following  statements that apply to you now:  
 
  My sense of smell has NOT CHANGED ( If not, please skip to question #23)  
  My sense of smell is ALTERED , that is, things smell peculiar  
 
  I experience a smell when noth ing is there (PHANTOM SMELL) 
 
  My sense of smell is HEIGHTENED (Hypersensitive) 
 
  My sense of smell is DIMINISHED (partial loss) 
 
  My sense of smell is  ABSENT (complete loss) 
 
 
14.  When did you notice this change?           /        /            (Month/Day/Year)  
 
 15.  For each type of smell problem you experience, indicate by a check how your  
  symptoms have changed in the past week:  
 
 Unchanged Improved Worsened 
  
SMELL LOSS    
HYPERSENSITIVITY    
SMELL DISTORTIONS    
PHANTOM SMELL(S)    
 
 IF YOU DO NOT EXPERIENCE AN ALTERED SMELL, PLEASE SKIP TO QUESTION 
#18 
 
 
16.  The kinds of odors that smell ALTERED  (peculiar) to you are (check all that 
apply):  
 
 FOODS/BEVERAGES (specify):          
  
 P E R F U M E S  ( s p e c i f y ) :            
  
 TOBACCO PRODUCTS (specify):         
  
 O T H E R  ( s p e c i f y ) :             
  
 EVERYTHING SMELLS ALTERED ________________ ____________________  
 
 
 
   
 2417.  Do all of the odors you believe  to be altered  now smell the same to you?  
 NO, ODORS STILL SMELL DIFFERENT, BUT THEY DO NOT HAVE THE 
SAME QUALITY THEY USED TO. 
    YES, THEY ALL SMELL THE SAME. 
IF YOU DO NOT EXPERIENCE A PHANTOM SMELL, PLEASE SKIP TO QUESTION 
#23 
 
18.  Do you currently experience more  than one type of phantom smell 
sensation?  
    NO 
    YES 
 
 
19.  The phantom odor(s) smell(s) like (check all that apply):  
 Not at All Weakly Moderately Strongly 
  
   INFECTED TISSUE     
   SMOKY/BURNT     
   FECAL     
   ROTTEN     
   MUSTY/MOLDY     
   SWEET     
   METALLIC     
   CHEMICAL     
   OTHER     
 S p e c i f y  q u a l i t y :           
 
  20.  How often do you experience the phantom odor(s)?  
    CONSTANTLY (ALWAYS PRESENT) 
    DAILY 
    AFTER EACH STUDY TREATMENT 
    ONLY OCCASIONALLY 
 
           
 25 
21.  How long does your phantom usually last?  
   THE PHANTOM ODOR IS  ALWAYS THERE. 
   24 HOURS OR MORE 
   SEVERAL HOURS 
   MINUTES 
   FLEETING 
  
22.  How strong is your phantom odor(s) usually?  
 VERY WEAK 
 WEAK 
 MODERATE 
 STRONG 
 
NUTRITIONAL INFORMATION 
 
23.  Since beginning this clinical trial, your appetite has been:  
  BETTER 
  UNCHANGED 
  WORSE 
 
 24.  Since beginning this clinic al trial, you have enjoyed food:  
       MORE 
       THE SAME 
       LESS 
 
 25.  Since beginning this cl inical trial, have you cha nged the way you eat (e.g., 
types of foods, meal a nd snacking frequency)?  
       NO 
       YES (describe change):          
           
 
26.  Since beginning this clin ical trial, have you altere d the amount of salt, sugar 
or spices you add to your food?  
       NO 
       YES (describe change):          
           
 
    
 2627.  Since beginning this clinical trial,  have you started to strongly dislike or 
avoid certain foods?  
      NO 
      YES (specify foods):           
          
 
 28.  Since beginning this clin ical trial, have you had a strong desire or craving for 
certain foods?  
  NO 
  YES (specify foods craved):        
            
 
 29.  Do you feel nauseated or  sick to your stomach often?  
 NO 
 YES      
  How severely?  
   MILDLY 
   EXTREMELY 
  W h e n ?            
 
 
 